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Abstract 
 
 
Stimuli responsive polymers offer potential applications as drug delivery 
systems. This thesis has focused on thermoresponsive N-isopropylacrylamide-
based nanogels, known to undergo a volume phase transition at a specific 
temperature depending on their chemical composition, and their potential 
application in dermal drug delivery.  
The first results and discussion chapter of this thesis presents the synthesis and 
characterisation of NIPAM nanogels, prepared with cross-linkers, and 
comonomers designed to introduce charges. The influence of the different 
polymerisation parameters on the morphology and physicochemical 
characteristics of the nanogels is described and evaluated. NIPAM nanogels of 
less than 40 nm in size were obtained and fine-tuned to respond to 
temperatures of around 35ºC, i.e. skin temperature. The nanogels were 
covalently linked with a fluorescent naphtalimide derivative, which was 
shown not to alter the properties of the polymers significantly. Drug uploading 
and in vitro release studies at different temperatures using flufenamic acid as 
the model drug are presented and discussed. 
The second results and discussion chapter describes the biological studies, in 
which the labelled drug carriers were tested for skin irritation, using the Zein 
protein test, cytotoxicity to and internalisation in keratinocyte cells, followed 
by evaluation of skin permeability properties, using excised human skin.  
The data presented in this thesis demonstrate that NIPAM nanogels cross-
linked with methylenebisacrylamide can be fine-tuned to respond to a 
temperature suitable for dermal applications. The nanoparticles, even when 
labelled with fluorescent tags or charged comonomers are non-cytotoxic when 
internalised by keratinocytes. When permeation enhancers are used, the 
nanogels are able to cross the skin barrier to deliver the drug efficiently. 
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1.1 General overview and aim of the project 
One of the limitations of traditional drug delivery methods is that the delivery 
of the active compound depends on its surviving the body’s physiological 
processes, for example the stomach acids, hepatic metabolism, intestinal 
absorption. Delivery through the skin, if possible, would enable drugs to be 
delivered without any metabolic impediment. The difficulty of this method of 
delivery is to be able to penetrate the skin which is, naturally, virtually 
impermeable. Until the development of nanotechnology and the associated 
extremely small particles, permeation on the skin was based in the use of 
penetration enhancers that damaged the skin barrier functions. 
The research for this thesis has been aimed at identifying a nanogel 
technology which would allow the delivery of a drug through to the skin. This 
chapter summarises the literature relevant to this thesis on thermoresponsive 
nanogels for drug delivery to the skin. Four sections are presented whith the 
most up-to-date information about nanotechnology (Section 1.2), drug 
delivery systems (Section 1.3), the human skin (Section 1.4) and smart 
materials (Section 1.5). 
1.2 Nanotechnology and Nanomaterials 
1.2.1 The concept 
The concept of nanomaterials was described for the first time in 1959, in the 
Annual Meeting of the American Physical Society at the California Institute of 
Technology, where Richard Feynman gave his famous talk titled ‘There is 
plenty of room at the bottom’.1 He discussed the possibility of controlling 
materials at the level of atoms and molecules to obtain new materials, as well 
as the possibility of manipulating materials in the nanoscale range. It was not 
until 1974 that Norio Taniguchi coined the term ‘nanotechnology’ and first 
described it in the Bulletin of the Japan Society of Precision Engineering.2 
Later, during the 1980s Kim Eric Drexler wrote the book ‘Engines of 
Creation; the coming era of Nanotechnology’3 and created the Foresight 
Institute to promote transformative technologies. It is thanks to his efforts to 
increase public awareness of Nanotechnology that this area of science has 
Chapter I: Introduction 
 17 
emerged. During the same decade two important discoveries helped the 
progress of the field: the development of a scanning tunnelling microscope 
(STM) by Gerd Binnig and Heinrich Rohrer4 at IBM and the synthesis of 
fullerenes (C60) by Richard Smalley, Robert Curl and Harold Kroto.5 
Following these discoveries came carbon nanotubes in 1991 developed by 
Sumio Iijima,6 the first quantum dots two years later by Murray, Noris and 
Bawendi7 and DNA motors8 in 2000 developed by Bell Laboratories and  
Oxford University.  
One of the most current and commonly accepted definitions of 
nanotechnology comes from the American National Nanotechnology Initiative 
and states that: “Nanotechnology is the understanding and control of matter at 
dimensions between approximately 1 and 100 nanometers, where unique 
phenomena enable novel applications. […] Encompassing nanoscale science, 
engineering, and technology, nanotechnology involves imaging, measuring, 
modelling, and manipulating matter at this length scale. […] Unusual physical, 
chemical, and biological properties can emerge in materials at the nanoscale. 
These properties may differ in important ways from the properties of bulk 
materials and single atoms or molecules.”9 
The European Commission definition of nanomaterials focuses on the amount 
of material and limits the definition of nanomaterials to one dimension: “A 
natural, incidental or manufactured material containing particles, in an 
unbound state or as an aggregate or as an agglomerate and where, for 50 % or 
more of the particles in the number size distribution, one or more external 
dimensions is in the size range 1 nm - 100 nm“.10 
There are a number of other definitions, however all agree on two key points; 
(1) the definition of nano particle size (between 1 and 100nm) and  (2) the 
novel properties that arise from the size. Some materials become subject to the 
laws of quantum physics when reduced from bulk to nano size, thereby 
changing their optical, magnetic or electrical properties. Nanomaterials have a 
high surface area-to-mass ratio and this enhances the reactivity, strength and 
electrical properties of the materials, which creates interesting potential 
applications. 
Chapter I: Introduction 
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1.2.2 The use of nanomaterials 
General 
Nanotechnologies are integrated into a large range of applications from 
aerospace materials to medicinal products. Nanotechnology is an expanding 
science that is already widely used in food, agriculture, textiles, electronics, 
renewable energy, biomedical applications and healthcare. Some the most 
interesting applications are described below. 
Textiles 
Nanomaterials are used to improve the properties of technical textiles, where 
function is the main criterion. Textiles surfaces can be modified by the use of 
nanofibers, and coating or extrusion with nanoparticles. Coating technologies 
create, self-cleaning and anti-stain textiles.11 The addition of nanotubes 
modifies the conductivity of materials (they are semi-conductors) and makes 
them 100 times stronger than steel and 6 times lighter.12 Using nanoparticles 
as additives gives textiles particular properties e.g.: silica to create fire-
retarding textiles13; ZnO particles for UV-protection;14 Ag particles as 
antibacterial textiles.15  
Food and agriculture 
Nano-structured foods like low fat mayonnaise, spread and ice-cream are 
nanoemulsions.16 Nanomaterials are also present in food packaging and food 
preparation machinery, for example, plastic polymers incorporate nanoclay as 
a gas barrier,17 nanosilver is used for antibacterial action18 and nanotitanium 
nitrade creates mechanical strength.16 Organic and inorganic nanosized 
materials are used as nanocarriers for the delivery of nutrients and 
supplements for food and feed applications. For example in the food industry 
lipid-based nano-encapsulated antioxidants.19 In addition, in agriculture, 
pesticides are being formulated in nanoparticles to increase their efficiency 
and water solubility.20  
Electronics  
Nanoscale patterning (nanoscale patterns on surfaces) of electronic circuits has 
already improved the field but the most promising applications are expected to 
Chapter I: Introduction 
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be in quantum computers.21  
Environment 
Examples of the improvements due to nanotechnology include; greener 
automobile catalysts22 (for more efficient combustion of diesel fuel); iron 
nanoparticles as pollution scavengers for cleaning up organic solvents that 
pollute groundwater;23 silicon nanowires embedded in a polymer, resulting in 
low cost but high efficiency solar cells.24  
Renewable energy 
Nanotechnology has made fuel cells more efficient. Fuel cells are chemical 
devices that produce electricity through a chemical reaction but they differ 
from batteries in the sense they cannot store energy. So far, fuel cells have 
been used mainly in vehicle traction and as a source of energy (usually 
backup) for industrial, commercial and residential purposes. The most 
common fuel cell reaction is between oxygen and hydrogen, which holds 
significant promise for clean energy because the cell's only by-product is 
water.  The development of increasingly efficient platinum nanoparticle 
catalysts25  able to absorb more oxygen and the use of graphene26 layers in the 
fuel cell’s tank to increases the amount of hydrogen that can be stored, are 
making fuel cells an environmentally friendly source of energy. 
Biomedical 
Biomedical applications are the most relevant application of nanotechnology 
for this thesis.  The end goal of nanomedicine (the medical application of 
nanotechnology) is to improve the diagnosis, treatment and prevention of 
disease. Amongst the most promising fields of nanomedicine are: 
1. tissue engineering and regenerative medicine;  
2. nanosensors;  
3. diagnostic imaging;  
4. drug delivery. 
(1) Tissue engineering and regenerative medicine 
Tissue engineering and regenerative medicine are multidisciplinary fields 
Chapter I: Introduction 
 20 
involving biology, medicine, material science and engineering that are 
completely changing the perception of the reconstruction, maintenance, or 
enhancement of tissue and organ function. Not only does tissue engineering 
have a therapeutic application, where the tissue is either grown in the patient 
or outside the patient and then transplanted; it also has diagnostic applications 
for in vitro testing of drug metabolism and uptake, toxicity or pathogenicity. 
The term regenerative medicine is often used when working with stem cell or 
progenitor cells to produce new tissues.  
Tissue engineering researches new materials to be used as scaffolds to direct 
the growth and differentiation of cells while forming a tissue.27 
Nanocomposites are a combination of nanomaterials embedded within a 
matrix material for tissue engineering. They are used to compensate for the 
matrix limitation of growing cells. For example, carbon nanotubes increase 
both Young’s modulus and tensile strength, overcoming weak matrix 
mechanical properties and increasing matrix conductivity.28,29 Synthetic 
nanospheres allow the controlled release of bio-molecules essential for the 
tissue growth.30 Magnetic nanoparticles are used to create vascular tissue and 
to control shape.31 Nanotitanium wires improve cell matrix interactions and 
increases cell adhesion.32 Finally, gold nanowires are use to control the 
localisation of bio-molecules within the scaffold.33  
(2) Nanosensors 
Nanosensors are usually chemical or physical sensors constructed using 
nanoscale materials, the purpose of which is mainly to obtain data on the 
molecular or atomic scale and convert it into data that can be analysed. 
Nanosensors are highly sensitive and can detect viruses, particles and proteins, 
such as the extra-cellular acid pH in cancer cells. Nanosensors measure 
changes in concentration, electrical and magnetical forces, pressure, pH or 
temperature of cells, and are therefore able to distinguish between cells at the 
molecular level, in order to deliver medicines or monitor a process taking 
place in specific areas in the body. The combination of a sensor with an 
imaging unit provides a tool for diagnostics. 
 
Chapter I: Introduction 
 21 
(3) Diagnostic imaging 
Medical imaging refers to a number of techniques (x-ray, magnetic resonance 
imaging, single-photon-emission and positron-emission tomography, and 
ultrasound) that can be used as non-invasive methods of looking inside the 
body and obtaining a visual representation of body parts, organs or tissues that 
can be used for diagnosis. In order to visualize abnormalities on a diagnostic 
image, contrast agents (materials that interact with the incident radiation to 
produce visible changes on the resulting image) are usually employed. It is in 
the development of novel and improved contrast agents, that nanotechnology 
is making a significant impact in the field.  
Through nanoscale manipulations, researchers are continuing to improve upon 
the sensitivity, biocompatibility, and bio-distribution profile of various 
contrast materials.34 The latest designs incorporate the relevant contrast-
generating materials, for example in the form of fluorescent, radioactive, 
paramagnetic nanoparticles. Many functionally active materials used to 
generate contrast for molecular imaging, have a very low biocompatibility, 
which leads to fast excretion, low circulating half-life, decreased stability and 
potential toxicity. This problem has been the subject of much research, in 
order to render these materials biocompatible; for example, by coating 
nanoparticles with polyethylene glycol. Examples of nano-contrast agents 
include iron oxide nanoparticles35 for magnetic resonance, gold nanoparticles 
for x-ray36 and quantum dots for fluorescence.37  
(4) Drug delivery 
Drug delivery systems are generally defined as a device capable of carrying a 
drug (or therapeutic entity such as a protein or nucleic acids) into the body and 
enhance its efficacy and safety by controlling the rate, time, and place of the 
drug’s release. Drug delivery systems protect the drug from degradation or 
metabolic clearance and enhance drug concentration in targeted tissues, 
thereby lowering the dose required.38 
The combination of a nanosensor with a drug carrier creates a targeted drug 
delivery system that can deliver the drug to a specific area of the body, 
reducing side effects and the therapeutic dosage.  
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Many nanoparticles have been developed as potential drug carriers though few 
have been sucessful.38 In the 1980s, the first nanoparticles developed for drug 
delivery were the liposomes made of lipid bilayers.39 Subsequently, 
nanoparticles were developed using inorganic materials such as silica, gold, 
iron oxide; and organic materials such as polymer-based nanoparticles. 
Commercially available drug delivery systems (drugs) currently include, 
liposomal doxorubicin for chemotherapy; amphotericin B in disc-shaped 
cholesteryl sulphate particles for the treatment of fungal infections; and 
Aprepitant, in nanocrystals, as an antinausea medicine.40  
Combining drug delivery systems with an entity that is detectable by an 
imaging technique has given rise to theranostics (a combination of therapy and 
diagnosis). For example, iron oxide nanoparticles are commercially available 
as Magnetic Resonance Imaging (MRI) contrast agents. They can be coupled 
with drug molecules so that the release of their payload can be controlled by a 
magnetic field.41 These drug delivery systems combine diagnostic and 
therapeutic capabilities in a single system, capable of providing a more 
personalized therapy. Nanoparticle-based theranostics are still at the 
development stage. 
 
1.2.3 The classification of nanomaterials 
Nanomaterials can be classified by their composition or by their dimensions. 
The composition of nanomaterials has become more and more complex with 
the mixing of organic and non-organic elements. Classification by dimension 
has remained constant. Three-dimensional nanomaterials include 
nanoparticles, nanopowders, nanocapsules, fullerens, quantum dots and 
nanopores. All these materials are nanosized in three-dimensions. Examples of 
two-dimensional nanomaterials include nanofibres, nanowires and nanotubes. 
Nano-thin films are an example of one-dimensional nanomaterials. 
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1.2.4 Nanoparticles  
1.2.4.1 Scale and basic properties of nanoparticles 
Nanoparticles are objects in the nano-size range, which behave as a whole unit 
with respect to their transport and properties, usually limited from 1-100nm 
lengths in two or three dimensions. Spherical nanoparticles, as spheres are 
perfectly symmetrical geometrical objects with the highest surface per volume 
ratio of any physical body (the largest volume for smallest surface area). The 
more surface the more they can interact with biological entities. 
The size of nanoparticles places them on the same scale as biological systems. 
Antibody proteins are around 10 nm, haemoglobin is around 5 nm in length. 
Nanoparticles are slightly bigger than most biological molecules (glucose is 
around 1nm), and smaller than viruses, which are around 100nm. This 
explains the great potential nanoparticles have for interact with biological 
systems. 
 
Figure 1.1 – The nanoworld, size comparison with molecules, biomolecules, small 
microorganisms up to micro world. Redrawn from Nano.gov 
 
Nanoparticles can be natural or man-made. Artificial nanoparticles are made 
of inorganic and organic materials or a combination of both. For example, 
organic nanoparticles, like liposomes, are made of natural or/and synthetic 
lipids; fullerens are made of carbon; micelles or vesicles are made of polymers 
and dendrimers; and even natural proteins such as ferritin, have been used as a 
nanoparticle. 
Inorganic nanoparticles can be made of metals, in some cases giving specific 
properties such as iron oxide producing supermagnetic nanoparticles, 
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lanthanide ions forming paramagnetic nanoparticles, and salts like CdSe or 
ZnS forming quantum dots (QD). 
1.2.4.2 Nanogels 
1.2.4.2.1 Definition 
Nanogels are polymeric nanoparticles, physically or chemically cross-linked, 
that swell and form stable colloids in the right solvent.42 Nanogels can be 
manufactured in different sizes, from a few nanometres to microns. Depending 
on the monomers used for their preparation, they can be either hydrophobic or 
hydrophilic. In the latter case they are usually referred to as hydrogels when 
the particles are soluble in water.  
1.2.4.2.2 Nanogel classification 
Nanogels can be classified by the type of linkages present in the chains of the 
structure: chemically cross-linked nanogels and physically cross-linked 
nanogels.42 
Chemically cross-linked nanogels have covalent bonds throughout the gel 
network. Usually these are obtained by reacting monomers with cross-linkers. 
There are also natural nanogels made of repeating units of sugars like 
chitosan. The cross-linking points of nanogels modify the entire 
physicochemical properties of the linear polymer chains. As a general rule, 
highly cross-linked systems are more rigid, less water-soluble and swell less. 
Physical cross-linked gels are formed by weaker linkages in between the 
polymers such as Van de Waals forces, hydrophobic or electrostatic 
interaction or hydrogen bonding. These systems are highly sensitive to the 
temperature, ionic strength and pH of the medium. Two classic examples of 
these gels are the amphiphilic block copolymer and the complexation of 
oppositely-charged polymeric chains.  
1.2.4.2.3 Synthesis of nanogels 
1.2.4.2.3.1 General 
The synthesis of nanogels is an important process that determines their size 
and properties. There are many techniques described in the literature.43 
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1.2.4.2.3.2 Photolithographic techniques 
Photolithographically prepared nanogels are synthesised and later released 
from a mould. This allows large-scale production of nanogels and microgels 
with highly controlled size and great reproducibility. It consists of 5 steps: 
firstly a UV cross-linkable monomer with non-wetting properties is applied to 
a silicon-coated surface. Secondly, a template made of quartz is pressed into a 
3D structure and (thirdly) then irradiated with UV light. Fourthly, the residual 
layers of polymer are oxidized (with plasma containing oxygen) and fifthly, 
the particles are collected by dissolution on a buffer or water.44  
 
 
Figure 1.2 – Photolithographic technique step by step. 
 
This category also includes the Particle Replication in Non-wetting Templates 
(PRINT) technique.45 PRINT enables the fabrication of sub-micron particles 
with highly controlled size, shape and composition. Silicon master templates 
are made by using electron beam lithography. The master template is covered 
with a photo-curable (UV light-induced hardening) fluoropolymer that acts as 
a mould and is a non-wetting material. This eradicates the problem presented 
by previous photolithographic techniques, namely the formation of a residual 
interconnecting film between the moulded objects, thereby allowing for the 
formation of isolated particles. The PRINT technique is also good 
manufacturing methods (GMP) compliant. 
1.2.4.2.3.3 Microfluidic methods 
Microfluidic methods have been extensively used for the preparation of nano 
and micro gels. The apparatus consists of two main inlets for monomers or 
oligomers and a continuous phase. In a microchannel with a gradually 
narrowing  junction, the two immiscible phases are merged. Emulsification 
occurs in the junction, when a liquid thread forming droplets breaks up the 
flow of monomers, and there is an in-situ cross-linking of the droplets 
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produced, by photopolymerisation or polycondensation.46 The limitation of 
droplets, flow rates of fluids and reaction time are crucial parameters for 
generating monodispersable particles. The preparation of nano and micron-
sized microgels is most commonly by chemical or physical gelation of both 
synthetic and biological polymers. 
 
Figure 1.3 – Microchanel, droplet formation of aqueous monomer solution on 
continuous oil phase. 
Chemical gelation uses photo-induced polymerisation methods to cross-link 
monomer droplets that have been stabilized by surfactants and dispersed in a 
continuous phase. 
Physical gelation, by ionic cross-linking, can be achieved in a microchannel 
by internal and external gelation. During internal gelation, droplets of the 
polymer and a cross-linker precursor are present in the continuous phase, 
which also contains an activator that diffuses into the droplets and reacts with 
the cross-linking agent precursors, thus forming the cross-linker that causes 
gelation. Alternatively, during external gelation, the droplets are emulsified in 
the continuous phase that contains the cross-linker. The diffusion of cross-
linking agents inside the droplets leads to gelation.  
1.2.4.2.3.4 Biopolymers 
Biopolymers are produced by organisms and classic examples include: 
polypeptides like poly(lactic-co-glycolic acid), nucleic acids and sugars. 
Naturally occurring carbohydrate-based biopolymers such as chitosan, 
hyaluronan, and dextran are extensively used for nano and microgel 
preparation. They are especially interesting due to their high functional group 
content, which allows cross-linking, functionalisation and bioconjugation. 
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There are four main methods for preparing gels using biopolymers: water-in-
oil heterogeneous emulsion, aqueous homogeneous gelation, the spray drying 
method, and chemical cross-linking.  
Water-in-oil emulsion methods consist of the emulsification of aqueous 
droplets of water-soluble biopolymers in a continuous oil phase with oil-
soluble surfactants and the use of a water-soluble cross-linker. For example, 
the literature describes cross-linkable hyaluronic acid carrying a hydrazide 
being dissolved in water and homogenized in mineral oil containing Span. A 
hyaluronic acid with an aldehyde is added and homogenized. The aqueous 
phase is allowed to evaporate with stirring.47  
The aqueous homogeneous gelation method consists of covalent chemical 
cross-linking in a preparation of biopolymer-based nanoparticles in water. As 
an example, chitosan amine moieties were reacted with polyethylene glycol 
(PEG) dicarboxylic acid using water-soluble carbodiimide obtaining chitosan-
based nanogels.48  
Spray drying is widely used in the pharmaceutical industry to prepare a variety 
of formulations. The device used consists of a spray dryer, composed of an 
atomizer and a drying chamber. Solutions or suspensions of monomers and 
cross-linkers are atomized to fine droplets. A beam of hot air produces a quick 
evaporation of solvent from the droplets in the drying chamber, forming the 
particles. The particles obtained are recovered in a collector and are further 
dried in a vacuum. The size of the resulting particles is determined by the size 
of the nozzle, flow rate, atomisation speed, and the amount of cross-linker 
used.49 
Formation of nano and microgels by chemical cross-linking has been reported, 
including carbodiimide coupling,50 Michael addition,51 and free radical 
polymerisation.52 
1.2.4.2.3.5 Heterogeneous free radical polymerisation 
Heterogeneous polymerisation reactions of hydrophilic or hydrophobic 
monomers in the presence of difunctional cross-linkers have been mostly 
utilized to prepare synthetic nano and microgels. All the polymerisation 
methods have the same reaction in common: free radical polymerisation. 
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Radical reactions are used to polymerise a double bond of vinyl monomers 
and the carbon-oxygen double bond in aldehydes and ketones. Amongst the 
most common techniques are: inverse (mini)emulsion, inverse microemulsion 
dispersion, precipitation, and dispersion polymerisation. 
Inverse (mini)emulsion polymerisation and inverse micro-emulsion 
polymerisation  are water-in-oil polymerisations that  consist of aqueous 
droplets (including water-soluble monomers) being dispersed with the help of 
oil-soluble surfactants in a organic medium. For the inverse emulsion process, 
stable dispersions are formed by mechanical stirring. In the case of the inverse 
miniemulsion polymerisation the particles are formed by sonification. The 
difference between these two methods is that inverse microemulsion 
polymerisation produces thermodynamically stable emulsions, while inverse 
(mini)emulsion polymerisation forms kinetically stable macroemulsions 
around or below the critical micellar concentration (CMC). Polymerisation 
occurs inside the aqueous droplets upon addition of radical initiators, 
producing stable hydrophilic and water-dispersible colloidal nanoparticles.53  
Dispersion polymerisation is a technique that produces micron-sized particles 
with low polydispersity. To start with, the reactants such as monomers, 
polymeric stabilizers and initiators are dissolved in an organic solvent, 
forming a continuous phase. At the start the polymerisation there is a 
homogeneous reaction mixture; but as the polymerisation progresses the 
polymers formed become insoluble in the medium, eventually forming a stable 
dispersion of polymeric particles because of the presence of stabilizers. 
Dispersion polymerisation has frequently been applied in the preparation of 
hydrophobic polymers including polystyrene and poly(methyl methacrylate).54 
As with dispersion polymerisation, precipitation polymerisation starts with a 
homogeneous mixture of reactants. The polymers formed would be soluble in 
the medium but the presence of a cross-linker isolates particles as the growing 
chains are linked. As a result particles often have irregular shapes and a high 
polydispersity.55 
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1.2.4.2.3.6 Heterogeneous Controlled/living radical polymerisation 
Controlled living radical polymerisation yields polymers with a highly 
controlled molecular weight. Controlled living radical polymerisation is a 
specific kind of radical polymerisation, characterised by the complete absence 
of terminating reactions, where the active polymer chain end is a free radical. 
Various methods for controlled living radical polymerisation have been 
developed and applied to the preparation of cross-linked and non-cross-linked 
nanogels. Examples of controlled living radical polymerisation include atom 
transfer radical polymerisation (ATRP),56 stable free radical polymerisation 
(SFRP),57 and reversible addition-fragmentation chain transfer (RAFT) 
polymerisation.58 Controlled living radical polymerisation reactions of 
hydrophobic monomers have been broadly reported for heterogeneous 
aqueous dispersions, including conventional emulsion, microemulsion, 
(mini)emulsion, dispersion, and suspension. Although less often used, 
controlled radical polymerisation of water-soluble or hydrophilic monomers in 
heterogeneous media have also been described.59,60  
1.2.4.2.3.7 Homogenous polymerisation: High Dilution free Radical 
Polymerisation 
Contrary to the methods just described, high dilution free radical 
polymerisation is a method for obtaining nanoparticles where the reactants and 
final product are in solution. This method, which does not require the 
utilisation of a surfactant, is based on the dilution and stabilisation properties 
of the solvent to produce nanogels. Further discussion about this method can 
be found in Chapter II (Section 2.2). 
1.2.4.2.4 Nanogel applications 
Nanogels are versatile and easily tuneable systems that offer excellent 
properties for use in multiple biotechnological applications.  
Nanogels have been successfully used as environmental scavengers for water 
treatment. The nanogels absorb contaminants (e.g. heavy metal pollutants) 
from an aqueous solution. Imprinted nanogels have been studied as catalysts 
for biological and non-biological reactions (the Kemp elimination reaction).61 
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Nanogel sensors are broadly described in the literature; one of the most 
recently reported is a sensor for Cr3+ in an aqueous solution; where a nanogel 
with covalently labelled rhodamine B urea derivatives is utilized as a sensitive 
fluorescent probe.62 Their chemical properties make nanogels excellent 
candidates as scaffolds, for example in osteoblastic bone formation induced by 
using nanogel-cross-linking hydrogel.63 (Osteoblasts are cells, which secrete 
the substance to form bones). Their size, the high number of functional groups 
also makes nanogels efficient imaging probes when tagged or loaded with a 
fluorescent dye, for example fluorescent dextran-based nanogels, for tracking 
adipose-derived stem cells.64 However, the highest number of publications on 
nanogels describe drug delivery applications and these are further described in 
the following section. 
1.3 Drug Delivery Systems 
1.3.1 Delivery systems: overview 
Drug delivery systems are defined as technologies, formulations and devices 
engineered for the targeted delivery and, sometimes, the controlled release of 
therapeutic agents to achieve the desired therapeutic effect efficiently. Drug 
delivery systems aim to control the rate at which, and the location in the body 
where, a drug is released. Many medications have undesired side effects due 
to the drug interacting with body parts that are not the target of the drug. 
Administering drugs locally rather than systemically (affecting the whole 
body) is a common way to reduce side effects and drug toxicity, while 
increasing therapeutic effect.  
Medications can be taken in a variety of ways for a systemic effect: orally; 
placed under the tongue (sublingual) or between the gums and cheek (buccal); 
by inhalation sprayed into the nose and absorbed through the nasal membranes 
(nasally); by absorption through the skin; by intravenous injection (by 
injection into a vein); intramuscular injection (into a muscle); intrathecal (into 
the space around the spinal cord); subcutaneous injection (beneath the skin); 
insertion into the rectum (rectally) or vagina (vaginally); placed in the eye (by 
the ocular route) or the ear (by the otic route); breathed into the lungs, usually 
through the mouth (by inhalation) or mouth and nose (by nebulisation); 
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cutaneously for a local (topical); or delivered through the skin (transdermally). 
Each method has advantages and disadvantages, and not all methods can be 
used for every drug.  
Drug delivery systems consist of a vehicle and cargo (drug or active 
pharmaceutical entity). Finding the right carrier for a drug helps to ensure that 
the active ingredient reaches its destination intact. Researchers are also 
exploring the use of genes, proteins, and stem cells as a cargo for drug 
delivery systems. Currently, much of the research on drug delivery systems 
describes targeted devices that release their contents in specific sites of the 
body. Targeting strategies aim to develop a drug delivery system that has a 
known target, for example an organ, a tissue, disease specific structures (like 
proteins in tumour cells), or specific organelles inside cells that would reduce 
the side effects of systemic treatments. 
1.3.2 Nanoparticulate Drug Delivery Systems 
1.3.2.1 Introduction 
Nanoparticles have high surface area to volume ratio and, because of their 
size, they are able to interact with biological systems at the same scale. 
Nanoparticles can be formulated as aerosols (solids or liquids in gas), 
suspensions (solids in liquids) or as emulsions (liquids in liquids). 
Nanoparticles have been formulated for different administration routes, 
including the skin. The small size required to penetrate the skin, the fact that 
the skin is the biggest human organ and that topical drug delivery is one of the 
most patient-compliant administrative routes for drugs, have made this a fast-
growing research area. 
Particles for skin applications can be classified by the nature of the carrier: 
lipid base nanoparticles, such as liposomes, deformable liposomes, ethosomes, 
solid lipid particles and nanostructured lipid carriers; Surfactant based 
nanoparticles like niosomes and nanoemulsions; Finally, polymer based 
nanoparticles as dendrimers and polymeric nanocapsules/nanoparticles. A 
summary of these nanoparticle characteristics, the mechanism of penetration 
and the applications for dermal and transdermal drug delivery systems are 
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described in the following sections, to provide a better understanding of the 
context in which this project was developed.  
1.3.2.2 Nanoparticulate Drug Delivery Systems for the Skin 
1.3.2.2.1 Liposomes 
Liposomes are defined as thermodynamically stable, nano or micron sized 
vesicular structures of amphiphylic lipids arranged in one or more concentric 
bilayers with a hydrophilic core. Liposomes can be made of natural occurring 
phospholipids or synthetic compounds such as: phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, and 
phosphotidylionositol.65 During the preparation of liposomes by mixing the 
phospholipids in an aqueous medium, the phosphate heads of the 
phospholipids orient themselves to the hydrophilic environment, forming uni-
or multilamellar vesicles. Cholesterol is frequently added to improve the 
stability of the vesicles, increase the fluidity of the membrane, and prevent the 
leakage of the contents of the liposome. It is also common to incorporate into 
the liposome, stearylamine or diacetylphosphate, to give rise to a net positive 
or negative charge respectively.66 When trapping drugs inside liposomes, 
hydrophilic drugs are incorporated in the hydrophilic core, while lipophilic 
drugs are trapped within the bilayer of the liposomes. In general, the 
entrapment efficiency of hydrophilic drugs is higher than that of lipophilic 
drugs.65  
Liposomes can be classified according to the size of the vesicles, into those 
with small unilamellar vesicles (SUV) or large unilamellar vesicles (LUV). 
They can also be classified on the basis of the number of bilayers, into those 
with multilamellar vesicles (MLV) or those with unilamellar vesicles (ULV).  
Figure 1.4 – Structure of different types of liposomes  
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In 1982, Mezei and Gulasekharam first described the use of liposomes as a 
topical drug delivery system.39 Liposomes were able to deliver four- to five-
fold concentrations of a drug compared to a classic lotion. In contrast, it has 
been proved that liposomes have little potential for transdermal drug 
delivery.67 The ability of liposomes to penetrate the skin is believed to be 
influenced by their composition, size, number of lamella and charge. It is 
widely accepted that liposomes penetrate the skin because of the penetration-
enhancing properties of phospholipids. The composition of the liposomes with 
phospholipids of different phase transition temperatures, influences their 
penetration.68 In general, at skin temperature, lipids in the liquid state 
penetrate deeper than lipids in the gel state. Studies have shown that there is a 
low correlation between the skin penetration of liposomes and their size.67 
This is easily explained because liposomes may break down into smaller and 
less lamellar structures during skin penetration. Liposomes absorb and merge 
with the skin surface, favouring partitioning of hydrophobic drugs. In contrast, 
complete liposomes penetrate through the appendage pathway; merge with the 
sebum, slowly releasing the drug.69 As a consequence, liposomes have mainly 
been used to target the follicles.70 Contradicting studies have shown that the 
effect of the surface charge on the skin penetration of liposomes is not clear, 
some studies claim that cationic71 liposomes penetrate better than anionic 
liposomes, whereas others have shown the opposite.72 
1.3.2.2.2 Deformable liposomes (or transferosomes) 
Deformable liposomes were developed to overcome the limited ability of 
conventional liposomes to penetrate the skin. To address the problem Cevc et 
al.73 developed a new class of deformable liposomes, the new element being 
the presence of an edge activator. These are surfactants (usually Span, Tween, 
sodium cholate, sodium deoxycholate, dipotassium glycyrhizinate, and oleic 
acid) that destabilize the vesicle, giving it more flexibility. Due to their high 
deformability, transferosomes squeeze through skin pores (20–30 nm), which 
are one-tenth of their size and reach deeper layers in the skin. The osmotic 
gradient caused by the hydration difference between the skin surface and the 
viable epidermis drives the skin penetration of deformable liposomes. 
Transferosomes have been shown to increase the delivery of drugs to and 
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through the skin into systemic circulation.73 The success of deformable 
liposomes in topical or systemic delivery depends on the amount of 
transfersomes applied per unit area of the skin. When reduced amounts of 
transfersomes are applied they only penetrate to a limited depth, before 
degradation occurs. Increasing amounts saturate the skin layers and then the 
transfersomes enter into systemic circulation. In contrast with conventional 
liposomes, transferosomes can penetrate the skin without breaking up and do 
not penetrate through the appendage pathway.74 Verma et al.75 found a direct 
correlation between the size of transferosomes and skin penetration; small 
transferosomes (around 300nm) were found to penetrate further than larger 
(600nm) transferosomes. As with conventional liposomes, the composition 
and membrane fluidity affect the skin penetration abilities of transferosomes.76 
1.3.2.2.3 Ethosomes 
Ethosomes were first reported by Touitou in 1985. Ethsomes are ethanol-
containing, phospholipid vesicles (with concentrations of ethanol from 20% to 
45%). The lipids and the drug are dissolved in ethanol, and it imparts high 
flexibility and malleability to the vesicles. Further mixing with an aqueous 
phase produces small (50–200 nm) multi-lamellar vesicles. Ethosomes are 
smaller than conventional liposomes.77 Generally speaking, the higher the 
alcohol content, the smaller the vesicle size and the higher the concentration of 
ethanol, the more unstable the vesicles. 78 Because of the presence of alcohol, 
encapsulation efficiencies of lipophilic drugs can be achieved due to the 
enhanced solubility.67 Ethosomes enhance drug permeation through the skin 
by releasing ethanol, which increases the fluidity of skin lipid membranes and 
partition enhancement. Ethanol provides the flexibility that helps the 
penetration of intact ethosomes. A study by Touitou et al. using ethosomes 
loaded with a hydrophilic fluorescent probe, penetrated to a depth of 160 µm 
in excised mouse skin, compared with 80 µm for a hydroalcoholic solution 
(30% ethanol) and and 60 µm for conventional liposomes.79 
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1.3.2.2.4 Lipid Nanoparticles 
Lipid nanoparticles are made of solid lipids or a combination of solid and 
liquid lipids which do not melt at room or body temperature.80 There are two 
kinds of lipid nanoparticles: solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC).81 NLC are made of a mixture of solid and 
liquid lipids while SLN are only composed of solid lipids. The fact that NLC 
contain liquid lipids makes them more flexible than SLN and this affects the 
encapsulation of the drug and its release. In SLN the drug is trapped in 
between the voids in the crystal lattice,82 whereas the NLC matrix has more 
imperfections and therefore higher drug entrapment takes place.83 SLN are 
usually made of highly purified lipids, such as tristearin, while NLC are 
prepared with mixtures of mono-, di-, and triacylglycerols, including 
monoacids and poly(acid acyl) glycerols. Encapsulation (percentage of drug 
incorporated) for lipophilic drugs is around 90–98%, whilst for hydrophilic 
drugs it is significantly lower (20–30%). There are two main methods of 
preparing lipid nanoparticles, hot or cold high-pressure homogenisation. In 
both methods, the solid lipid is melted and the drug is dissolved in the lipid 
matrix.  
 
Figure 1.5 – Structure of lipid nanoparticles 
Lipid nanoparticles form an occluding film when applied to the skin that leads 
to increased skin hydration and reduces the corneocyte packing, leading to a 
better skin penetration.84 The nanoparticle lipids interact with the skin lipids 
and act as penetration enhancers. Lipid nanoparticles can be incorporated into 
conventional topical formulations such as creams, gels or lotions.85  
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1.3.2.2.5 Niosomes 
Niosomes are self-assembled vesicles of non-ionic surfactants, with closed 
bilayer structures similar to, but much more stable and less expensive than 
liposomes.86 Unlike conventional liposomes, the hydrophobic part of the 
surfactant faces toward the core, whilst the hydrophilic parts face the aqueous 
media. Niosomes are made of amphiphilic surfactants that present a 
hydrophilic head group and a hydrophobic tail. The hydrophobic tail is an 
alkyl chain made of 12 to 18 carbons. The hydrophilic head groups include 
ethylene oxide, glycerol, crown ethers, polyhydroxy groups, sugars and amino 
acids. The most commonly used non-ionic surfactants are Span and Brij. 
Cholesterol and its derivatives are included in niosomes as steric stabilizers to 
prevent aggregation and the phase transition of niosomes from the gel to liquid 
state, thereby reducing drug leakage from inside the niosomes.87 Aggregation 
can be reduced further by the addition of charged molecules such as dicetyl 
phosphate, which prevents aggregation by charge repulsion. 
The literature contains examples of hydrophilic and hydrophobic drugs 
encapsulated in niosomes. To upload the drug into the niosomes two 
techniques are used: a dehydration-rehydration technique, and the creation of a 
pH gradient within both the aqueous solution and the niosomes. In vitro 
testing has shown that the rate of drug release from the niosome is dependent 
on the surfactant type and its phase-transition temperature.86 In the literature, 
thermoresponsive niosomes that release the encapsulated drug when heated 
above 35°C have been reported, eg in sunscreen, formulations in which the 
contents of niosomes are released upon exposure to the sun.86 Fang JY et al.88 
describe span niosomes that showed significantly higher skin permeation and 
partitioning of enoxacin than those shown by liposomes and the control free 
drug. These niosomes were mainly localized in the stratum corneum, but 
experimental evidence shows that they can penetrate deeper layers of the skin 
by dissociating. Moreover, the flexibility of niosomes in the skin is supported 
by the fact that a decrease in cholesterol content increases the drug penetration 
through skin strata.89 Additionally, non-ionic surfactants are penetration 
enhancers that modify the intercellular lipid structure in the stratum corneum 
to enhance skin permeability.90  
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1.3.2.2.6 Nanoemulsion 
Nanoemulsions are kinetically stable oil-in-water emulsion systems, stabilized 
by a thin layer of emulsifier (surfactants). Generally, they appear to be either 
transparent, if the droplet size is under 100 nm, or milky when it is higher.91 
Thermodynamically speaking, nanoemulsion formation is a non-spontaneous 
process and a large amount of emulsifier or energy is required to break a 
droplet of submicron size into smaller ones. The formation of a nanoemulsion 
is dependent on the right combination of oil, water, surfactant, and co-
surfactant at very specific ratios. Frequently, a co-surfactant (an amphiphile) is 
used to lower interfacial tension and fluidize the surfactant, thereby further 
reducing the fluidity of the water-oil interface and thereby increasing the 
entropy of the colloidal system.92 Non-ionic and zwitterionic surfactants are 
commonly used in nanoemulsions because of their tendency to be less toxic 
and irritant than their anionic, and particularly their cationic, counterparts. The 
selection of the right oil phase is crucial in a nanoemulsion formulation as it 
dissolves hydrophilic drugs. Edible plant-seed oils, such as flaxseed and 
soybean oil, are readily ingested and raised virtually no safety issues. Hence, 
they are often used in oral administration formulations. Nananoemulsions are 
dynamic systems and the phases are in equilibrium, making it difficult to 
characterize them. As these systems have water and oil phases, both 
hydrophilic and hydrophobic drugs can be delivered using nanoemulsions.  
 
Figure 1.6 – Structure of nanoemulsion 
 
The surfactants on nanoemulsions can modify the intercellular lipid structure 
and act as penetration enhancers. The oil phase is an occluding agent and can 
increase skin hydration. Nanoemulsions have been found to penetrate further 
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than macroemulsions.93 Controversially, a comparative study of 
macroemulsions and nanoemulsions found no significant difference in the skin 
penetration of an anaesthetic drug.  Izquierdo P et al.94 hypothesise that the 
reason for this is that emulsion droplets may collapse and merge with the skin 
and so the size of the emulsion particles may have no impact on skin 
penetration. Nanoemulsions have also been shown to penetrate through the 
hair follicles.95 
1.3.2.2.7 Dendrimers 
Dendrimers are three-dimensional, branched, spherical polymers. The particle 
size of dendrimers can be very small (from 1 to 10 nm). Dendrimers can 
encapsulate the drug inside the core (nanocontainers), they can bind the drug 
to their structure, or they can be joined to the surface functional groups 
(nanoshells). Dendrimers have a large number of surface functional groups 
that can be linked to high amounts of a drug or be linked to recognising units 
(for targeting). Only a few studies have explored the potential of dendrimers 
for transdermal drug delivery.96 Studies with fluorescent-labelled 
poly(propyleneimine) dendrimers  have shown that the penetration of 
dendrimers is dependent on their surface charge (cation dendrimers being 
better).97 The skin penetration of these cationic dendrimers is not fully 
understood but it is mainly localized to the stratum corneum, viable epidermis, 
and hair follicles. Possible mechanisms include increased drug solubility and 
higher skin partitioning. The use of dendrimers has shown an increase in the 
skin penetration of both hydrophilic and hydrophobic drugs compared to the 
free drug.98,99  
 
Figure 1.7 – Structure of a dendrimer 
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1.3.2.2.8 Polymeric Nanocapsules and Nanoparticles 
1.3.2.2.8.1 General 
Nanocapsules and nanoparticles made of synthetic or naturally occurring 
polymers, can be used to form drug delivery systems where the drug is 
entrapped in the core or dispersed in the polymeric matrix, respectively. Drugs 
can be absorbed, complexed, covalently linked or conjugated to the 
nanoparticles. In the literature, a variety of materials have been used for 
preparing such nanoparticles as topical or transdermal drug delivery systems. 
Amongst the most reported are: poly(vinyl alcohol)–fatty acid copolymers,100 
tyrosine-derived copolymers,101 poly(lactide-co-glyocolide),102 
polymethacrylate,103 poly(butylcyanoacrylate),104 poly(caprolactone)105,106 and 
chitosan.107  
 
Figure 1.8 – Structure of nanoparticle and nanocapsule 
 
The two most common methods for preparing drug loaded nanoparticles/ 
nanocapsules are by solvent evaporation and solvent displacement.108 In the 
case of the solvent evaporation technique, the polymer is dissolved in an 
organic solvent. This organic phase is dispersed in an aqueous phase 
containing the surfactant and then emulsified with the help of sonication or a 
high-pressure homogenizer. Afterwards, the organic solvent is removed from 
the system by evaporation under reduced pressure or by evaporation under 
continuous stirring to obtain polymeric nanoparticles. When using this 
technique, a hydrophobic drug is dissolved in the organic solvent, for 
uploading into the polymeric matrix. In the second method, solvent 
displacement, the polymer is dissolved in a water-soluble organic solvent and 
injected into an aqueous medium and stirred in the presence of the surfactant. 
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Polymer deposition on the interface between the water and the organic 
solvent, caused by fast diffusion of the solvent, leads to the instantaneous 
formation of a colloidal suspension. 
It is widely accepted in the literature that polymeric nanoparticles only reach 
the stratum corneum and any further penetration is the skin is achieved by 
penetration through the follicles. Alvarez-Roman et al.109 studied the effect of 
size in penetration through pigskin, by using fluorescent-tagged, polystyrene 
latex nanoparticles of 20 and 200 nm. The results show that no particles were 
found in the korneocytes or intercellular spaces but they accumulated in the 
follicles where more 20nm nanoparticles were found. Vogt et al.110 obtained 
similar penetration results by testing 40, 150 and 750 nm nanoparticles in 
excised human skin, using polystyrene-based spheres, internally dyed using 
solvent swelling dye entrapment. The large particles of 750 and 150 nm, did 
not penetrate the follicles, whereas the 40 nm nanoparticles were found to 
accumulate there.  
To take advantage of this accumulative behaviour of nanoparticles, the 
potential of the hair shaft as a drug-reservoir has been investigated. 
Fluorescent poly(lactide-co-glycolide) nanoparticles in the range of  300 to 
400 nm were applied to human volunteers.111 By tape-striping the skin and 
visualisation on the confocal microscope, the nanoparticles were detected in 
hair follicles even 10 days after application, while the particles on the stratum 
corneum were cleared after 24 hours. The storage reservoir capacity of the 
stratum corneum and the hair follicle infundibulum and canal were compared, 
demonstrating a 10 times longer storage within the hair follicles. The authors 
hypothesised that the rigid hair shaft acts as a geared pump, moving the 
particles deeper into the hair follicle.  
The literature also contains studies on the influence of the surface charge on 
the polymeric nanoparticles and the permeation through the skin. In a 
comparative study using positive, negative, and neutral latex nanoparticles, 
ranging from 50 to 500 nm, it was found that only the negatively-charged 
nanoparticles of 50 and 500 nm were able to penetrate the stratum corneum 
and reach the viable epidermis.112 Positively-charged and neutral particles of 
all sizes, and negatively-charged particles of 100 and 200 nm, did not 
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penetrate. Particles that permeated were both negatively-charged and did not 
follow a size dependency. The larger surface of the smaller 50 nm particles 
and the high charge density in 500 nm particles were significant factors in 
their higher skin penetration. The higher penetration is attributed to the charge 
repulsion between the negatively-charged skin lipids and the carboxylate 
groups in the negatively-charged nanoparticles.  
NIPAM-based nanogels, a subclass of polymeric nanoparticles, are the focus 
of this thesis. The general characteristics and the use of these materials for 
skin applications are described in the following section. 
1.3.2.2.8.2 NIPAM nanogels for Skin Drug Delivery  
Penetration studies 
In the last decade, two active groups have studied NIPAM micro and nanogels 
for skin applications. Both research teams prepared particles based on NIPAM 
because of their thermoresponse or VPTT (volume phase transition 
temperature) close to body temperature. NIPAM nanogels shrink delivering 
their load (drug). In depth explanations of this properties can be fund in 
Section 1.5.3 of this Chapter. Their research has focused on obtaining NIPAM 
drug delivery systems for the skin, which were usually tested using Franz 
Cells with porcine and human skin. 
The Franz Cell apparatus is an in vitro skin permeation assay, frequently used 
in the development of topical formulations. The cell consists of two primary 
chambers separated by a membrane. Human excised skin, animal tissue 
(usually ear skin), polymeric membranes and human skin equivalents can be 
used for the testing. The formulation is applied to the membrane via the top 
chamber. The bottom chamber is maintained at a constant temperature of 37°C 
and contains fluid from which samples are taken for permeation analysis at 
regular intervals. A Franz cell assay determines whether a particular 
formulation delivers a drug through the skin. Testing has poor reproducibility, 
particularly when using synthetic membranes (where tissue associated 
variability has been removed).113 
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Figure 1.9 - Scheme of Franz Cell 
 
In 2004 Snowden et al.114 used NIPAM-co-butylacrylate MBA (N,Nʹ-
methylenebis acrylamide) cross-linked microgels. The particle size at room 
temperature was approximately 480 nm. When they uploaded ibuprofen, the 
size increased to 570 nm. Methylparaben and propylparaben were also 
uploaded. No purification method is described for the free drug (not 
uploaded). Samples were tested in a Franz cell using excised human skin. The 
paper compares the saturated solution of the drugs with a saturated solution of 
the drugs with thermoresponsive microgels, and reports that the second 
formulation transported the drug through the skin. In 2005 they described the 
results of NIPAM-co-butyacrylate-co-methacrylic acid microgels (around 800 
nm in the swollen state), uploaded with salycilamide, methyparaben and 
propyl paraben.115 The paper compares results from a solution of the drugs 
with those from a solution of pH-thermoresponsive microgels containing the 
drugs. The Franz cell experiment concluded that there had been no difference 
in drug release in different pH. On the other hand, no experiments on the 
effect of thermoresponsivness in drug release were reported. 
In 2010 Heard et al.116 used (NIPAM-co-acrylic acid), MBA cross-linked 
nanoparticles of 250 nm and 350 nm, which they put in a Franz Cell, using 
porcine ear skin. The penetration of the formulation through skin was proved 
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by observing what the buffer solution contained in the receiving compartment, 
using TEM analysis and visualising the nanoparticles. Citric acid was used as 
a pH modulator. The thermoresponse of the nanogels was analysed by DSC at 
20mg/mL, and obtained a thermoresponse of 33°C and 31°C respectively. The 
paper concludes that (NIPAM-co-acrylic acid) penetrated the skin better and 
the use of the pH modulater enhanced the penetration further.  
Later in the same year, Heard et al. used NIPAM-co-butylacrylate particles 
and uploaded Methotrexate.117 The calculated uploaded efficiency was around 
32%. The paper describes the use of a Franz Cell (with porcine skin) to 
quantify the permeation of the methotrexate. The paper also includes a study 
of the hydrodynamic radius of the nanoparticle against temperature 
(performed at 0.1w/v%). At 10°C the macrogel has a size of 270 nm, which 
slowly decreases with increasing temperature to approximately 150 nm at 
30°C, finally dropping to 100 nm at approximately 60°C. The particles did not 
present a sharp transition temperature, unlike a linear NIPAM polymer. A 
complementary study of the effect of the drug in inhibiting the biosynthesis of 
prostaglandins in the skin, concluded that the biosynthesis of PGE3 
(prostaglandins) was reduced by the drug transported in the nanogels.  
In 2012 a further paper by Heard et al. described the penetrating abilities of 
NIPAM-co-acrylic acid and NIPAM-co-butylacrylate nanogels through a 
porcine ear in a Franz cell.118 The effect of both nanoparticles on the 
expression of COX-2 (pro-inflammatory response) was studied. The paper 
concludes that NIPAM-co-Acrylic Acid was more skin-compatible. In 2013, 
the authors reported work on NIPAM and NIPAM-co-acrylic acid, MBA 
cross-linked and loaded with caffeine (with an entrapment efficiency of 25-
30%).119 The study of the thermoresponse of the non-uploaded particles 
showed a transition temperature starting from 30°C and finishing at 40°C for 
both microgels (measured at 0.1w/v%). There was no difference in the 
thermoresponse only in their size. The thermoresponse of the uploaded 
microgels was measured by DSC, at 50%w/v obtaining a VPTT of 
approximately 32°C for the NIPAM polymer and 37°C for the NIPAM-co-
acrylic acid microgels. The study of the in vitro drug release, using a Franz 
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Cell with porcine ear, showed a better performance for the NIPAM-co-acrylic 
acid macrogels. 
None of the papers described above, studied the drug release of the uploaded 
particles at different temperatures nor do they explain the mechanism by 
which the microgels penetrated the skin; which would be of interest, as the 
literature suggests that particles above 40nm hardly penetrate the stratum 
corneum. 
Toxicological studies 
There are several publications on testing NIPAM nanogels in different cell 
lines. Naha et al. describe cell viability as not being different from a control of 
untreated cells (keratinocytes and colon cells), with up to 1mg/mL of NIPAM, 
MBA cross-linked nanogels of 50-90 nm tested for 48h.120 The authors linked 
the nanogels through an ester bond to a Rhodamine derivative in order to track 
the nanogels inside the cell and conduct co-localisation studies. Nanogels were 
found in the lysosomes after 24h. A genotoxicity test was also carried out to 
determine the cause of cell death; no damaged DNA was observed.  
Qian et al.121 tested HeLa cells with 50 nm MBA cross-linked NIPAM 
nanogels. The nanogels also carried an isoquinoline derivative linked by an 
ester bond. The nanogels were found in the lysosomes after 30min. The 
fluorescence was studied with the pH and temperature. The authors found that 
more particles were internalised at 37°C than at 25°C and that the fluorescent 
tag showed different fluorescence, being higher at higher temperatures.  
Nguyen et al.122 tested MBA cross-linked, NIPAM nanogels of 100-200 and 
500 nm in three different cell lines: fibroblasts, human aortic smooth muscle 
cells and human micro-vascular endothelial cells. The cell viability tests gave 
impressive results of up to 1mg/mL, proving that the materials show no 
cytotoxicity for an exposure of up to 96h. The unreacted monomer was 
quantified to identify the possible effect on the cytotoxicity of the monomers. 
No difference in cytotoxicity was identified in relation to the size of the 
microgels.  
Mozumdar et al.123 made studies of cell viability using HeLa cells of MBA 
cross-linked, NIPAM-co-vinylpyrrolidone nonogels of 170 nm and 400 nm. 
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The maximum concentration tested successfully was 0.2 mg/mL. The authors 
uploaded the microgels with BSA and identified a zero order profile for the in 
vitro drug release.  
In general, the conclusion to be drawn from these publications is that NIPAM 
nanogels are a promising material for achieving the necessary, low 
cytotoxicity reported in the literature. The fluorescent tag nanoparticles seem 
to indicate that nanogels can be internalised into cells. All the systems 
described have a covalently linked fluorescent moiety, with an ester bond 
widely known to be hydrolysed in vivo and in vitro, so the presence of the 
nanoparticle is uncertain. 
1.3.2.3 Summary of nanoparticles for Skin Drug Delivery Systems 
After the description of all these drug delivery carriers there are four factors 
that affect the skin penetration abilities of the nanoparticles: size, flexibility, 
charge and lipophilicity. 
Reviewing the literature on nanosystems for the skin, there is no clear 
consensus on the optimal size for skin penetration. The influence of particle 
size on skin penetration is complex and linked to the physicochemical 
properties of the carrier, including the shape and the formulation in which it is 
incorporated. The few successful passive diffusion transdermal drugs have a 
molecular size with a hydrodynamic radius of less than 2 nm, whereas the skin 
pore size varies from 2 to 30 nm. Furthermore, the presence of appendages 
provides an additional transport pathway, although this pathway accounts for 
only 0.1% of the skin surface, it appears to be an important pathway for 
particulate systems.  
Rigid vesicles, or particles, deposit in the hair follicles. The follicles can also 
serve as a long-term reservoir for surrounding cells in the skin. On the other 
hand, the intercorneocyte penetration of particles is dictated by the flexibility 
of the carriers and their interaction with the intercellular lipids.  
The surface charge on the nanosystems also plays a significant role in skin 
penetration. It is known that the skin carries a negative charge at the 
physiological pH due to the carboxyl residues from skin proteins and lipids. 
Surprisingly, even negatively-charged liposomes and polymeric nanoparticles 
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have been found to penetrate the skin very well. On the other hand, in case of 
dendrimers, the positively-charged dendrimers penetrated better than the 
negatively-charged or neutral dendrimers. The difference may be due to the 
other skin–carrier interactions, in addition to the charge interactions. 
Stability of the nanosystem is important for drug delivery. Generally speaking, 
lipid vesicles are unstable and suffer from drug leakage and fusion of the 
vesicles in the long term. On the other hand, solid lipid nanoparticles, 
nanostructured lipid carriers, and polymeric nanoparticles have excellent 
stability. Furthermore, the polymeric nanoparticles and lipid nanoparticles are 
better in terms of sustaining the drug release over other systems. Of the 
various nanosystems, solid lipid nanoparticles, liposomes, nanoparticles and 
nanoemulsions appear to be promising for topical drug delivery, whereas 
ethosomes and ultradeformable liposomes offer good potential for both topical 
and systemic drug delivery. In addition to passive delivery, these nanosystems 
can be combined with active penetration enhancers further to boost drug 
delivery through the skin. 
To summarise the findings on the nanoparticles for drug delivery systems: 
polymeric nanoparticles can be uploaded with hydrophilic and lipophilic 
drugs, have a very good sustained drug release profile, are highly stable, have 
low irritation potential (absence of surfactant) and are, in general, good for 
topical drug delivery and poor for systemic delivery. 
 
1.4 Skin  
1.4.1 The importance of the skin 
The skin is the biggest human organ, accounting for 15% of the body weight 
and measuring about 1.7 square meters for an adult.124 Skin varies in thickness 
according to anatomical site, gender and age of the individual. Skin thickness 
varies from 0.04 mm on the eyelids to 1.4 mm on the sole of the foot. 
1.4.2 Functions 
The skin is a protective barrier against pathogens, impacts or pressure, 
microorganisms, radiation and chemicals. It controls water loss by sweating, 
Chapter I: Introduction 
 47 
and regulates temperature by insulating.125 Skin contains an extensive network 
of nerve cells that detect changes in the environment. The functions of the skin 
can be classified as: (1) protection (UV, dehydration, microrganismes), (2) 
sensation (pressure, hot/cold, pain), (3) temperature regulation (release of 
sweat or regulating blood flow), (4) immunity (Langerhan cells and 
phagocytic cells detect and eliminate pathogens), (5) mechanical (permits 
movement and growth, skin is extremely flexible), (6) excretion (elimination 
of water, urea, ammonia and uric acid), (7) endocrine (synthesis of Vitamin 
C). 
1.4.3 Structure 
Skin can be divided into three layers, each one of them divided into more sub-
structures. There are three main layers, starting from the exterior, the 
epidermis, the dermis and the hypodermis (or subcutaneous layer).126 
 
Figure 1.10 – Morphology of the skin and skin layers (epidermis, dermis and 
hypodermis). Redrawn from WebMed.com 
 
1.4.3.1 The epidermis 
1.4.3.1.1 General functioning 
The epidermis is the waterproof layer that acts as a barrier against infections. 
It has no blood vessels and it is formed by four cell types, keratinocytes, 
Merkel cells (touch receptors), melanocytes (pigment producing cells) and 
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Langerham cells (antigen-presenting immune cells). It is, itself, divided into as 
many as 5 layers, depending on the location; starting from the exterior: 
stratum corneum, stratum lucidum, stratum granulosum, stratum spinosum and 
stratum basale or germinativum.127  
The epidermis is maintained by the division of cells in the basale layer. The 
new cells change structure (shape) and composition while going up through 
the strata. This process is assisted by the progressive and increasing lack of 
blood flow. Cells lose their nucleus and organelles and become almost 
completely filled with keratin, a fibrous structural protein. Metabolism ceases 
and the cells enter programmed death. Eventually, cells reach the uppermost 
layer (the stratum corneum) where there is a gradual desquamation. Cells are 
constantly shed and replaced.  This cornified, or keratinized layer of the 
epidermis is responsible for making the skin a barrier to infection and water 
loss. Keratinocyte cells contain a structural matrix of keratin, which makes 
this layer of the skin almost waterproof and, together with collagen and 
elastin, gives skin its flexibility and strength. Constant rubbing and pressure 
cause thickening of this cornified layer and may form protective calluses.  
 
Figure 1.11 – Detailed structure of the epidermis structure 
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1.4.3.1.2 The epidermis structure 
The stratum basale 
The stratum basale is the innermost layer of the epidermis, adjacent to the 
dermis, and is between 1 and 3 cells thick. It is made up of constantly dividing 
keratinocytes, which are themselves attached to the base membrane by 
hemidesmosomes, protein structures that attach a cell to the extracellular 
matrix. In addition to the keratinocytes, the stem cells of the epidermis, there 
are also melanocyte, Merkel and Langerhans cells. Melanocytes contain 
melanin, the pigment which provides protection against ultraviolet radiation, 
and are characterised by their ability to grow dendrites, which stretch over 
neighbouring keratinocytes. Langerhans cells are dendritic, immunologically 
active cells derived from the bone marrow. Although found throughout the 
epidermis, they are mainly located in the stratum spinosum, where they play a 
significant role in the immune reactions of the skin (antigen-presenting cells). 
The stratum spinosum is formed when the stratum basale cells divide. 
The stratum spinosum 
As basal cells mature, they move up towards the outer layer of skin, forming 
the stratum spinosum. The stratum spinosum is in between the basale and the 
granulosum. In this layer, keratinisation begins and the keratinocytes become 
polyhedral. Their nucleus produces cytokeratin, which aggregates to form 
tonofibrils, desmosomes and intercellular bridges between adjacent 
keratinocytes.  
The stratum granulosum 
In the stratum granulosum the keratinocytes flatten, lose their nuclei and 
organelles and form Keratohyalin granules, which bind the keratin filaments 
together. The cells start secreting keratinosomes (or lamellar bodies), which 
fuse with the cell membrane and release their contents into the extracellular 
space. They are full of the lipids (ceramides), proteins and enzymes that are 
required for skin shedding (in the stratum corneum) and form a hydrophobic 
lipid-containing membrane that serves as a water barrier.  
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The stratum lucidum 
The stratum lucidum is a layer only present in areas of thick skin, e.g. the 
palms of the hands, soles of the feet and sometimes the knees, elbows, 
knuckles, where it helps reduce the friction and shear forces between the 
stratum corneum and the granulosum. It is formed of layers of dead 
keratinocytes filled with eleidin, an intermediate form of keratin. 
The stratum corneum 
The stratum corneum is the outermost layer of the epidermis and consists of 
flat hexagonal-shaped, non-viable corneocyte cells with neither nuclei nor 
organelles. The cytoplasm of these cells is full of keratin. In most areas of the 
skin the thickness is 10-40 mn.128,129 
Each corneocyte is surrounded by a protein envelope and is filled with water 
retaining, keratin proteins. The cellular shape and orientation of the keratin 
proteins add strength to the stratum corneum. The extracellular space contains 
stacked lipid bilayers. It is as if the corneocytes are the bricks and the lipid 
layer is the mortar in this wall of skin.130 
The resulting structure provides the natural physical and water-retaining 
barrier of the skin. The corneocyte layer can absorb three times its weight in 
water but if its water content drops below 10% it no longer remains pliable 
and cracks.  
The movement of epidermal cells up to this layer usually takes about 40-56 
days and this is known as the epidermal transit time. The process of shedding 
cells balances the formation of new keratinocytes in the stratum basale. 
1.4.3.2 The dermis 
The dermis is the layer of the skin beneath the basale layer of the epidermis 
and above the hypodermis. It is connected to the epidermis by a basement 
membrane. Its main cells are fibroblasts (which synthesise the extra-cellular 
matrix and collagen), macrophages (which find and digests cellular debris, 
microbes, foreign substances, and cancer cells) and adipocytes (for fat 
storage). The dermis is made of collagen (about 70%), which gives it strength 
and toughness; elastic fibre, which gives elasticity (elastin protein); and 
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reticular dermis (glycoaminoglycans, proteoglycans and glycoproteins) that 
provide viscosity and hydration.131 
The dermis contains nerve endings, hair follicles, sweat, apocrine and 
sebaceous glands, and also the lymphatic and blood vessels that nourish and 
clear the basale layer of the epidermis and the dermis. 
The dermis varies in thickness from 0.6 mm on the eyelids to 3 mm on the 
back, palms and soles. The dermis is divided into the papillary region (thinner) 
and the reticular region (thicker).  
The papillary region is composed of loose connective tissue, made up of 
finger-like structures called papillae, which penetrate the epidermis, 
strengthening the connection between the two layers of skin. 
The reticular region is beneath the papillary region, is composed of dense, 
irregular, reticular fibres and also contains the hair roots, sebaceous glands, 
sweat glands, receptors, nails, and blood vessels. 
1.4.3.3 The hypodermis 
The hypodermis mainly contains fat (stored in cells called adipocytes, which 
account for 50% of the body’s fat) and provides insulation and padding. The 
hypodermis is composed of connective tissue that links the skin to the bone 
and muscle and contains blood vessels and nerves.126 
1.4.4 Drug delivery to and through the skin 
1.4.4.1 Overview 
Topical application of drugs can be divided into treatments for the skin and 
those for systemic diseases. In the first case the drug stays in the skin and in 
the latter, it goes through it. Drugs have been formulated in the form of 
creams, powders, gels, solutions, pastes, sprays, suspensions, ointments, 
emulsions, and patches. Dermatological formulations deliver medicaments to 
treat skin disorders such as, eczema, acne, and psoriasis. For all these 
dermatological preparations it is important to maximize drug retention in the 
skin, while avoiding systemic circulation. On the other hand, the aim of 
transdermal applications is to boost drug absorption in systemic circulation. 
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The nature of the drug formulations is critical, since it affects the rate and 
extent of drug penetration into skin or into systemic circulation. 
1.4.4.2 Advantages of topical applications 
Dermal and transdermal drug delivery is one of the most patient-compliant 
administrative routes for drugs. The skin is a large and readily accessible 
surface for absorption. Cutaneous drug delivery improves the efficacy of the 
drug because of its continuous release. The toxicity is reduced, because there 
are no peaks, and the total dose can be reduced, because it avoids the hepatic 
first-pass metabolism and the gastro intestinal side effects/metabolism 
(reducing the overall cost of the treatment). Finally, the treatments are easy to 
terminate. 
1.4.4.3 The challenges 
Drug delivery through or to the skin presents some problems. The formulation 
may cause skin irritation or a possible allergic reaction to the drug or the 
excipients. In cases where the drug diffusion through the skin is poor, 
penetration enhancers are added to the formulation that boost the penetration 
abilities of the drug by disrupting skin bilayers and damaging the skin barrier 
properties. For the transdermal delivery of drugs to be efficient, the 
concentration required in plasma has to be low, in order to be considered a 
viable route of administration. In addition, enzymes in the epidermis may 
destroy the drug. So far, only a few drugs, with a diameter of 2 nm have been 
able to penetrate the skin. 
1.4.4.4 Drug penetration pathways and diffusion 
The dense layer of corneocytes in the stratum corneum presents the main 
resistance to penetration through skin. There are two pathways that a drug can 
follow to pass through the skin, transepidermal and transfollicular.132 
Transepidermal penetration is at the same time subdivided into two different 
possibilities; intracellular or transcellular (through the corneocytes) and 
parcellular (through the lipid layers around the coreneocytes). The 
transfollicular route uses the hair follicles and pores, which account for 1% of 
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the surface of the skin, to access the dermis, using the sebaceous and eccrine 
glands.  
 
 
Figure 1.12 – Penetration routes through the skin:  paracellular, transappendageal 
(transfollicular) and transcellular. Redrawn from Medscape.com 
 
The stratum corneum barrier is lipophilic, with the intercellular lipids forming 
a route through which drugs must diffuse to reach the vascular system and 
systemic circulation. For this reason, lipophilic drug molecules are better at 
penetrating the stratum corneum. A molecule must first be liberated from the 
formulation and released into the first layer of the stratum corneum, before 
diffusing through the entire thickness, and it must then pass into the more 
aqueous viable epidermis underneath. Ideally, a drug must be amphiphilic 
(soluble in lipids and water): however, if it is too hydrophilic, the molecule 
will be unable to penetrate into the stratum corenum; if it is too lipophilic, the 
drug will remain in the stratum corneum. 
As healthy skin provides a significant barrier to drug absorption, the 
parameters that affect the permeability of this barrier are significant. While 
cutaneous effects are usually achieved by using a semi-solid formulation (gel, 
cream, ointment), systemic administration is usually achieved by using 
patches. 
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In both cases, the drug is administrated at the surface of the skin for diffusion 
through the stratum corneum. Transdermal drug delivery is governed by 
Fick’s law of diffusion,133  in which the stratum corneum is considered a 
limiting membrane that allows permeation at a steady flux of a drug J (rate of 
absorption) described by the following equation: 
! = !"#ℎ  
 
Where D is the diffusion coefficient, K the partition coefficient (membrane 
vehicle partition coefficient), C the concentration of drug in the vehicle and h 
the thickness of the membrane. From the equation, the importance of the 
vehicle in drug penetration can be inferred. Firstly, the vehicle has to be able 
to dissolve the drug (C is greater) and, secondly, the partition coefficient K, 
defined by the following equation, describes the ability of a drug to transfer 
from the vehicle (V) to the stratum corneum (SC): 
! = !!"!!  
 
The main reason topically applied drugs are poorly absorbed by the skin is 
because only a small fraction is released into the stratum corneum.  
After a drug has been released into the membrane, it must be sufficiently 
mobile to diffuse across the stratum corneum. Because of the high viscosity of 
the lipid matrix, diffusion within biological membranes does not obey the 
Stokes–Einstein equation; which assumes spherical particles in a continuous 
fluid medium. More usefully, diffusion has been described in terms of the free 
volume theory, where diffusion takes place by the dynamic exchange of 
molecules with regions of free volume (or gaps) within the membrane.133 
Diffusion has been shown to follow the equation: !! = !!!!!!! 
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where Dm is the permeant diffusivity within the membrane, Do is the 
membrane diffusivity of an hypothetical molecule of zero molecular 
volume, β is a constant that is characteristic of the membrane, and MV is the 
molecular volume of the permeant. Diffusion decreases exponentially with the 
molecular volume (and therefore with molecular weight), limiting effective 
permeation of the skin when size increases. 
1.4.5 Summary 
The key factors for successful transdermal drug delivery are low molecular 
mass <600 g/mol and partition coefficient of 1 or grater. 
For this thesis the key factor related to the skin is obtaining small nanogel with 
a good hydrophobicity-hydrophilicity balance in order to pass through the 
stratum corneum without getting trapped in the hydrophobic layers of the 
corenocytes but soluble enough to diffuse through the viable epidermis. 
1.5 Smart Materials  
1.5.1 Overview 
Stimuli-sensitive or smart materials show large and abrupt responses to small 
changes in the environment. The most important and commonly used stimuli 
are: pH, ionic strength, electric or magnetic fields, temperature and 
ultrasounds. Such materials, although applied in variety of fields, are 
especially useful for developing the timing of a drug’s release. 
The most significant systems, from a biomedical point of view, are those 
sensitive to pH or temperature. For example, in the case of pH-sensitive 
materials such as polymers, the key element is the presence of ionisable, weak 
acidic or basic moieties, attached to a hydrophobic backbone. Upon ionisation, 
the coiled chains extend dramatically responding to the electrostatic repulsions 
of the generated charges. The human body presents variations in pH along the 
gastrointestinal tract, in some specific areas such as tumour tissues (because of 
the accelerated metabolic activity) and in sub-cellular compartments like 
lysosomes where pH sensitive materials can respond. Temperature responsive 
materials with critical temperatures close to human body temperature, offer 
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many possibilities in the biomedical field, and will be discussed in the 
following sections. 
1.5.2 Smart thermoresponsive materials 
Thermoresponsive materials respond to fluctuations in temperature and 
include proteins and natural/synthetic polymers. The structure of a 
thermoresponsive material changes with temperature, acquiring different 
physical-chemical properties. For example, when exposed to changes in 
temperature; polymer chains undergo a coil to globule transition (the extended 
coil collapses).134 During this process the hydrogen bonds decrease in number 
and the hydrophobic interactions increase. The lowest temperature at which a 
water solution of a material responds in this way is called the lower critical 
solution temperature (LCST). Thermoresponsive materials become insoluble 
in water when closer to the LCST, thereby forming two phases. Less 
commonly, some materials present an upper critical solution temperature 
(UCST), at which point they become soluble in water. Due to the low entropy 
of mixing, miscibility gaps are often observed for polymer solutions. Many 
polymers show UCST or LCST behaviour in organic solvents. 
 
Figure 1.13 – Phase diagrams for LCST and UCST 
 
The coil to globule transition is entropically favoured, because the molecules 
of water that are forming hydrogen bonds are highly organised in the coil 
state, whilst the degree of order decreases when the globe state is achieved and 
the majority of interactions are hydrophobic. The coil to globe transition is a 
reversible process; when the temperature drops under the LCST the materials 
become soluble in water again.135 
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Figure 1.14 – NIPAM solution at room temerpature (left) and over the LCST (right). 
 
There are several families of polymers known to be thermoresponsive: N-
substituted poly(acrylamide)s, N-substituted poly(methacrylamide)s, 
poly(methyl-2-alkylamidoacrylate)s; poly(oxazoline)s, poly(oxide)s, 
poly(vinylether)s, and poly(phosphoester)s, being amongst the most 
commonly used.134 
 
 
Figure 1.15 – Structures of thermoresponsive polymers that present LCST. (A) N-
substituted poly(acrylamide)s,  (B) N-substituted poly(methacrylamide)s, (C) 
poly(methyl-2-alkylamidoacrylate)s, (D) poly(oxazoline)s, (E) poly(oxide)s, (F) 
poly(vinylether)s and (G) poly(phosphoester)s. 
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1.5.3 NIPAM 
1.5.3.1 General 
A widely used and comprehensively described example of thermoresponsive 
materials is N-isopropylacrylamide (1), which has an LCST of approximately 
32°C.136 The NIPAM monomer, can be described in three parts: the vinyl 
group that reacts by radical polymerisation and forms the backbone or 
skeleton of the polymer (in red); the hydrophilic moiety, able to form and 
accept hydrogen bonding, formed by the amide group (in green); and the 
hydrophobic moiety: the isopropyl group (in blue). NIPAM polymers have 
surface tension because of this hydrophobic-hydrophilic structure, like the 
head and tail on surfactants.  
 
In solution, when the temperature is under the LCST, the hydrophobic unit is 
solvated by water and the amide group is involved in hydrogen bonding with 
water. Above the LCST, the hydrogen bonding with water is displaced by 
hydrogen bonding between the NIPAM units, while the isopropyl groups form 
hydrophobic interactions.  
O NH
(1)
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Figure 1.16 – Phase transaction for NIPAM polymer. Solvated structure, soluble under 
the LCST (left) and hydrophobic interactions when over LCST (right) collapsed 
structure. 
Thermosensitive polymers with a critical temperature close to the human skin 
temperature, like NIPAM, offer many possibilities in the biomedical field. The 
LCST of polymers in water solutions can be modulated by incorporating 
hydrophilic or hydrophobic comonomers.137 For example, when NIPAM is 
copolymerized with 18% of hydrophilic monomers such as acrylic acid (AA), 
the LCST increases up to about 45ºC, whereas the LCST decreases to about 
10ºC when 40% of hydrophobic N-tert-butylacrylamide (N-tBAAm) is 
incorporated. Also documented in the literature is the influence of the cross-
linker concentration on the LCST. In depth explanations on the effect of 
copolymerisation and crosslinking can be found in sections 2.5 and 2.6. 
LCST modulation can also be obtained by copolymerisation with other 
monomers, as described above, in order to have an LCST close to human body 
temperature (37ºC), which is suitable for drug delivery applications.  
1.5.3.2 Thermoresponsive NIPAM nanogels for drug delivery 
Smart nanogels are a subclass of responsive polymers. In describing the 
thermoresponse of macro or nanogels, some researchers prefer the use of the 
term volume phase transition temperature (VPTT), which refers to the volume 
shrinkage that thermoresponsive particles undergo. LCST is the term selected 
for this thesis.138 When the temperature of the nanogel rises to the LCST, 
thermoresponsive nanogels with a drug trapped inside the polymeric structure 
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should contract, expelling the contents. This is why thermoresponsive 
nanogels are very interesting for the topical or transdermal delivery of 
drugs.139 A nanogel with a LCST close to skin temperature would be able to 
shrink and release the drug on contact with the skin. 
1.6 Scientific objectives of the project 
The aim of this work was to synthesise thermoresponsive nanogels for 
transdermal drug delivery.  
For this purpose NIPAM nanogels were selected. The first step was to 
optimise and develop a reproducible and controllable polymerisation 
procedure to obtain nanogels. It was therefore necessary to control all the 
parameters that influence the polymerisation reaction and the final product. To 
understand the physical-chemical properties of the materials, an in-depth 
characterisation was carried out, in order to evaluate nanoparticle size, 
morphology, solubility and surface charge.  
 
 
As the final objective was that the nanogels penetrate the skin, they were 
labelled with fluorescent tags, to allow these particles to be studied in 
biological systems. 
The research for this thesis consisted of two main elements: i) the 
development of polymers and the testing of their physicochemical properties 
(Chapter II); ii) the biological testing of the samples on cells and human skin 
(Chapter III). 
Figure 1.17 – Drug loaded nanogels going through the phase 
transition temperature 
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2.1 Introduction 
This chapter describes the synthesis and characterisation of thermoresponsive, 
cross-linked, NIPAM-based nanogels as potential drug delivery vehicles. 
NIPAM has been widely studied as it is one of the most thermoresponsive 
polymeric materials and it responds efficiently and rapidly to small changes in 
temperature.  The use of NIPAM as a monomer for polymers in skin 
applications is of interest because of its response temperature, which, for 
linear NIPAM is around 32-33°C, close to the human body temperature.1  
Section 2.2 of this chapter, describes the selection of the polymerisation 
method and the polymerisation parameters that affect it.  
Section 2.3 presents the tools and methods used to characterise the polymers 
synthesised in this work: development and validation of thermoresponse 
measurement via turbidimetric analysis, size and zeta potential measurements 
via DLS. 
Sections 2.4 and 2.5, describe the work carried out to optimize the 
polymerisation reaction parameters (concentrations, initiator required, reaction 
times, cross-linkers and cross-linking densities). An in-depth study was carried 
out, to understand the properties of the new polymers, the most critical being 
the particle size and the thermoresponse of these nanogels.  
The goal was to achieve the smallest possible size, i.e. less than 40 nm 
according to literature2, with a thermoresponse of around 35-37°C (human 
skin temperature, in a healthy human at an ambient 25°C).3  
Section 2.6 describes the incorporation of comonomers in order to change the 
charge of the nanoparticles by the addition of an acidic or basic monomer to 
the polymerisation. The modification of the overall charge gives nanogels new 
properties and the possibility of interacting with biological membranes in 
different ways.  
Section 2.7 describes the incorporation of a fluorescent tag (florescent 
comonomer) for in vitro and ex vivo tracking purposes. The tag allows 
imaging of the nanoparticles, in cells and skin during the experiments.  
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Section 2.8 describes “imprinting polymerisation”, which is presented here as 
a means of uploading a well-known model drug (flufenamic acid) into 
different fluorescent nanogels.  
To conclude this chapter, Section 2.9, describes the drug release profiles of the 
imprinted polymers at different temperatures; in order to demonstrate the 
variation in the release of the drug above and below the thermoresponse 
temperatures of these novel materials. 
2.2  The method: High dilution radical polymerisation  
High dilution radical polymerisation is a homogenous polymerisation method. 
The radical polymerisation reaction takes place in very low and controlled 
concentrations, to restrain the length of the forming polymer chains. The 
reaction is carried out in such diluted conditions that polymer chains grow far 
apart from each other and make the likelihood of termination by two radical 
chains recombining negligible. The monomers react and form a stable colloid.  
This method was first reported in 1998, by Graham et al.,4 who discussed how 
both the solvent and the monomer concentration were the keys to obtaining 
microgels. The polymeric particles formed are stabilised via steric hindrance, 
which depends on the solvating power of the solvent. An effective solvent will 
isolate the growing polymer chains and prevent precipitation, leading to strong 
repulsive forces between individual particles. On the other hand, when a poor 
solvent is used, these chains will collapse and the repulsive forces will be 
weak, resulting in intermolecular cross-linking, macrogelation and the 
formation of an insoluble material. Subsequent research, carried out in our 
research group, demonstrated that if the concentration of monomers was low 
enough, nanogels could be obtained using this polymerisation method.5 
High dilution radical polymerisation has two big advantages compared with 
other polymerisation techniques: first, and most importantly, is the ability to 
obtain very small particle size (in the nanometre range); second, is the absence 
of the purification step (removing the surfactant or emulsifying agents 
required by heterogeneous methods). The only potential drawbacks are that 
sometimes yields can be low or reaction times slow as a result of the high 
dilution. 
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High dilution radical polymerisation may therefore lead to either exclusively 
soluble products (colloid), irrespective of reaction time, or to gelled 
(insoluble) products, if the reaction is continued far enough in inadequate 
conditions. Gelation occurs only when there is the possibility of unlimited 
growth in three dimensions and a critical number of intermolecular linkages 
have been exceeded. In the picture below a Wheaton bottle contains a gelled 
polymerisation; the jelly-like textured polymer has formed a 3D network and 
trapped the solvent inside it. The picture (Fig 2.1) shows a macrogel 
preparation and the bottle is upside down. 
 
Figure 2.1 – Upside down Wheaton bottle containing gelled polymer. Composition: 
NIPAM 50%, EBA 50%, AIBN 1%, CM 5%, DMSO under N2 after 1 hour at 70°C 
(DF3). 
 
Graham et al., studied in depth the parameters affecting the outcome of high 
dilution radical polymerisation. As stated before, the solvent and the total 
concentration of the monomer are crucial for a successful polymerisation: two 
parameters, the solvent solubility parameter and the critical gelation 
concentration are considered when studying this reaction. 
The solubility parameter or Hildebrand solubility parameter (δ) describes the 
ability of a given solvent to stabilize the formation of a growing chain, by 
measuring its relative solvency behaviour. This parameter reflects the strength 
of the Van der Waals forces between solvent and solute. The Hildebrand 
parameter is derived from the cohesive energy density of the solvent, which in 
turn is derived from the heat of vaporisation. The choice of solvent is, 
therefore, dependent on the solubility parameter and is the key to a successful 
polymerisation. 
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The overall monomer concentration should be lower than the Critical Gelation 
Concentration (CGC). CGC values are determined experimentally. The CGC 
is the highest value of total monomer concentration at which a stable colloid 
can be obtained without macrogelation. The CGC is also dependent on the 
polymerisation solvent, cross-linking degree, nature of monomers and 
temperature.  
The figure below shows an example of different CGC, determined 
experimentally, and expressed as CM values (concentration of monomer) on 
the y-axis. The x-axis is made up from several ketonic solvents and their 
combinations, with different δ values. The plot is derived from mixtures of 
cross-linker and monomer (30/70 ethylene dimethacrylate and methyl 
methacrylate), reacted at 80°C and 3wt% of AIBN.6 The area underneath the 
curve represents the concentration of the monomer where particles are 
obtained. The area above it represents the concentrations that lead to a gelled 
preparation. 
  
2.3 Characterisation methods for polymers  
2.3.1 Overview 
The thermoresponsive polymers prepared during this project required a 
detailed characterisation to determine their different physicochemical 
properties. This next section will provide a general description of the 
Figure 2.2 - CGC values determined experimentally for a mixture 30/70 ethylene 
dimethacrylate and methyl methacrylate versus solubility parameter (δ) of the 
polymerisation solvent used. CH = cyclohexanone; CP = cyclopentanone; EC = 
ethylene carbonate; the numbers represent the volume fractions of the two 
components in the solvent mixture. Graph from Graham et al. Macromol. Chem. 
Phys., 2001, 202, 163-171. 
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techniques used: in particular, LCST determination by turbidimetric analysis 
and size and surface charge by Dynamic Light Scattering.  
2.3.2 LCST determination by turbidimetric analysis 
The thermoresponsive character of a polymer solution in water is indicated by 
the Lower Critical Solution Temperature (LCST). LCST is the temperature 
below which the components of a mixture are miscible and it can be evaluated 
using three different techniques: (1) Differential Scanning Calorimetry (DSC), 
(2) Dynamic Light Scattering (DLS) or (3) turbidimetric analysis. DSC 
provides very accurate data and thermodynamic information on the phase 
transition, however it requires an instrument equipped with a very powerful 
sensor to be able to measure the LCST. Usually, for this technique, high 
amounts of materials are used (10-50 mg of polymer) which are then difficult 
to recover after the measurement. The second method, DLS, is based on the 
observation of variations in size as a result of changes in temperature. This is a 
useful technique when samples are monodispersed and the difference in 
polymer sizes can be monitored. The third, and more commonly used 
technique, is the measurement of the increasing turbidity of a solution with 
temperature, in which variations in transmittance using UV-Visible 
spectroscopy are recorded. As the solution of a thermoresponsive polymer 
starts to be insoluble and precipitates, the turbidity of the samples increases 
sharply due to the light scattered by the particles in the sample. The 
transmittance curve starts at 1 (absorbance = 0), where the solution is clear 
and transparent. As the precipitate starts forming, the transmittance decreases 
until the sample is completely turbid and the light is completely scattered by 
the precipitate: transmittance = 0. An example of a curve of transmittance 
against temperature is shown below (Figure 2.3). LCST is assigned at the 
point where the slope takes its maximum value. This is calculated by 
differentials of the transmittance versus the temperature: ΔT. Usually this 
point coincides with a value of 0.5 in transmittance. 
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Figure 2.3 – Representation of the change in transmittance of a sample against 
temperature. The calculation of the derivative at each point ΔT indicates the point with 
the highest slope, identifying the LCST value. 
 
The thermoresponsive properties of a polymer depend mainly on its 
concentration in solution, its molecular weight and the ionic strength of the 
solvent. This is why it is important to determine the LCST of the materials in 
conditions that are closely related to the desired application (e.g. similar 
concentration, buffer or media). In addition, the measurements in the 
spectrophotometer are also known to be affected by the rate at which the 
temperature changes in the thermostatic chamber. In order to establish the 
significance of this phenomena a number of experiments were carried out and 
the data are shown in the Figure 2.4. 
When the solution was heated too quickly (10°C/min) the profile suggests a 
lower LCST temperature, probably the result of inaccurate and non-
homogenous reading of the sample. At the opposite end if the heating rate was 
as low as 0.1°C/min, the polymer precipitated and a false reading was 
obtained, as the solution remained clear.  However, when the temperature rate 
was increased by 1 or 2°C per minute, consistent data were obtained. For this 
project it was decided to keep the rate at 1°C /min, a value that is also often 
used in the literature.7,8 
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Figure 2.4 – Influence of heating rate on the measurement of transmittance 
measurements on a same sample of polymer.  
 
The accurate determination of the LCST was essential for this work, as the 
polymers developed in the project are designed to work as thermoresponsive 
drug delivery vehicles targeting the skin. One concern that was raised at the 
beginning was whether the temperature values read on the spectrophotometer 
probe where actually matching the real temperature in the solution inside the 
cuvette. In order to verify the accuracy of the measurements, a special probe 
was inserted into the solution and the variations in temperature were recorded. 
Figure 2.5 shows a very good linear relationship between the temperatures 
reported by the instrument and the temperature inside the cell in the interval 
evaluated (15 to 65°C). This relationship is provided by the following 
equation:  !!"## = 1.01!!"#$ + 2.39 
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Figure 2.5 – Representation of the temperature registered by the instrument against the 
temperature given by the sensor dipped inside the cell. 
 
The results indicate that the Tinst (temperature reported by the instruments) is 
almost two and a half degrees lower than the real temperature of the sample 
being analysed Tcell. 
In order to verify that the experimental protocol developed at this stage would 
provide consistent data, a control experiment was carried out using a sample 
of linear NIPAM. This polymer is widely used in the literature and its LCST is 
well known to be 32°C. When the polymer was tested on our system a value 
of LCST of 32-33°C was obtained dependent on the concentration of the 
polymer used. This is fully in agreement with the data in the literature, and 
therefore provided evidence that the experimental setup was adequate.  
 
 NIPAM Yield LCST 1mg/mL LCST 10mg/mL 
DF49 100% 88% 33°C 32°C 
Table 2.1 – Preparation of linear NIPAM for validation. Readings of LCST at different 
concentrations. 
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2.3.3 Size and Zeta potential by Dynamic Light Scattering 
2.3.3.1 Size 
Dynamic Light Scattering (DLS: also known as PCS: Photon Correlation 
Spectroscopy or QLS: Quasi Elastic Spectroscopy) measures the Brownian 
motion and relates this to the size of the particles. Brownian motion is the 
random movement of particles suspended in a fluid due to the collision with 
the molecules of the fluid that surrounds them. Small particles move quickly 
and large particles move more slowly. During a measurement, particles are 
irradiated with a polarised monochromatic laser and the instrument analyses 
the intensity fluctuations in the scattered light (Figure 2.6). The relationship 
between the size of a particle and its speed is defined in the Stokes-Einstein 
equation, where the diffusion of a particle (D) is calculated as follows:  
 
! = !"! 16!"# 
 
where R is the gas constant, T the absolute temperature, N the Avogadro’s 
number, Z the viscosity of the medium and r the particle’s radius. The 
instrument measures the speed (diffusion) and then uses this equation to 
calculate the size of the particles.  
 
Figure 2.6  – DLS instrument schematic: Laser, cell (containing sample), detector of light 
scattered by particles, attenuator, digital signal processor and computer. Redrawn from 
Zetasizer Nano Series User Manual, Issue 1.1 2003. 
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DLS data are usually represented in three different ways: size, by number 
volume and intensity distributions: examples of this are in shown in Figure 
2.7.  
 
Figure 2.7 – Representation of size distribution by Number, Volume and Intensity of a 
mixture 1:1 of nanoparticles of 3 and 30nm. The plot by number show two peaks of the 
same area as the mixture of particles is 1:1. The plot by volume show a peak are 1000 
times bigger for the 30 nm particles as the diameter is 10 times bigger, therefore the 
volume is 1000. Finally, in the plot by intensity, the intensity of the peak of the 30 nm 
particles in a mixture 1:1 is one million times higher due to the d6 on Rayleighs 
approximation of light scattered. Redrawn from Zetasizer Nano Series User Manual, 
Issue 1.1 2003. 
 
The representation of the size distribution by intensity is very sensitive to the 
size of the particles. From Rayleigh’s approximation for a particle size < 1 /10 
wavelength, the light scattered by a particle is proportional to its size to the 
sixth power of its diameter from.  
 
! = !! 1+ !"#!!2!! 2!! !! − 1!! + 2 !2 ! 
 
Large particles scatter much more light than small particles. Therefore the 
presence of any small contaminant in the sample, even dust, would have a 
significant impact on the measurement. This is why the samples for the 
research for this thesis were prepared at a low concentration (0.1mg/mL), 
filtered just before measurement to minimize any aggregation peak and 
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remove any contaminant. For this reason, the determination of particle size 
was mainly done by evaluating the data for size distribution, by number and 
volume. As it can be seen in the plots below (Figure 2.8), some nanogels 
samples presented two peaks for intensity (attributed to some aggregation) but 
only one peak for volume. 
 
 
 
2.3.3.2 The zeta potential  
It is commonly accepted that colloidal particles are stabilized by either steric 
or electrostatic repulsion. In the latter case, the magnitude of the zeta potential 
is a good predictor for the stability of the system. Large negative or positive 
zeta potential values indicate that particles repel each other and they have a 
minimal tendency to aggregate.  
In solution, the net positive/negative surface charge of the particles attracts 
concentrations of counter ions. This forms an electrical double layer around 
each particle, the Stern layer, which is in direct contact with the surface where 
the ions are strongly bound, and a more diffuse layer where they are less 
attached. 
When a particle in solution moves, not all the ions present in the diffuse layer 
move with it. The boundary at which the ions move with the particle is called 
the slipping plane (or surface hydrodynamic shear). The electric potential that 
exists at this distance from the particles is known as the zeta potential and is 
measured in mV. As such, it measures the ability of the particle to attract 
counter ions in a solution. 
Figure 2.8 - Comparison of representation by Intensity and Volume. The sample 
presents two peaks by Intensity, but the size distribution by volume confirms the 
presence of one population of particles around 15 nm. 
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Figure 2.9 – Schematic representation of stern, diffuse and electric double layers; 
localisation of slipping plane (where zeta potential is measured). Redrawn from 
Zetasizer Nano Series User Manual, Issue 1.1 2003. 
 
The same instrument that measures particle size is used to measure the surface 
charge of nanoparticles (the zeta potential). The instrument measures the 
Electrophoretic Mobility, the velocity of a particle in an electric field, and then 
calculates the zeta potential from theoretical considerations (Figure 2.10). The 
electrophoretic mobility of a sample is evaluated by measuring the speed of 
the particles when an electric field is applied to a cell equipped with electrodes 
(Figure 2.11). The charged particles move towards the electrodes with an 
opposite charge and the instrument reads their mobility. 
 
Figure 2.10 – Representation of light scattered by particles to determine their 
electrophoretic mobility. Redrawn from Zetasizer Nano Series User Manual, Issue 1.1 
2003. 
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Figure 2.11 – Representation of the particles moving inside the cell during an 
electrophoresis experiment. Redrawn from Zetasizer Nano Series User Manual, Issue 1.1 
2003. 
 
The velocity of the particle is dependent on the following factors: (1) the 
electric field, (2) the dielectric constant of the medium, (3) the viscosity of the 
medium, (4) the zeta potential. Henry’s equation9 relates electrophoretic 
mobility with zeta potential: 
!! = 2!"# !"3!  
where UE is the electrophoretic mobility, z is the zeta potential, ε dielectric 
constant of the media, η viscosity and f(Ka) is Henry’s function that can take 
the values of 1.5 or 1.0 depending on the approximations on the calculations 
(Figure 2.12). The Smoluchowski approximation assumes that the 
measurement is made in water, the particles are at least 200 nm and that they 
are in a low electrolyte concentration (less than 10 mM) f(Ka), in this case is 
1.5. Alternatively, the Huckel approximation is for small particles in low 
dielectric constant media, where f(Ka) becomes 1.0.  
Figure 2.12 – Representation of Hückel and Smoluchowski approximation 
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During an electrophoresis experiment the velocity of moving particles is 
measured by Laser Doppler Velocimetry (LDV). A detector collects the light 
scattered by the moving particles at an angle of 17° and compares it with the 
reference beam. The fluctuations in the intensity of the scattered light have 
characteristic frequencies that are proportional to the speed of the particles. An 
example plot of such readings is given in Figure 2.13. 
 
Figure 2.10 – Example of reading of zeta potential values for a negatively-charged 
nanoparticle. 
 
2.4 Choice of polymerisation parameters 
2.4.1 Overview 
This section describes the work carried out to optimise the polymerisation of 
cross-linked NIPAM nanogels. A starting set of experimental conditions were 
selected based on the group’s know-how, followed by a series of 
modifications made to obtain optimal reaction conditions. Although no 
previous work had been done in the research group using NIPAM, there was a 
considerable expertise in the synthesis of nanogels and microgels using 
acrylamide as the monomer for high dilution radical polymerisation.  
The following components were therefore selected on the basis of previous 
experience in the research group10–13: the cross-linker (ethylenebisacrylamide, 
EBA) (2), the initiator (azoisobutyronitrile, AIBN) (3), and, the solvent 
(dimethylsulfoxide, DMSO), all of which had been successfully used in the 
synthesis of nanogels and microgels. Similarly, the initial monomer 
concentration CM of 5% and the length of polymerisation (4 days) were 
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derived from earlier work. The reactions were all carried out under N2, to 
exclude oxygen and with the temperature set at 70°C. These components and 
conditions, summarized in the table below, were initially investigated and 
validated in this project using NIPAM.  
NIPAM is usually reacted with bisacrylamide cross-linkers to form water-
soluble microgels. Both monomer and cross-linker have the same functional 
group, the acrylamide unit, which ensure that both components have similar 
reactivity rates.14 This produces a final composition of the nanogels, which is 
both homogeneous and still maintains the ratio of the components.  
DMSO was selected for the high dilution radical polymerisation because of its 
high solubility parameter (δ = 26.4 MPa1/2),15 as explained in Section 2, and its 
ability to dissolve all the required components for the polymerisation. AIBN is 
a radical initiator soluble in the solvent of the polymerisation (DMSO). 
 
Reaction 
conditions 
Reaction 
time 
CM Concentration 
cross-linker 
Percentage of 
initiator 
70°C, N2 4 days 5% 30-70% 1% of the total 
double bonds 
Table 2.2 – First experimental conditions for the high dilution free radical 
polymerisation 
Chemical type Chemical name 
Monomer NIPAM (1) 
Cross-linker EBA (2) 
Radical initiator AIBN (3) 
Solvent DMSO 
Table 2.3 – Reactants used for the polymerisation 
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2.4.2 The total concentration of monomer (CM) and cross-linker 
In this section the first experiments carried out towards the preparation of 
EBA cross-linked NIPAM based nanogels are described. The first step 
focused on the determination of the values for CM and CGC for this particular 
set of monomer and cross-linker in a given solvent. For that, two 
polymerisation parameters were simultaneously investigated: the total 
concentration of monomer CM and the concentration of cross-linker.  
The concentration of monomer is the percentage of the mass of the monomers 
in a reaction divided by the mass of all the components of the reaction: it is a 
key parameter in a high dilution free radical polymerisation. Previous work 
with the acrylamide nanogels suggested that values for CM are very low, 
around 0.1-5%.  
The cross-linking degree is the molar percentage of cross-linker in the 
polymer. In this research group, working concentrations of cross-linker used 
were usually high (50-70%) for the preparation of rigid imprinted polymers. It 
was decided to study a broader range of cross-linking concentrations ranging 
from 30 to 70%. 
The first set of experiments aimed to evaluate how variations in the values of 
CM and in the percentage of cross-linker could impact the formation of the 
polymer. At this stage, the objective was to observe whether macrogelation 
occurred in any of the preparations, and if not, to study the solubility of the 
isolated polymers. 
A number of experiments were carried out using concentrations of cross-linker 
at 30%, 50% and 70% and various levels of CM (5%, 3%, 2% and 1%). The 
results are summarised in Table 2.4.  
 
O
N
H
H
N
O
NNC N CNO NH
(1) (2) (3)
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Reaction Code NIPAM EBA CM Gelation Solubility in water 
DF3 50% 50% 5% Yes - 
DF5 70% 30% 3% No 1mg/mL 
DF11 50% 50% 3% Yes - 
DF8 30% 70% 3% Yes - 
DF35 70% 30% 2% No 1mg/mL 
DF34 50% 50% 2% Yes - 
DF33 30% 70% 2% Yes - 
DF38 70% 30% 1% No 1mg/mL 
DF37 50% 50% 1% No 1mg/mL 
DF36 30% 70% 1% No 1mg/mL 
Table 2.4 – Experimental conditions to test macrogelation. Values of CM% ranging from 
1 to 5% with simultaneous variations of cross-linker content EBA from 30 to 70%. 
 
The data clearly indicate that a CM of 5% was too high and led to 
macrogelation. When the CM was lowered to 3 and 2% the concentration of 
crosslinker played a key role on the macrogelation. While nanogels with lower 
cross-linking degrees were soluble (30%) DF5 and DF35, the polymers with 
higher cross-linking concentrations formed a macrogel. Only when the CM 
was lowered to 1% did all the polymerisation solutions give rise to stable 
microgels. After purification and isolation, all three preparations, DF36, DF37 
and DF38 showed good solubility in water up to 1mg/mL. The results clearly 
show that as the percentage of cross-linker increases so does the risk of 
observing gelation. This result was to be expected, because cross-linking can 
join two growing particles, producing an insoluble, bigger, merged one.  
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Radical polymerisation is a random process and therefore there were some 
concerns regarding the reproducibility of the data obtained. A number of 
experiments were therefore repeated, where the CM was fixed at 1% while the 
cross-linker was varied from 30% to 70%. Each preparation was repeated four 
times to verify the reproducibility of the process. The results are shown in 
Table 2.5. 
 
 NIPAM EBA AIBN CM Yield Average Yield 
DF15 30% 70% 1% 1% 92% 
91% 
DF16 30% 70% 1% 1% 91% 
DF17 30% 70% 1% 1% 90% 
DF36 30% 70% 1% 1% 90% 
DF18 50% 50% 1% 1% 73% 
81% 
DF19 50% 50% 1% 1% 87% 
DF20 50% 50% 1% 1% 71% 
DF37 50% 50% 1% 1% 91% 
DF21 70% 30% 1% 1% 80% 
75% 
DF38 70% 30% 1% 1% 65% 
DF32 70% 30% 1% 1% 78% 
DF23 70% 30% 1% 1% 78% 
Table 2.5 –Polymerisations to assess reproducibility of reaction. Three degrees of cross-
linking: 30-50-70% EBA. 
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The data indicated a good degree of consistency, with all polymers leading to 
microgels. The data suggested a certain degree of variability in the chemical 
yield, with values generally above 75% for all degrees of cross-linking. There 
was a clear tendency for the yield to increase with the amount of cross-linker; 
from 75% (for 30% cross-linker), to 91% (for a 70% cross-linker). That was 
expected because every time a cross-linker molecule reacts, the polymer is 
branched and two reacting points are created making the polymerisation yield 
higher.  
Given the nature of the polymerisation reaction and the isolation via dialysis, 
some experiments were carried out using different concentrations of initiator 
to evaluate its impact on the polymer formation. 
2.4.3 The initiator    
In radical polymerisation, formation of the active species is usually by thermal 
decomposition or photolysis of an initiator. The chosen initiator, AIBN (3), is 
soluble in DMSO and, at around 70°C, undergoes a homolytic cleavage, 
releasing nitrogen.  
 
 
 
The total number of double bonds in the polymerisation is the basis for the 
calculation of the amount of AIBN necessary, which is important for the 
reaction yields and particle size. The amount of AIBN used (1%) was selected 
on the basis of similar polymerisation conditions carried out in the group for 
the synthesis of acrylamide nanogels. 
In general, a higher concentration of initiator increases the yields because 
more radicals are formed. For the same reason since more initiation points are 
created in the solution, smaller nanogels can be synthesised. The nanogels 
formed, can be so small that they can be lost during dialysis and yields be 
affected. 
NNC N CN NC
N N2
Δ
(3)
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Three polymerisation reactions were set up with a percentage of EBA of 50% 
(mid range) to assess the impact of the initiator on the nanogels formed.  
 
 NIPAM EBA AIBN CM Solvent Temp Time Size[nm]  Yield 
DF19 50% 50% 1% 1% DMSO 70°C 4 days 14±3 87% 
DF13 50% 50% 3% 1% DMSO 70°C 4 days 15±2 81% 
DF14 50% 50% 5% 1% DMSO 70°C 4 days 14±2 84% 
Table 2.6 – Polymerisations with different amounts of initiator AIBN. Size 
measurements with standard deviation (n=3). 
When the AIBN concentration was increased from 1% to 3% and 5%, no 
significant difference was observed in the size of the particles (Table 2.6). 
These results indicate a clear control of the particle size by high dilution 
radical polymerisation. These preparations were the first evidence that the 
selected reaction parameters were able to produce particles smaller than 
microgels, ie nanogels. No further research was carried out, since the particle 
size and the yields were not affected by the amount of initiator used.  
The procedure for the synthesis and isolation of the nanogels was quite 
lengthy, because of the 4-day reaction time, followed by the dialysis over 2 
days. This limited the number of preparations that could be evaluated. In order 
to improve the number of polymerisations, experiments were carried out to 
determine the optimal reaction time. 
2.4.4 The reaction time 
The initial time frame of 4 days was taken from previous investigations in the 
research group using acrylamide microgels. To try to shorten the time needed, 
experiments were carried out over 4 days, 1 day, and 6 hours, under identical 
experimental conditions (AIBN 1% and CM 1%, DMSO, N2). 
The table below shows the results of the yields and the particle size for three 
different preparations (with different degrees of cross-linking at 30%, 50% 
and 70%) over three different reaction times. 
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Sample NIPAM EBA TIME Yield  Size [nm] 
DF36 30% 70% 4 days 90% 16±4 
DF30 30% 70% 1 day 87% 16±2 
DF43 30% 70% 6 hours 93% 21±2 
DF37 50% 50% 4 days 91% 13±1 
DF31 50% 50% 1 day 94% 14±5 
DF44 50% 50% 6 hours 86% 16±3 
DF38 70% 30% 4 days 65% 14±3 
DF32 70% 30% 1 day 78% 12±5 
DF45 70% 30% 6 hours 60% 9.9±1.3 
Table 2.7 – Reactions to assess reaction time: polymerisations with three degrees of 
cross-linking carried out during 6hours, 1 day and 4 days to determine reaction time. 
The data (Table 2.7) show that the reaction yields and sizes obtained were not 
significantly different in the three sets of experiments (4 days, 1 day and, 6 
hours).  
It was difficult to compare the reaction times with the literature, since almost 
all the micro and nanogels previously described were not prepared in DMSO 
and the polymerisation techniques were different. Most of these 
polymerisations were carried out in water and the initiators were also water-
soluble (unlike AIBN). Published experiments frequently give reaction times 
of 6 hours in water.16,17  
The polymerisation in DMSO seemed to be fast and, envisaging the possible 
addition of further components in the reaction, it was decided to select 1 day 
as a reaction time. In view of the results obtained in the last three sections 
above, all the polymerisations from this point onwards in the research, unless 
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otherwise stated, were carried out with a CM of 1%, at 1% of AIBN, over 1 
day at 70°C, under N2 (summary in Table 2.8). 
 
Reaction 
conditions 
Reaction 
time 
CM Concentration 
cross-linker 
Percentage of 
initiator 
70°C, N2 1 day 1% 30-70% 
1% of the total 
double bonds 
Table 2.8 – Optimised experimental conditions for high dilution radical polymerisation. 
 
2.5 Impact of cross-linking on polymer characteristics 
2.5.1 Thermoresponsive properties of EBA-based nanogels 
In this section the data related to the LCST of EBA-based nanogels is 
presented and discussed. The thermoresponsive behaviour of the nanogels was 
examined using the techniques described in Section 3.2. This measurement 
would provide essential information for evaluating their potential application 
as a thermoresponsive drug delivery vehicle for skin. 
The presence of the cross-linking agent affects the ability of the nanogels to 
undergo the phase transition. It has previously been reported that cross-linked 
microgels have higher LCST compared to NIPAM.18 NIPAM particles were 
found to have less sharp but higher LCST temperature transition when 
compared with linear NIPAM polymers. These differences were attributed to 
the broad length distribution of the branched chains inside the particles and the 
fact that the chains are shorter.19  
As stated above in Section 2.4.2 (Table 2.7), the polymers prepared with 70%, 
50% and 30% EBA cross-linking levels, were obtained in good yields and 
shown to be nanosized.  
Three polymers DF30, DF31 and DF32 (Table 2.7) were analysed by 
turbidimetric analysis at 1mg/mL and their LCST determined. 
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 NIPAM EBA Yield LCST  
DF30 30% 70% 87% 75° C 
DF31 50% 50% 94% 68° C 
DF32 70% 30% 78% 66° C 
Table 2.9 – LCST values in water for EBA cross-linked polymers at 1mg/mL. 
 
As shown in Table 2.9, DF30 – DF32 responded at temperatures higher than 
66°C. The LCST had changed significantly, compared to that of the linear 
NIPAM (32°C), because of the incorporation of EBA. The data suggests that 
the LCST of the nanogels increased with the amount of cross-linker used, as 
reported in the literature. This could be explained by the increased rigidity of 
the polymer, which makes the coil to globe transition more difficult for the 
nanogels, requiring higher temperatures. These LCST values were too high for 
the intended application of the nanogels. 
As described in Section 2.3.2, thermoresponsive behaviour depends on the 
concentration of polymer. As performed for linear NIPAM (Table 2.1), 
solutions of DF32 were analysed at three different concentrations: 0.1, 1 and 
10 mg/mL.  
 
LCST 0.1mg/mL 1mg/mL 10mg/mL 
DF32 75° 66° 59° C 
Table 2.10 – Nonanogel DF32 LCST values in water with concentration. 
 
As the concentration increased from 0.1 to 10 mg/mL, the LCST decreased 
from 75°C to 59°C. Diluted solutions of the polymer were further away from 
the solubility limit and a higher temperature was required to precipitate the 
polymer. After cross-linking with EBA, the LCST of the nanogels 
substantially increased, 66°C being the lowest value, at 1 mg/mL (for the least 
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cross-linked nanogel). In order to reduce the LCST back to a level appropriate 
for human skin applications, and having observed the clear correlation 
between the phase transition temperature and the amount of cross-linker, 
polymer preparations with a lower degree of cross-linking were synthesised 
and these are discussed in the next section.  
2.5.2 Impact of using a reduced EBA cross-linking content on nanogels 
properties  
A number of nanogels were prepared with decreasing concentrations of EBA, 
ranging from 20% to 5%, with the aim of reducing the LCST. Given the 
random process of radical polymerisation, there was an interest in studying the 
reproducibility of the experiments and for this reason each set of nanogels was 
prepared in triplicate. The table below shows the LCST, yields and size of the 
materials obtained when the EBA percentage was reduced.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 NIPAM EBA Yield Size [nm] LCST 
DF74 80% 20% 67% 8.4±1.2 45°C 
DF128 80% 20% 65% 7.2±0.8 45°C 
DF129 80% 20% 67% 7.5 ±0.6 45°C 
DF75 90% 10% 50% 6.2±0.4 42°C 
DF131 90% 10% 53% 6.5±1.0 42°C 
DF132 90% 10% 57% 6.5±0.3 42°C 
DF133 90% 10% 47% 6.1±0.4 42°C 
DF76 95% 5% 61% 5.9±0.2 39°C 
DF134 95% 5% 32% 3.8±1.0 39°C 
DF135 95% 5% 44% 5.3±0.5 39°C 
DF136 95% 5% 55% 5.9±0.1 39°C 
Table 2.11 – Composition, yield, size and LCST of nanogels with 20, 10 and 5% EBA. 
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The polymerisation resulted in nanogels with a particle size smaller than 10 
nm. All the samples were highly soluble in water (up to 50 mg/mL). 
Compared to the nanogels obtained with 70%, 50% and 30% EBA (Section 
2.4.2, Table 2.5), the size of the new polymers appeared to decrease 
significantly with the lower percentage of cross-linker. However this was also 
coupled with a decreased yield, most likely the result of the procedure used for 
the isolation of the polymers, which involves dialysis, and leading to loss of 
the smallest polymer chains.  Cross-linking significantly lowered the response 
temperature, to below 50°C and closer to human body temperature. However, 
temperatures above 39°C are still too high for transdermal drug delivery 
applications. It was therefore decided to study a different cross-linker in an 
attempt to obtain nanogels that responded at a lower temperature. 
2.5.3 Thermoresponsive properties, size and charge of MBA based 
nanogels  
Methylenebisacrylamide (4) (MBA) is an inexpensive, widely used cross-
linker that only differs from EBA by one CH2 unit.  
 
The study of the effect of the concentration of MBA cross-linking in 
microgels has been reported in the literature.18 There is a general consensus 
that the increase in the degree of cross-linking affects the rigidity of the 
polymers and the overall hydrophobicity. This can also influence the LCST 
values. In this thesis these properties were tailored to achieve the desired 
target of a nanogel that is thermoresponsive at a temperature of around 37-
38°C. 
Woodward et al. investigated the thermoresponse of NIPAM microgels (400-
500nm) using different degrees of cross-linking, ranging from 0.25% to 30% 
of MBA, and studied the swelling behaviour using DLS, turbidimetry and 
DSC. The study concluded that high cross-linker concentrations undergo a 
conformational transition at increased temperature. Whilst NIPAM particles 
O
N
H
N
H
O
(4)
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with a low degree of cross-linking (0.25% to 5%) almost behave like linear 
NIPAM, with a thermoresponses of around 34°C, when the percentage of 
MBA increases to 10% and 20 %, the LCST increases to 40° and 46°C. When 
the density of MBA is increased further, to 30%, the turbidity of the sample 
does not give sigmoidal-type, transmission versus temperature curves, 
indicating that the phase transition occurs over a broad range of temperatures.  
Kratz et al.19 studied MBA cross-linking between 0.66% and 11.73% in 
microgels of 270−350 nm. It was observed that the degree of swelling 
decreased with an increasing amount of MBA. This was attributed to 
constraints introduced into the polymeric network through an increasing 
number of intramolecular cross-linking points. It was found that the phase 
transition temperature did not change significantly with the concentration of 
MBA  
McPhee et al.20 investigated the properties of NIPAM microgel particles with 
MBA cross-linker 2−30% concentrations. The particle transition temperature 
increased with the amount of cross-linker used in the preparations. Like Kratz 
et al.,19 it was also reported that cross-linker concentrations greater than 20% 
displayed anomalous behaviour and caused association of microgel particles.  
Crowther et al.21 compared NIPAM microgels using different proportions of 
cross-linker: 1%, 2%, 4.5% and 9% MBA. In agreement with data previously 
reported, it was concluded that a decrease in cross-linker concentration led to a 
greater degree of collapse and a lower LCST. All these studies described the 
effect of different proportions of MBA on microgels.  
For this thesis, a series of experiments was carried out to determine the 
properties of NIPAM nanogels with different percentages of MBA cross-
linker. In order to be able to compare the results with the data obtained using 
EBA, the same degree of cross-linking was used to prepare the new polymers. 
The table below shows the effects of adding increasing amounts of MBA to 
the nanogel preparation, on the yield, size, LCST and zeta potential of the 
nanogels. 
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 NIPAM MBA Yield Size [nm] 
Zeta Potential 
[mV] LCST 
DF71 30% 70% 97% 34±1 -3.8±0.4 No response 
DF72 50% 50% 88% 20±7 -3.1±1.0 37.5°C 
DF73 70% 30% 81% 7.4±0.8 -3.7±1.6 40°C 
DF98 80% 20% 55% 7.2±0.5 -1.6±0.4 42°C 
DF99 90% 10% 49% 4.5±0.5 0.3±0.7 40°C 
DF100 95% 5% 53% 5.8±0.0 -1.1±0.1 38°C 
Table 2.12 – Characteristics of NIPAM nanogels cross-linked with 5% to 70% of MBA. 
 
The data show that there is a positive correlation between the yield of the 
polymers obtained and the amount of MBA used: with preparations DF71-73 
isolated with yields of over 80%, and significantly lower yields (<55%) with 
less than 30% of the cross-linker.  
The same trend can be observed for the particle size. Increasing the amounts 
of cross-linker produces bigger nanoparticles. While the hydrodynamic radius 
remains almost constant, below 10 nm, for low concentrations of cross-linker 
(DF73 to DF100), when the percentage of MBA is increased to 50% and 70%, 
the particle sizes are around 20 and 30 nm respectively. As described above, 
yield and polymer sizes are related. While increasing amounts of cross-linker 
favour the growth of the nanoparticles (for each cross-linker two branches are 
formed), the tendency towards lower yields, when the polymer size is smaller, 
can be explained by the loss of materials during dialysis.   
The zeta potential of these materials was determined, to understand their 
surface charge when in water. The values obtained were close to zero, which 
is to be expected because none of the reacting materials used (NIPAM, MBA 
or AIBN) have any charge. 
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A discussion of the nanogels’ LCST needs a specific analysis and, to facilitate 
this, a plot of LCST against percentage of cross-linker is provided below in 
Figure 2.11 based on Table 2.12. The plot shows that the temperature rises to a 
maximum of 42°C with 20% of MBA and then falls. Up to 20%, increasing 
the amounts of MBA increases the rigidity of the polymer matrix, making the 
phase transition more difficult by restraining conformational changes. When 
the percentage of MBA is higher than 20%, another factor dominates the 
properties of the material. The polymer has become progressively more 
hydrophobic (because of the diminished content of NIPAM), favouring 
aggregation and resulting in a decreased LCST. Finally, at 70% of MBA 
(DF71) the nanogels showed no thermoresponsive behaviour at all, due to the 
low amount of NIPAM in those nanogels. 
 
Figure 2.14 – Representation of nanogels’ LCST versus percentage of MBA cross-linker. 
Nanogels with MBA therefore present a behaviour similar to that reported in 
the literature for microgels.18 The lower LCST associated with nanogels 
containing MBA, particularly at concentrations below 20%, make them 
suitable for skin preparations. Given the results obtained thus far, it was 
decided that nanogels with a 20% MBA content would be optimal.   
As one of the key objectives of this work was to study the effect of the 
polymer composition, its physicochemical properties and suitability as drug 
delivery vehicle, the next phase of the work focused on the synthesis of 
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nanogels containing comonomers able to add a charge to the surface of the 
nanoparticles because a charge could improve skin penetration. 
2.6 Introduction of comonomers to modify the surface charge of the 
nanogels 
2.6.1 Introduction 
The MBA-polymers obtained so far in this work, and described in Section 
2.5.3, were characterised by a neutral surface charge according to zeta 
potential measurements by DLS. There is significant literature data available 
to suggest that charged nanoparticles have different skin penetration 
characteristics.2,22,23 Therefore in this project it was decided to synthesise both 
positively and negatively-charged nanoparticles in order to evaluate the impact 
on their morphology, physicochemical properties, cell viability and 
internalisation, and skin penetration properties. This was achieved by 
introducing comonomers carrying functional groups into the polymerisation 
solution. In physiological conditions, these comonomers would give rise to 
negatively and positively-charged nanoparticles. For the purpose of this work, 
acrylic acid (5) (AA) and N-(2-aminoethyl)acrylamide hydrochloride (6) AEA 
were chosen.  
2.6.2 Negatively-charged nanogels: acrylic acid 
Acrylic acid (5) has been reported as a suitable comonomer for NIPAM, in 
nanogel polymerisations, as it modifies the polymer properties by increasing 
hydrophilicity and hydrogen bonding, as well as introducing a negative charge 
as a result of its pKa of 4.2 in water. 
AA has been copolymerised with NIPAM and MBA to produce nanoparticles 
and several reports can be found in the literature.24 In these papers, AA is 
always used in small amounts, usually under 10%, because the impact on the 
LCST is very significant. Heard et al.,16 described how the addition of AA to 
microgels increased the LCST from 33°C, for the homopolymer, to 37°C. 
OH
O
(5)
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However when the analysis was performed in the presence of citric acid, the 
LCST dropped to 31°C. Data suggest that the LCST of AA nanogels is 
strongly affected by the properties of the solvent: specifically the pH and ionic 
strength. For example, Shea et al. 25 described the effect of introducing 5% 
and 10% of AA into the preparation of imprinted polymers, to be used for a 
screening test that would selectively recognise proteins. The introduction of a 
negative charge increases the affinity of the polymers for specific proteins 
(basic proteins, that are positively-charged). The authors describe how the 
LCST of these nanogels, with 5% of AA (and 2% MBA), was 11°C in a saline 
phosphate buffer (PBS). There are a few examples in the literature where AA 
(7.25%) is added to NIPAM microgels (MBA 1.6%) for skin drug delivery. 
The microgels with the comonomer showed better skin penetration, compared 
to a control without AA.16,26 
To a explore this possibilities a number of polymers were therefore prepared, 
using a fix amount of AA (5%), in line with the literature, and varying the 
cross-linking between 5% to 20% of MBA, for the purpose of comparison 
with the materials described in Table 2.12. The results are presented in Table 
2.13.  
 
 NIPAM MBA AA Yield Size [nm] LCST 
Zeta Potential 
[mV] 
DF172 75% 20% 5% 63% 7.9±0.4 48°C -20±3.1 
DF173 85% 10% 5% 62% 6.2±0.9 46.5°C -19.7±3.0 
DF174 90% 5% 5% 37% 6.1±1.1 42°C -34±1.0 
Table 2.13 – Characteristics of nanogels with 5% of AA. 
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Figure 2.11 – LCST of negatively-charged nanogels with 5% of AA compared with 
neutral nanogels. 
 
When compared with the results previously obtained for the neutral nanogels 
without the comonomer, a significant increase in the LCST in water for all the 
samples was observed (see the comparative chart).  AA raises the LCST 
because it increases the hydrophilicity of the nanoparticles, with the phase 
transition occurring at higher temperatures. Interestingly, the impact of the 
cross-linker remained the same. In both sets of polymer it can be observed that 
there is a trend for the LCST to increase with the concentration of cross-linker. 
As expected, the charge of the nanoparticles, measured by DLS, is negative, 
with values ranging from -20 to -34 mV. The characteristics of the colloid 
remained mainly unaltered by the incorporation of AA with particle size 
values all under 10 nm. Chemical yields are within reason with some slightly 
abnormal results (37%). Due to time constrains and with the main focus of this 
thesis being the study of the influence of AA on the LCST no replicates were 
carried out. All the LCST values obtained were too high, and therefore 
unsuitable in the context of thermoresponsive dermal drug delivery. 
In order to further explore the effect of AA incorporation into the NIPAM 
nanogels, three new polymer preparations were synthesised. Knowing the 
effect of the cross-linker on the LCST, the lowest concentration of MBA (5%) 
was chosen and the concentration of AA was varied from 2.5% to 10%. The 
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table below shows yields, size, zeta potential and the values of LCST obtained 
when increasing amounts of AA were used (Table 2.14).  
 
 NIPAM MBA AA Yield Size [nm] LCST 
Zeta Potential 
[mV] 
DF230 87.5% 5% 2.5% 38% 5.2±2.2 38.5°C -24±8 
DF231 90% 5% 5% 51% 6.5±2.2 42°C -33±3 
DF232 85% 5% 10% 34% 23.8±1.1 59°C -51±2 
Table 2.14 - Characteristics of nanogels with 2.5, 5 and 10% of AA. 
 
As the percentage of AA added to the polymerisation mixture increased, the 
LCST of the nanogels rose significantly, by almost 50%. This is clearly the 
result of augmented hydrophilicity due to higher levels of AA, as confirmed 
by the increasing values of negative voltage in the zeta potential 
measurements.  
Polymer DF231 was prepared under the same conditions as DF174 (described 
in Table 2.13) and showed good reproducibility in terms of zeta potential, size 
and LCST. The only parameter that shows significant variability is the 
chemical yield, however this can easily be explained as being a result of the 
experimental protocol used for the isolation of the nanogels, which requires 
multiple steps of dialysis followed by freeze drying. 
To conclude, the use of AA successfully introduced a negative charge into the 
NIPAM nanogels. However, this has also been shown to lead to significant 
increases in the value of the LCST. Having studied the effect of the 
incorporation of AA on the LCST and surface charge, the next step focused on 
the study of the incorporation of a comonomer that would give rise to 
positively-charged nanoparticles. 
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2.6.3  Positively-charged nanogels: N-(2-Aminoethyl)acrylamide 
hydrochloride (AEA) 
There are several reports in the literature describing the incorporation of 
positively-charged comonomers in NIPAM particles, mostly using primary or 
secondary amines (tertiary and quaternary amines are considered cytotoxic 
and therefore less popular). 
Katanchalee et al. prepared a copolymer of NIPAM with N-(3-aminopropyl) 
methacrylamide and studied the phase transition behaviour. Increasing 
amounts of the amine, varying from 5% to 15%, raised the LCST from 37°C 
to over 45°C respectively.27 
Amino-containing cationic NIPAM particles, conjugated with oligo nucleic 
acids to diagnose the hepatitis-B virus (HBV), were described by Delair et 
al.28 2-aminoethylmethacylate hydrochloride was added to the polymerisation 
to obtain positively-charged nanoparticles. The measurements of the zeta 
potential of the particles (with values around 20 mV) confirmed the presence 
of the comonomer. The results did not show a big difference in the LCST 
temperature, with 5% of the positively-charged comonomer.  
Jean et al.29 described the phase separation of a cationic NIPAM copolymer in 
water. The positively-charged comonomer used was N,N-
(dimethylamino)propyl acrylamide. This had consequences on the solution 
behaviour of the polymer that responded at temperatures above the LCST of 
NIPAM, where phase separation would have been expected for the 
homopolymer. The LCST values were found to be between 40°C and 50°C 
respectively for a 5% and 10% concentration of the comonomer. 
As what was described for AA, in the case of positively-charged nanoparticles 
the percentage of monomer used appears to be consistently under 10%, 
because higher percentages would have an impact on the LCST values 
obtained. The introduction of positively-charge monomers has been shown to 
increase the LCST. 
For this thesis, a number of commercially available comonomers bearing a 
primary amine were considered, but most of them contained a methacrylate 
group. Given the structure of NIPAM and MBA it was decided that having a 
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comonomer with an acrylamide group was essential for obtaining 
homogeneous polymers. AEA (6) was selected because of its simple linear 
structure and it was synthesised from ethylenediamine and acryloylchloride 
and purified to remove the undesired double acylated product (see Chapter 
IV). The amine group of AEA, with a pKa of approximately 10, was expected 
to provide positive charges in aqueous solutions. 
 
Several polymerisations were carried out with the comonomer AEA, and the 
results are shown in the table below (Table 2.15). As in the case of AA, 5% of 
AEA was added to the polymerisation mixture with varying concentrations of 
20%, 10% and 5% of MBA to allow comparison with the neutral and the 
negatively-charged nanogels already described in this chapter. 
 
 NIPAM MBA AEA Yield Size [nm] LCST 
Zeta Potential 
[mV] 
DF137 75% 20% 5% 63% 7.8±1.8 44°C 9.0±0.8 
DF138 85% 10% 5% 58% 4.6±1.9 41°C 4.3±0.6 
DF139 90% 5% 5% 63% 7.2±1.7 39°C 3.2±0.9 
Table 2.15 - Characteristics of nanogels with 5% of AEA. 
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Figure 2.12 - LCST of positively-charged nanogels with 5% of AEA compared with 
neutral and negatively-charged nanogels. 
 
The data showed that the LCST increased by 1-2°C when 5% of AEA was 
used, and the incorporation of the positively-charged comonomer was 
confirmed by the values of the zeta potential which were found to be positive, 
ranging from 3 to 9 mV. The LCST increased but to a lesser extent than with 
AA (see comparative chart). Equally, it was observed that the impact of the 
cross-linker on the LCST was maintained while introducing the AEA 
comonomer; the more cross-linked the nanogels, the higher the LCST. The 
incorporation of AEA did not affect the size of the nanogels that remains 
unaltered (under 10 nm). 
In order to explore the effect of incorporating AEA into nanogels, a middle 
range concentration of 10% MBA cross-linking was selected. This study is 
equivalent to that carried out for nanogels with AA, but in this case a higher 
amount of MBA was selected because of the lower values of LCST obtained 
with AEA. Three polymer preparations were synthesised by adding increasing 
amounts of AEA (2.5%, 5% and 10%) to the reaction mixture. The results are 
presented in the table below (Table 2.16). 
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 NIPAM MBA AEA Yield Size [nm] LCST 
Zeta Potential 
[mV] 
DF227 87.5% 10% 2.5% 65% 6.2±0.5 36°C 3.5±0.7 
DF228 85% 10% 5% 50% 6.6±0.6 40.5°C 7.7±0.5 
DF229 80% 10% 10% 79% 12±2 42°C 23±2 
Table 2.16 - Characteristics of nanogels with 2.5%, 5% and 10% of AEA. 
 
The incorporation of AEA shows a clear tendency for the LCST to increase, 
from 36°C to 42°C. The values of the zeta potential also become increasingly 
positive, confirming the presence of the comonomer. DF228, was prepared 
under the same conditions than DF138: the characterisation showed a 
reasonably good reproducibility of the physicochemical properties between 
batches of the material. The effect on the thermoresponsive behaviour was 
found to be the same as that observed with AA, the more comonomer is added 
to the polymerisation, the higher the LCST. AEA introduces hydrophilicity to 
the polymer, increasing the temperature at which the phase transition takes 
place.  
To summarise the results obtained so far, AEA introduces a positive charge 
into the NIPAM nanogels, increases the LCST by 1-2°C and does not 
significantly modifies the colloidal size. The next stage of the project focused 
on the introduction of a fluorescent tag in the nanogels, an essential feature for 
studying cell internalisation and skin penetration. 
2.7 Study of the fluorescent labelling 
2.7.1 Overview: Labelling techniques and essential features 
To investigate tissues, cells and cellular processes it is very important to 
visualize structures and compartments within cells. Labelling of molecules, 
polymers, biomolecules and other entities enables researchers to detect, 
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quantify and selectively identify specific components in complex biological 
systems. 
Some of the most interesting types of labelling systems include: paramagnetic 
nanoparticles for Magnetic Resonance Imaging (MRI), gold nanoparticles for 
TEM and dark field microscopy, isotopic labelled and fluorescence 
nanoparticles for imaging such as quantum dots and organic fluorophores. 
MRI is used to investigate the anatomy and physiology of the body. MRI 
scanners use strong magnetic fields to form images of the body. MRI can be 
used as an imaging technique by using paramagnetic nanoparticles (as a 
labelling tag) coupled with a probe able to identify biomoecules in a specific 
organ or tissue, such as an antibody. MRI requires very expensive equipment 
but allows in vivo tracking. 
Gold nanoparticles scatter light and can produce an array of colours under 
dark-field microscopy and are currently used for biological imaging 
applications. Also, gold nanoparticles are relatively dense, making them useful 
as probes for transmission electron microscopy (TEM). Gold nanoparticles 
can be almost as small as organic fluorophores, but due to their metallic nature 
they offer enough contrast to be imaged with electron microscopy. The 
resolution of electron microscopy is much better than for optical microscopy 
and biological structures can be visualized with nanometre resolution. 
Unfortunately, TEM can only be used with fixed samples (dead).  
Isotopic labelling is a technique used to track the presence of an isotope 
through a reaction or a metabolic pathway. A molecule is labelled by replacing 
a specific atom by its isotope. This labelling technique is mainly used to 
investigate cellular metabolic pathways. To detect the presence of a labelling 
isotope three techniques are commonly used: mass spectrometry (detects the 
difference mass of an isotope), infrared spectroscopy (detects the difference in 
the isotope's vibrational modes) and finally nuclear magnetic Resonance 
(detects atoms with different gyromagnetic ratios).  
One of the most common techniques used in cell biology is fluorescence 
labelling.  
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Traditional organic fluorophores have their limitations. After optical 
excitation, they can undergo irreversible reactions such photo-oxidation, 
leading to loss of fluorescence. This phenomenon is known as photobleaching, 
and it limits the time for which such labels can be observed under a 
fluorescence microscope. The advantages of fluorescence over radioactive 
labelling are several: fluorescence is much safer and more convenient to use. 
Several fluorescent molecules can be used simultaneously given that they do 
not overlap, while with radioactivity only two isotopes can be used provided 
that they have different energy windows. Finally, isotopic labelling requires 
special machinery and waste disposal. 
Recently, quantum dots have been studied as an alternative to organic 
fluorophores. Quantum dots do not show any photobleaching, which makes 
them excellent candidates for labelling when long-term photostability is 
required, especially in live-cell imaging and dynamics studies. Quantum dots 
present very narrow, symmetrical emission spectrum that reduces interchannel 
cross-talk on the microscope. They possess very high quantum yields, 
however frequently they are made of heavy metals and often present poor 
solubility in water and require surface ligand stabilization agents to be 
hydrophilic. 
Of the various methods of labelling, fluorescence is the most commonly used. 
Fluorescent labels are highly sensitive even at low concentration. Also, they 
present a variety of colours and they are small. Although fluorescent dyes may 
not have the same sensitivity as radioactive probes, they are able to show real-
time activity of biomolecules in vitro. The development of fluorescent 
microscopy has allowed the visualisation of fluorescent tags in both fixed 
(dead) and live cell images. Fluorescence instrumentation is widely available 
and inexpensive compared to the techniques described before, making it the 
most popular choice. 
The ideal fluorescent tag for this thesis would have: (1) an acrylamide group 
for polymerisation, (2) present a high quantum yield, (3) have very good 
stability (as it would have to be able to withstand being in solution in buffers, 
cell media, cells and the skin). Two essential requirements would be that the 
fluorescent labelled nanogels should be soluble in water (in order to be 
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thermoresponsive), and the incorporation of the tag into the nanogels should 
have a minimal effect on the LCST properties of the material. 
The following section describes the synthesis of fluorescent nanogels by 
copolymerisation with vinyl-bearing fluorescent molecules for the purpose of 
in vitro and ex vivo tracking experiments. To minimise the impact of 
incorporating a comonomer for tracking purposes, the monomer was kept at 
low concentrations. A number of candidates were considered: firstly a 
coumarin derivative, secondly a fluorescein derivative and, lastly, a 
naphthalimide derivative. The work carried out for the synthesis of nanogels 
incorporating each of the above fluorescent tags is reported below. 
2.7.2 Coumarin derivative labelling 
Work carried out within the research group had demonstrated the suitability 
and fluorescent properties of the commercially available 7-(3-
trifluoremethylcoumarin) acrylamide TFMCA (7). This fluorescent monomer 
was previously polymerised with acrylamide to form nanogels.  This monomer 
is soluble in organic solvents such as acetronitrile, tetrahydrofuran and DMSO 
and could therefore be copolymerised with NIPAM. 
 
To minimise the impact of adding TFMCA on the properties of the nanogels, 
such as LCST, a low concentration of TFMC was added to the polymerisation 
solution. Three reactions were carried out to polymerise NIPAM with the 
TFMCA keeping its concentration at 5%, while varying MBA (10% and 20%) 
and CM.  
O
CF3
ON
H
O
(7)
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Reaction NIPAM MBA AIBN CM TFMCA Yield 
Soluble H2O 
(0.1mg/mL) 
DF140 75% 20% 1% 1% 5% 85% No 
DF141 85% 10% 1% 1% 5% 60% No 
DF143 75% 20% 1% 0.5% 5% 85% No 
Table 2.17 – Solubility of different nanogels containing 5% of TFMCA. 
 
The data presented in Table 2.17 show that all nanogels obtained were not 
soluble in water at 0.1mg/mL. Although only 5% of TFMCA was added to the 
polymerisation mixture, this molecule is so hydrophobic that its incorporation 
into the nanogels disturbs the morphology of the nanoparticles to the extent of 
preventing the formation of a stable colloid in water. 
An attempt to improve colloidal dispersability by reducing the total 
concentration of monomer CM to 0.5% (DF142) resulted in polymers that were 
still not soluble. The only available option at this stage was to reduce the 
concentration of the coumarin tag but it was deemed not viable because 
previous florescent data with acrylamide showed that such low concentrations 
of fluorophore would lead to nanogels with such low fluorescence properties 
that they could not be used. 
The solubility data obtained for the coumarin-labelled nanogels were 
surprising, given that the untagged nanogels had shown high water solubility 
up to 50 mg/mL. Therefore research with TFMCA was abandoned and work 
was carried out on a fluoresceine derivative.  
2.7.3 Fluorescein derivative labelling 
Fluorescein-o-methacrylate (8) is a commercially available fluorescent 
monomer widely used in biochemical science. It is soluble in tetrahydrofuran, 
chloroform, toluene and DMSO so it is suitable to be polymerised with 
NIPAM. 
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The presence of a methacrylate group, which has a different reactivity in 
radical reactions, was a reason for concern. Furthermore, the fact that the ester 
bond links the fluorescein to the polymerisable unit and that such bonds are 
known to be hydrolysed in vivo and in vitro by esterases, raised issues of the 
long term stability of the fluorescent tag link. Despite its limitations, the 
solubility of the product was tested to see if its incorporation would afford a 
water-soluble polymer. 
 
Three reactions were set up (DF59 to DF60), with 5% of fluorescein-o-
methacrylate. Three different degrees of cross-linking were used 20%, 10% 
and 5% in order to have consistency and data for comparison with the non-
fluorescent nanogels. 
 
Reaction NIPAM MBA CM 
Fluorescein-o-
methacrylate Yield 
Soluble H2O 
(0.1mg/mL) 
DF59 75% 20% 1% 5% 86% No 
DF60 85% 10% 1% 5% 80% No 
DF61 90% 5% 1% 5% 74% No 
Table 2.18 - Solubility of different nanogels containing 5% of Fluorescein-o-MA. 
 
As seen in the table, the resulting polymers were insoluble in water. 
Fluorescein-o-methacrylate was not a suitable candidate, because of the 
methacrylate double bond, the ester bond and because its hydrophobicity gave 
rise to non-soluble nanogels. A water-soluble fluorescent tag, which would not 
O
O
OHO
O
O
(8)
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interfere in the solubility of the nanogels, was needed, which led to a 
consideration of a naphthalimide derivative tag. 
2.7.4  Naphthalimide derivative labelling 
2.7.4.1 Properties of naphtalimide derivatives  
1,8-naphthalimide derivatives have found applications in a number of areas 
including fluorescent markers in biology, anticancer agents and analgesics in 
medicine, fluorescence switches and sensors, light emitting diodes, 
electroluminescent materials, liquid crystal displays due to their strong 
fluorescence and good photostability.30–33 
The effects of substituents on the fluorescent properties of these compounds 
have been actively investigated.34 Electron-donating substituents at position 4 
are in direct conjugation with the carbonyl groups of the molecule.35 These 
substituents, red-shift the fluorescence spectrum and substantially increase the 
fluorescence quantum yield (reaching levels up to 0.7-0.8).36 
Naphthalimide derivatives are a special class of environmentally sensitive 
fluorophores. For instance, the fluorescence quantum yields show 
considerable solvent dependence, increasing in polar solvents.37 Many 1,8-
naphthalimide derivatives are water-soluble. 
2.7.4.2 Selection of a naphtalimide derivative fluorescent tag and its 
fluorescent properties (Photo-induced Electron Transfer) 
The naphtalimide derivative, N-2-(6-(4-methylpiperazine-1-yl)-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)ethyl)acrylamide (9) was selected as a 
fluorescent tag for this thesis project for all the above mentioned qualities. 
This tag was first synthesised and used by another member of the same 
research team (Dr. Paolo Bonomi).38  
This fluorescent tag enables Photo-induced Electron Transfer (PET), which 
makes it an excellent candidate for a sensor.39–41 Moreover, this monomer is 
soluble in water (1M solution in water). When dissolved in water the 
absorption maximum of the monomer is recorded at 395 nm and the 
fluorescent emission is at its maximum at 530 nm (emitting green light). 
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The structure of the fluorescent tag (9) can be divided into three parts, the 
acrylamide binding moiety, the naphtalimide body, which gives the 
fluorescence, and the methylpiperazine sensing moiety. The nitrogen in 
position 4 in the methylpiperazine has a pKa42 of 8.5 and plays an important 
role as an on-off switch. The same amine group provides an anchoring point 
for an acid drug (which is further discussed in Section 2.8 of this Chapter).  
 
 
When the fluorescent tag is not protonated, the molecule is in the off-state and 
there is a minimal fluorescence (the fluorescence is quenched). When in an 
acidic media, the nitrogen becomes protonated and the fluorescent tag is in the 
on-state. To explain this on-off switch it is necessary to discuss molecular 
orbitals and the electrons involved in the fluorescence. 
When the pH is higher than the pKa, the lone pair of electrons from the 
nitrogen in the methylpiperazine moiety can occupy the vacant space left by 
the excited electron of the fluorophore. This prevents the delocalised electron 
from returning to the highest unoccupied molecular orbital (HUMO). 
Alternatively, when the pH is lower than the pKa, the lone pair from the 
nitrogen forms a bond with the H+. The excited electron in the lowest 
unoccupied molecular orbital (LUMO) is therefore able to relax and emit 
photons, in order to reduce its energy emitting fluorescence. 
N
N
N
OO
NH
O
(9)
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Figure 2.13 – Schematic explanation of the PET mechanism on the fluorescent monomer. 
 
2.7.4.3 Synthesis and PET fluorescent properties of the naphtalimide 
derivative fluorescent tag 
The synthesis of this fluorescent tag was carried out following previous 
reactions described by Dr Paolo Bonomi. Details of the synthesis and analysis 
of the three intermediate molecules and the final product can be found in in 
Chapter V. The diagram below shows the steps followed to obtain the 
fluorescent monomer. 
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Once the fluorescent tag had been synthesised and purified, the PET effect in 
water was assessed in order to quantify the fluorescence enhancement of the 
tag. Solutions of the monomer at 0.1mM in different pH were prepared and the 
readings of the fluorescence emission were recorded and are shown in the 
graph below.  
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Figure 2.14 - Fluorescent monomer (FM) at 0.1mM buffered at different levels of pH in 
McIlvaine universal buffers43 (i.e. a mixture of citric acid with Na2HPO4).  
 
The plot above shows that the fluorescent tag emission increased by 7-fold 
from pH 8 to pH 5.5 giving evidence of the PET effect. The next step was to 
polymerise the fluorescent tag in the nanogel.  
2.7.4.4 Water-soluble fluorescent nanogels 
Several experiments were set up with 5% of the fluorescent monomer (FM) 
(9) with a degree of MBA cross-linking in the polymerisations ranging from 
5% to 20%, for comparison with previously synthesised nanogels and to test if 
they were soluble in water (see Table 2.19). 
 
Reaction NIPAM MBA AIBN CM FM Yield Soluble H2O 
(10 mg/mL) 
LCST 
DF161 75% 20% 1% 1% 5% 43% Yes 35°C 
DF162 85% 10% 1% 1% 5% 32% Yes 34°C 
DF163 90% 5% 1% 1% 5% 36% Yes 32°C 
Table 2.19 – Properties of water-soluble flurescent nanogels. 
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Figure 2.19 – LCST comparison of NIPAM nanogels MBA cross-linked, with and 
without fluorescent monomer FM. 
 
Unlike the attempts described above with other fluorescent monomers, the 
preparation of the nanogels containing the naphthalimide derivative (9) gave 
rise to highly soluble nanogels (10 mg/mL): polymers DF161-163.  
Although the yields were considerably lower (compared to those of the 
nanogels without the fluorescent monomer), the polymers obtained were 
considered potential candidates for further study. One possible reason for the 
low yields could be the presence of the fluorescence molecule itself acting as a 
radical scavenger and therefore reducing the reactivity rate. 
Incorporation of the fluorescent tag led to a nanogel preparation with a lower 
LCST. Although the FM (9) was water-soluble, it was still introducing 
hydrophobicity into the nanogels. This is the reason why the phase transition 
to a hydrophobic state took place at lower temperatures. As reported above the 
influence of the cross-linker can still be observed. 
2.7.4.5 Fluorescent tag incorporation 
To ensure a secure bases for later measurements i.e. the PET effect the drug 
uploading it was necessary to confirm the amount of fluorescent tag 
incorporated in the polymer. The amount of fluorescent tag added to the 
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reaction and the final amount incorporated in the nanogels were easily 
quantified by UV-Visible spectroscopy. 
To be able to quantify the amount of the FM in the nanoparticles, several 
solutions of the free fluorescent monomer were dissolved in water and 
absorbance readings taken at 395nm. The calibration curve obtained is shown 
below (Figure 2.20). 
 
Figure 2.15 – Calibration curve for the fluorescent monomer (FM) in water 
Known concentrations of fluorescent nanogel preparations (DF161-163) in 
water were then prepared and their absorbance recorded. Using the calibration 
curve, the amount of the fluorescent tag contained in the polymer was 
calculated. The percentage of fluorescent monomer with respect to the total 
amount of polymer was calculated and the results presented in the table below. 
For this experiment and subsequent calculations, several assumptions were 
made: (1) NIPAM, MBA and any traces of the initiator would not present any 
absorption at 395nm, (2) the polymer was homogeneous, the rate of 
polymerisation of NIPAM, MBA and FM being similar, (3) the absorbance of 
the free fluorescent monomer and the polymerised monomer is the same, and 
is not affected by the presence of NIPAM or MBA. 
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Reaction NIPAM MBA FM added Molar % of FM in the polymer 
DF161 75% 20% 5% 5.6% 
DF162 85% 10% 5% 5.8% 
DF163 90% 5% 5% 4.8% 
Table 2.20 – Comparison for FM added in the polymerisation and found. 
 
The values suggest that the fluorescent tag (5%) added to the reaction mixture 
is incorporated in the polymers in the same percentage as present at the 
beginning of the reaction (in the polymerisation mixture). The results are 
highly satisfactory and small variation can be attributed to incorrectly weighed 
amounts, approximations in the calculations of the molecular weights and the 
assumptions being made on the absorption readings. 
2.7.4.6 Dependence of the nanogel fluorescence on the pH value 
As described in Section 2.7.4.3 (Figure 2.18), the fluorescence of FM (9) is 
dependent on the pH value as it presents a PET effect. To assess whether the 
fluorescent nanogels obtained could also be switched on-off by changes in pH, 
six solutions of nanogel DF163 were prepared with different pH, ranging from 
5.5 to 8, using McIlvaine universal buffers. The nanogel concentrations in the 
solutions were calculated to ensure a 0.1 M concentration of the fluorescent 
tag, the same used for the data described in Section 2.7.4.3 in order to allow 
direct comparison. This was made possible by use of the calibration curve 
obtained with the fluorescent monomer and the successive determination of 
the exact fluorescent monomer content in the resulting nanogels. The results 
of the fluorescence measurements are shown in the plot below (Figure 2.21). 
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Figure 2.16 - Fluorescence of 0.1mg/mL nanogel DF163 buffered at different levels of pH 
in McIlvaine universal buffers. 
 
The nanogels showed a similar behaviour to the fluorescent tag. In this case it 
can be seen how the fluorescence intensity is 5.3-fold higher at pH5.5 than at 
pH8. For the fluorescent tag alone, the fluorescence increased by 7-fold. A 
possible reason for this difference may be due to the inability of UV-vis 
spectroscopy to make very accurate measurements of concentration in the 
polymer. Another contributing factor could be that part of the fluorescence tag 
inside the structure of the nanogel and is being shielded from the spectroscope. 
Having obtained water-soluble nanogels and studied their fluorescence 
properties, other polymer characteristics were analysed to understand the 
suitability of those new materials for drug delivery applications. 
 
2.7.4.7 Study of the influence of the incorporation of the fluorescent tag 
on the size, zeta potential and thermoresponsive behaviour of the 
nanogels 
As with previous comonomers, a detailed study of the influence of the 
incorporation of the fluorescent monomer was carried out while maintaining 
the amount of cross-linker constant. Having observed the influence of the 
fluorescent tag on the LCST, a high amount of MBA was selected to carry out 
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the study, in order to avoid the transition temperature dropping to dramatically 
low values.  
Increasing amounts of fluorescent tag were added to the polymerisation 
solution (5%, 7.5% and 10%) while the cross-linker content remained fixed at 
20%, in order to study the impact of this addition on the size, LCST and 
charge of the resulting particles. The higher concentration of fluorescent tag 
was required, as preliminary tests on skin had identified issues with the 
visualisation of the nanoparticles in the samples, as a result of low 
fluorescence.  
 
 NIPAM MBA FM Yield Size [nm] LCST 
Zeta Potential 
[mV] 
DF241 75% 20% 5% 40% 5.9±1.2 35°C 6.9±0.8 
DF243 72.5% 20% 7.5% 35% 4.9±0.8 27°C 8.9±1.0 
DF239 70% 20% 10% 42% 6.2±0.3 25°C 10 ±1 
Table 2.21 – Characteristics of NIPAM nanogels with 20%MBA and 5, 6.5 and 10% of 
FM. 
 
The results shown in the table above indicate that the LCST decreased as the 
amount of the fluorescent tag used increased. This result was to be expected 
because the fluorescent monomer introduced hydrophobicity into the nanogel 
that made the phase transition occur at lower temperatures. The response 
temperature dropped by 10°C compared to DF241 (nanogels without 
fluorophore) and DF239 (nanogel with fluorophore). The size of the 
nanoparticles remained under 10 nm, unaffected by the incorporation of the 
fluorescent tag. The measurements of the surface charge of the nanogels 
showed values from 7 to 10 mV, increasing with the content of the 
fluorophore, which confirmed the tag incorporation. This is due to the amino 
groups on the fluorescent tag that become protonated in water, therefore 
shifting the zeta potential for the polymer to positive values. The results 
demonstrated that the addition of higher percentages of fluorescent monomer 
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is not a viable option, because the resulting polymers respond at temperatures 
deemed too low for applications in drug delivery. The next step therefore 
focused on the addition of different monomers that would be able to add 
charges to the nanogels, with the aim of increasing the LCST. The next section 
will describe how charged fluorescent nanogels were prepared and 
characterised.  
 
2.7.4.8 Study of the influence of the incorporation charge on the 
fluorescent nanogels: size, zeta potential and thermoresponsive 
behaviour  
Once the introduction of the fluorescent tag had been completed and the 
influence on the LCST well understood, the next step was the addition of a 
charge to the fluorescent nanoparticles, as carried out with the non-fluorescent 
nanogels. Two polymerisations were set up with 20% MBA as a cross-linker 
to compensate as much as possible for the drop in LCST that the FM would 
introduce. The table below shows the effect of adding 5% AA (DF183) and 
5%AEA (DF184) to a fluorescent nanogel, while the data for DF241 are 
presented for comparison (neutral florescent nanogels). 
 
 NIPAM MBA AA AEA FM Yield Size [nm] LCST 
Zeta 
Potential 
[mV] 
DF183 70% 20% 5% - 5% 54% 5.5±1.1 37°C -23±1 
DF184 70% 20% - 5% 5% 41% 6.9±0.9 35°C 13±1 
DF241 70% 20% - - 5% 40% 5.9±1.2 35°C 6.9±0.8 
Table 2.22 – Neutral, negatively and positively-charged fluorescent nanogels 
characteristics (20% MBA). 
 
In comparison with DF241 (which contained the same amount of cross-linker 
and fluorescent monomer), DF183 showed slightly higher LCST while DF184 
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remained unmodified. This confirmed the trend for an increased LCST with 
the addition of AA, already presented in Section 2.6.2. As observed 
previously, AA introduces a higher rise in thermoresponsiveness than AEA; 
this is probably the reason why a change in temperature cannot be observed 
with this later one. 
Nonetheless, in both cases the addition of the charged monomer modified the 
surface charge, confirming the incorporation of the comonomer: DF183 
presents a negative value of -23 mV whilst DF184 was +13 mV.  
 
 
Figure 2.17 – TEM images of fluorescent neutral nanogels stained with OsO4 
 
Figure 2.18 TEM images of fluorescent negatively-charged nanogels stained with OsO4 
 
Figure 2.19 – TEM images of positively-charged nanogels stained with OsO4. 
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The TEM imaging of the samples was performed using OsO4 as the staining 
agent. NIPAM polymers are almost transparent to the electron beam and 
require a heavy metal staining. The images confirm the morphology of the 
particles. The presence of OsO4, which is commonly used in biological 
samples to fix (cross-link) and add contrast, creates the effect of chained 
beads. The nanoparticle size on the pictures is slightly bigger (between 15-20 
nm) than those obtained by DLS. This is a reported phenomena linked to the 
reduced amount of cross-linker in these preparations; the swollen nanogels 
spread out on the surface of the grid and they appear to be bigger than in 
solution.44 It is also known that OsO4 can increase the size of polymers and 
therefore it is also an artefact of the staining.45  
To summarise the data obtained so far, the incorporation of the fluorescent tag 
affected the LCST of the polymer, which became more hydrophobic, 
responding at a lower temperatures. Increasing amounts of fluorescent 
monomer led to a drop in the thermoresponsiveness, to values close to room 
temperature. However, a successful polymerisation with a fluorescent tag was 
possible when using a fluorescent monomer at 5% concentration with a 
comonomer (AA, AEA) also at 5%. The addition of a charged comonomer 
(AA) partially compensated for the drop in LCST caused by the fluorescent 
tag. 
At this point of the research, some of the nanogels showed characteristics that 
would make them potential candidates for skin drug delivery applications: 
fluorescent nanogels with and without a comonomer that are water-soluble 
and respond at temperatures of around 35-37°C, making them suitable for skin 
applications. The next step consisted in uploading a drug into those carriers. 
 
2.8 Study of the Drug Uploading 
The drug selected was flufenamic acid (FA, 10), which is used as a non-
steroidal anti-inflammatory, antipyretic and anti-rheumatic drug, derived from 
anthranilic acid, which inhibits the synthesis of prostaglandins. It is used in 
topical formulations, usually containing a concentration of 3% or 5%, to treat 
pain and inflammations associated with muscles, bone and joint disorders.46 
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Different products containing flufenamic acid are commercially available and 
are administered via the dermal route. Topical application reduces the 
undesired gastrointestinal side effects and the first pass metabolism.47  
This drug was selected as the basis for research for three reasons: (1) it is 
useful as a skin treatment, (2) it is a hydrophobic molecule (solubility in water 
9.09 mg/L at 25°C) and therefore will not be released from the nanoparticle in 
aqueous media, and (3) it contains a carboxylic group that will be able to 
interact with the basic amino group of the fluorescent tag via an ionic bond. 
 
The structure of flufenamic acid has two aromatic rings and a carboxylic acid. 
The drug and the fluorescent tag present two interactions: π-π stacking (both 
compounds have aromatic rings) and ionic interaction between the carboxylic 
acid of the drug and the amino group of the fluorescent tag. The importance of 
the acidity of the drug (pKa 3.9) lies in the fact that it activates the 
fluorescence of the tag. The drug acts as the ‘on’ switch.  
The interactions of the drug with the fluorescent tag are described in the 
following sections. 
2.8.1 Drug-fluorescent tag interaction 
To demonstrate the interaction of the fluorescent tag in the nanogels with the 
flufenamic acid, several samples of the polymer DF163 (not loaded with the 
drug) were dissolved in ethanol and mixed with increasing amounts of 
flufenamic acid.  
F
F
F H
N
O OH
(10)
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Figure 2.25 - Fluorescence of 0.1mg/mL nanogel DF163 solution, adding equivalents of 
FA to the tag. 
As can be seen in the plot above (Figure 2.25), when adding equivalents of 
flufenamic acid to the tag, after the addition of 10 equivalents the fluorescence 
of the nanogels is enhanced by 8-fold, proving that the PET effect can also be 
observed in the nanogels interacting with the drug. The fluorescence 
enhancement is higher than that observed for the nanogels in different pH 
buffered solutions. This last experiment was performed in methanol (due to 
the insolubility of the drug in water), not in a buffer, and the solvent 
(methanol) is affecting the fluorescence. As discussed above in Section 
2.7.4.2, the amino group of the piperazine moiety of the florescent monomer 
plays an essential role in the enhancement of the fluorescence. The nanogels 
were dissolved in methanol where the amine group was not protonated as it 
was in water. Therefore, the fluorescence of the tag in the methanol is lower 
and the enhancement caused by the interaction with the drug higher.  
The strong interaction of the drug-fluorescent tag is due to two major forces: 
the electrostatic interaction between the carboxylic acid group of FA and the 
basic amino group of the piperazine moiety of the fluorescent monomer, and 
the π−π stacking interactions of the aromatic rings of both molecules. 
FA and the fluorescent tag are a weak acid and weak base respectively so they 
will tend to have equilibrium, which is the reason why a lot more FA is 
required to reach saturation. The experiment demonstrates the interaction of 
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FA and the fluorescent monomer, and shows evidence of the influence of the 
media. This interaction in vivo would be difficult to sustain. 
Having described the properties of flufenamic acid and evaluated the 
interaction between the fluorescent nanogels and the drug, in the following 
sections the general methodology available in the literature for nanogel 
uploading will be described. Subsequently, the two methods used to upload 
the drug for this thesis are described: particle suspension and imprinting 
polymerisation. 
 
2.8.2 Methods for uploading active compounds into NIPAM cross-
linked nanogels 
2.8.2.1 Overview 
There are two types of methods for uploading active compounds (drugs) into 
cross-linked nanogels described in the literature: those where the drug is 
uploaded while the nanogels are being formed and those where the uploading 
is performed after the particles are polymerised and purified. 
For the first approach, the uploading is done by the chemical linking of the 
drug to the polymeric network. This is usually performed by modifying the 
drug, adding a vinyl moiety to it, and then proceeding to polymerise.48 This 
approach does not involve any controlled drug release by phase transition. 
Alternatively, the drug can be uploaded during the formation of the polymer 
by an interaction between the nanoparticle and the drug (molecular 
imprinting). 
The second approach, where the drug is uploaded after the nanoparticles are 
formed and isolated, can be achieved in several ways. The most common 
approach is by dissolving a drug in a solvent and then suspending the nanogels 
in this solution (the nanogels do not dissolve). Subsequently, the suspension is 
stirred for several hours. Finally, the suspension is centrifuged to recover the 
nanogels. After recovering the particles they may require washing to remove 
any drug that is not strongly trapped in the polymeric structure.  Some 
researchers have reported that the best results for this method are obtained if 
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the particles are stirred at low temperature, where the nanogels swell. It should 
be noted that for this method16 to be successful, the nanogels have to remain 
not dissolved.  
A second possibility is to chose a highly volatile solvent which can be slowly 
evaporated, forcing the drug to enter the nanoparticles, which produces a high 
concentration of the drug in the solution thereby forcing it to be incorporated 
into the nanogels.49 The third option is to react a drug with a comonomer. For 
example, using a free amine or carboxylic acid group comonomer, adding a 
coupling reagent and a carboxylic acid or amine bearing-drug, chemically 
links the drug to the pro-drug nanoparticle.50 This option forces the use of a 
comonomer able to provide a reactive group into the nanoparticle and limits 
the choice of drugs to those that can be chemically coupled. However, when 
the drug is covalently linked to a nanogel in this way, the drug releasing 
mechanism is not linked to the thermoresponse and therefore this approach 
was of no interest for the final application envisaged for this project. 
In the context of this project two approaches were investigated: a suspension-
based method and molecular imprinting.  
2.8.2.2 Uploading flufenamic acid by suspension 
The first method that was explored consisted of finding a solvent that would 
dissolve flufenamic acid and form a suspension with nanogels. 
After several trials, acetonitrile was selected as a solvent because it can 
dissolve 10 mg/mL of flufenamic acid and it dissolves less than 0.01 mg/mL 
of the fluorescent nanogels. DF196 (described below) was selected for this 
uploading experiment because of its LCST and its MBA content, which made 
it more rigid (less prone to lose its load). 
 
Reaction Code NIPAM MBA FM Yield Size [nm] LCST 
DF196 75% 20% 5% 34% 12±3 35°C 
Table 2.23 – Characteristics of the fluorescent nanogels used for drug uploading. 
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A series of sealed vials equipped with a stirring bar were prepared with a final 
content of 2 mg/mL of flufenamic acid and 0.2 mg/mL of an unloaded 
polymer (DF196) in 4mL of acetonitrile. The drug/polymer mass ratio was 
1:10. Samples were stirred for 72 hours, one at 4°C (DF196A), one at 25°C 
(DF196B) and one control without the polymer for each condition. 
The samples were centrifuged to remove the supernatant containing the excess 
drug. The supernatants were analysed by high performance liquid 
chromatography (HPLC) to determine the amount of drug inside the nanogels. 
The success of the uploading was calculated using the encapsulation 
efficiency and the nanogel loading.  
Entrapment efficiency is defined as the amount of loaded FA/the amount of 
added FA × 100%. The FA acid loading in w/w was calculated as follows: 
amount of loaded FA/amount of polymer × 100%. The results are presented 
below. 
 
Sample Uploading temperature Entrapment Efficiency Loading 
DF196A 4°C 8% 0.8% 
DF196B 25°C 9% 1,1% 
Table 2.24 – Summary of uploading experiment at two temperatures: entrapment 
efficiency and loading 
 
The entrapment efficiency was low (under 10%) and the loading too. The 
highest values for these parameters on MBA cross-linked NIPAM micro- and 
nanogels with MBA in the literature usually ranges from 25 to 35% for 
entrapment efficiency and from 0.2 to 0.5 for loading.51,52 Such low 
entrapment efficiencies (<10%) means than more than 90% of the drug is 
wasted during the uploading and this was deemed too low.  
The uploading conditions, reported by other groups to be of influence, seem 
not to have affected the entrapment of the drug showing no significant 
difference from 4°C to 25°C. The process was long and unsuccessful in 
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uploading the drug. Probably, the poor success of this approach was due to the 
flufenamic acid being highly soluble in acetonitrile and the competition with 
the nanogels’ fluorescent tag not strong enough to remove the drug from 
solution and be incorporated in the structure of the nanoparticle.  
Due to the difficulty in finding an appropriate solvent for this process a new 
approach to flufenamic acid uploading was evaluated using molecular 
imprinting.  
2.8.2.3 Imprinting the nanogels with flufenamic acid 
In the early 1930s Polyakov reported the first system of molecular imprinting 
when he described the behaviour of silica gels that had a preference for re-
binding a solvent additive (benzene) when the additive was present during the 
preparation of the silica gel.53 The first example of organic imprinted polymer, 
was described by Wulff et al.54 in 1972, which was able to separate a 
racemates. 
The molecular imprinting approach for organic polymers is based on the self-
assembly of functional monomers around a template or target molecule. The 
functional monomer is polymerised in the presence of a cross-linker. Once the 
reaction is completed, the template is removed via specific washing. This 
results in the formation of a 3-D cavity whose structure is complementary to 
the template used. A template is often used, rather than the target molecule, 
for creating a molecular imprinted polymer. 
Figure 2.20 – Molecular imprinted approach.  
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The key feature of molecular imprinting is the interaction between the 
template and the functional monomer. The stronger and more specific the 
interaction between these two entities is, the higher the selectivity of the 
imprinted polymer. The nature of the interaction of the functional monomer 
with the template can be based on covalent, semi-covalent and non-covalent 
bonds. 
In the covalent method a covalent bond (bond energy of ~85 kcal/mol) is 
formed between the template and the monomer, which can be broken and 
reformed in a specific environment. In this approach, the release of the 
template molecules is mainly through hydrolysis. In the semi-covalent 
approach, the template molecule is initially bound via a covalent bond. Once 
the template is released, the target molecule re-binds to the polymer matrix via 
non-covalent interaction.  
The most commonly described molecular imprinting method in the literature 
is the non-covalent approach, where strong interactions such as ionic bonds 
(~5 kcal/mol), hydrogen bonds (~3 kcal/mol), π–π stacking (~10 kcal/mol), 
(dipole – dipole interactions (~1.4 kcal/mol), and Van der Waals (~1 
kcal/mol), can be found between the functional monomers and the template 
molecules.  In this last case, the re-binding of the template occurs using the 
same non-covalent interactions used to form the complex.  
Molecular imprinting has been applied in many areas of research including 
sensors, solid phase extraction, catalysis, chiral separation, but also to drug 
development.55 The first reports of imprinted polymers that offered a sustained 
release mechanism were described by Norell et al.56 Polymers were imprinted 
with theophylline, a drug used in the treatment of asthma. The polymers were 
prepared by the non-covalent technique using methacrylic acid as the 
functional monomer and ethylene glycol dimethacrylate as the cross-linker.  
The ability to modulate the release of a drug from a delivery system has been 
exploited by copolymerisation with thermoresponsive imprinted polymers. 
Watanabe et al.,57 copolymerised NIPAM with acrylic acid as the functional 
monomer and methylenebisacrylamide as the cross-linker in the presence 
of DL-norephedrine hydrochloride or DL-adrenaline hydrochloride. The two 
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gel preparations displayed very specific changes in swelling ratios, only 
displaying a change in the swelling ratio in the presence of their respective 
template. Gels without the functional monomer (acrylic acid) did not display 
any volume changes in the presence of the molecules.  
Molecular imprinting polymerisation was therefore used to prepare the 
fluorescent nanogels in the presence of flufenamic acid. The aim was to 
prepare nanogels with cavities that have a high affinity for flufenamic acid. In 
this case the fluorescent monomer acts as a functional monomer, because it 
interacts with the “template”, the model drug. The fluorescent monomer 
should be able to anchor the nanogels by ionic interaction (acid-base) and 
through π-π stacking (Figure 2.27). 
Figure 2.21 – Ionic interaction and π-π  stacking between fluorescent monomer and 
flufenamic acid  
 
Reaction Code NIPAM MBA FM FA/FM 
DF190  
85% 10% 5% 1:1 
DF191 
DF199 
75% 20% 5% 1:1 
DF223 
Table 2.25 - Experiments in duplicate to assess uploading by imprinting polymerisation 
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To prove the success of this uploading method, two polymers were prepared, 
with 10% and 20% of crosslinking, to maintain a balance between the values 
of LCST and the rigidity of the matrix. Imprinted polymers are known to 
benefit from high degrees of crosslinking where a cavity (recognition site) is 
formed. The rigidity of the polymer makes the nanogels’ affinity for the 
substrate stronger. The ratio drug to fluorescent tag used was 1:1, assuming 
that one molecule of fluorescent monomer can interact with one molecule of 
flufenamic acid. These polymers were prepared in duplicates to assess the 
reproducibility of the uploading process and purification step. The 
preparations are shown in the table below. 
After polymerisation, a very mild dialysis process was performed with water, 
which removes any unreacted monomers like the fluorescent tag and any 
flufenamic acid that is not strongly interacting with the fluorescent monomer 
of the nanogels. After this the polymers were characterised by DLS, and both 
entrapment efficiency and drug loading were evaluated by HPLC. These 
results are shown in the Table 2.26 below. 
 
Sample Size [nm] Entrapment Efficiency Loading  
DF190  15±2 33% 4% 
DF191  13±7 29% 3% 
DF199  14±3 39% 8% 
DF223 17±4 38% 8% 
Table 2.26 – Entrapment efficiency and loading of imprinted nanogels. 
 
The size of the nanogels obtained with this approach is only slightly larger 
than the one obtained without drug incorporation, which were 5 to 10nm. The 
small hydrophobic drug is incorporated in the cavities of the nanogels and this 
results in a slightly larger particle. 
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The entrapment efficiency obtained with this method is around 30-40%, a 
value that is higher when compared to the other system previously used and is 
also consistent with the best data reported in the literature for similar 
materials.16,51 Although the amount of fluorescent monomer is the same in 
both polymerisations, the nanogels with higher content of cross-linker (MBA) 
achieve a significantly higher entrapment efficiency. This is likely to be due to 
the combination of two effects: on one side the higher cross-linked matrix will 
allow for a better encapsulation while at the same time the more hydrophobic 
nature of the polymer, due to the higher cross-linker, improves the retention of 
the hydrophobic drug. The values of drug loading, especially in the case of 
DF199 and DF223 are very good. It is important to note that in both cases of 
10% and 20% cross-linker the data obtained are consistent and can be repeated 
very accurately. 
Having obtained a satisfactory method for drug uploading, the next step of this 
thesis focused on studying the drug release behaviour of nanogels as a 
function of temperature 
2.9 Study of in vitro Drug Release 
2.9.1 Overview 
In vitro drug release testing is a measurement of the drug released from the 
matrix or carrier, in controlled laboratory conditions. It is a key process in the 
development of the final formulation of a medicine. In vitro experiments 
conducted on a formulation (carrier and drug), will induce drug release under 
a specific set of conditions, which will allow quantification. It is the test that 
elucidates the difference in performance between potential carriers. It can be 
used to predict the time span of the drug release and, if set up to simulate the 
appropriate conditions, to model in vivo behaviour.  
To conduct an appropriate drug release experiment, the volume of the 
dissolution medium should be sufficient to dissolve the expected amount of 
the drug released from a drug delivery system. This ability of the medium to 
dissolve the expected amount of the drug is known as a sink condition. If, as 
expected, a drug delivery system releases 100% of the drug, it cannot be 
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measured unless there is sufficient medium present. The sink condition is 
therefore an experimental requirement for the quantification.  
The release of the drug is typically measured by dialysis. The drug contained 
inside the nanoparticles is released into the dialysis chamber, diffused across 
the dialysis membrane and accumulated in the receiving compartment (the 
sink). Although having two steps, this process is generally treated as a simple 
first-order process. Either the disappearance of the drug nanoparticles from the 
dialysis chamber or their appearance in the receiving compartment can be 
measured experimentally.  
2.9.2 Characterisation of the uploaded nanogels 
In Section 2.8 of this Chapter, it explored the methodology to upload nanogels 
by imprinting polymerisation. To test the drug release performance of the 
nanoparticles obtained by this technique, four new fluorescent nanogels were 
prepared with flufenamic acid. These formulations were neutral and 
negatively-charged (5% AA) fluorescent nanogels with concentrations of 5% 
and 10% fluorescent tag. At this stage of the research, concerns about the 
fluorescence intensity of the nanogels during skin experiments were taken into 
consideration and nanogels containing 10% of fluorescent tag were evaluated 
although it was known that the LCST could be too low. Fluorescent 
positively-charged nanogels were not considered because of their performance 
in the cell toxicity experiments (fluorescent positively-charged nanogels were 
found to be not suitable, see Chapter III). To compare these drug-uploaded 
nanogels, four control-nanogels having the same polymeric composition, have 
been included in this section for comparison. 
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 NIPAM MBA FM AA FA/FM Loading 
Entrapment 
Efficiency 
LCST 
Size 
[nm] 
DF247 70% 20% 5% 5% 1:1 6% 23% 37°C 15±3 
DF248 75% 20% 5% - 1:1 11% 37% 34°C 13±1 
DF249 65% 20% 10% 5% 1:1 7% 32% 28°C 17±2 
DF250 70% 20% 10% - 1:1 15% 39% 22.5°C 18±5 
DF240 70% 20% 5% 5% - - - 37°C 5.5±1.0 
DF241 75% 20% 5% - - - - 35°C 5.9±1.2 
DF238 65% 20% 10% 5% - - - 28°C 11±4 
DF239 70% 20% 10% - - - - 23°C 10±1 
Table 2.27 – Characteristics of uploaded nanogels and non-uploaded nanogels (controls). 
 
The values shown in the first table, for the drug entrapment efficiency of the 
naongels, are comparable or slightly higher than those found in the literature 
for NIPAM micro- and nanogels.16,51 The values obtained for the loading are 
good and confirm a very efficient uploading process by imprinting 
polymerisation of the drug by interaction with the fluorescent monomer.  The 
solubility of the flufenamic acid loaded nanogels in water is around 1 mg/mL 
(except for DF250 where this value is only true at 20°C, due to the low LCST 
of the material). This solubility by itself is a proof of the loading of the drug, 
because the same amount of flufenamic acid would not be soluble at this 
concentration (solubility of FA in water is 9.09 mg/L). 
The fluorescent nanogels containing 5% of AA (DF247 and DF249), both 
showed lower drug loading and entrapment efficiency compared to their 
uncharged counterparts. This can be explained by the repulsion between the 
negatively-charged nanogels (containing AA) and the flufenamic acid.  
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The LCST values of the nanogels with and without flufenamic acid are similar 
to the nanogels incorporating acrylic acid, but slightly lower (0.5-1°C) than 
the neutral nanoparticles. The incorporation of flufenamic acid introduces 
hydrophobicity to the nanogel; this is why this effect is more obvious in the 
fluorescent, neutral, nanogels formulations because they contain more 
flufenamic acid (DF248 and DF250 have a higher loading of the drug).  
The size of the particles is slightly affected by the incorporation of the drug; as 
can be seen by comparing the results of the DLS measurements of the 
uploaded nanogels with the control samples. This is most probably due to the 
increased repulsion caused by the incorporation of the drug. 
Having successfully synthesised and characterised these four samples, the 
work focused on the next step, involving the drug release experiments. 
 
2.9.3 Drug release profiles 
The preparations DF247 – DF250 described in the previous section were 
tested in sink conditions, at two different temperatures, 20°C and 37°C, using 
a dialysis system containing a water solution of the nanogels to obtain the drug 
release profiles.  The purpose of this experiment was to elucidate the different 
behaviour of these samples, above and below their LCST. All the nanogels 
should not release their load at 20°C although some diffusion may take place. 
On the other hand, all the samples should release the flufenamic acid 
contained inside the polymeric matrix when the experiment is carried out at 
37°C.  
A 1mg/mL water solution of nanogel was placed on a dialysis device floating 
inside a 3L container equipped with a stirring bar. Both samples were 
incubated for the length of the experiment at 20°C and 37°C respectively. 
Because of the low solubility of the flufenamic acid in water, it was not 
possible to measure the amount of drug in the receiving compartment (amount 
released) and it was done by measuring the amount of drug still remaining in 
the nanogels by analysing samples taken from the dialysis compartment. A 
sample at time zero was kept for comparison, before starting the drug release 
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experiment, in order to calculate the amount of drug released. The results for 
each of the four samples at two temperatures are presented below. 
 
 
Figure 2.22 – Cumulative drug release DF247, fluorescent (5%FM) negatively-charged 
(5%AA) nanogel. 
 
Figure 2.23 - Cumulative drug release DF248, fluorescent (5%FM) neutral nanogel. 
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Figure 2.24 - Cumulative drug release DF249, fluorescent (10%FM) negatively-charged 
(5%AA) nanogel. 
 
Figure 2.25 - Cumulative drug release DF250, fluorescent (10%FM) neutral nanogel. 
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fluorescent tag (DF249-DF250) had a higher drug release at 20°C, reaching up 
to 20% cumulative release after 6 hours. This could be explained by two 
factors. Firstly, the LCST of these samples is lower (23°C and 28°C 
respectively) as shown in Section 2.9.2 (Table 2.27). Secondly, they have a 
higher load, and some of it may not be strongly incorporated within the 
matrix. The samples that contained acrylic acid (DF247 and DF249) and were 
therefore negatively-charged, had an unwantedly fast drug release profile at 
37°C, which showed that 80% of the drug had been released within the first 
two hours, followed by a slower release phase. This is probably due to the 
presence of the negative charge, which facilitates the release. The fluorescent 
neutral nanogels, however, showed a slower drug release at 37°C, closer to a 
first order drug profile (characterised by a slope of the cumulative drug release 
versus time).  
Unfortunately due to a lack of time it was not possible to explore this 
phenomena further by carrying out more detailed experiments at various 
temperatures and by preparing nanogels with different amounts of acrylic 
acidic to probe the impact of this comonomer on the formulation. However the 
key finding from these experiments confirmed that the nanogel formulations 
uploaded with the drug were showing a stimuli responsive behaviour and were 
able to release the drug selectively when the temperature was close to the 
LCST values. 
 
2.10 Chapter summary 
This chapter has described the successful development of a methodology for 
the preparation of nanogels uploaded with drugs that can be released under 
controlled conditions as a function of temperature. 
Section 2 described the suitability of high dilution polymerisation for 
producing nanosized particles. In Section 3 a technique was validated for the 
accurate measurement of the thermoresponse of the nanogels by turbidimetric 
analysis. 
Section 4 described the selection and subsequent fine-tuning, of the initial 
polymerisation components and parameters. The experiments defined the 
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appropriate concentration of the monomer (CM) and the crosslinker, the 
negligible influence of the initiator and the most suitable reaction time for the 
polymerisation. 
Section 5 described the influence of the crosslinkers on the final properties of 
the material: ie size, zeta potential and thermoresponse characteristics. The 
suitability of two crosslinkers (EBA and MBA) was discussed, as well as the 
selection of MBA as the most satisfactory candidate, because it yields 
nanogels with a thermoresponse close to human body temperature. Section 6 
discussed the modification of the nanogel properties by the addition of 
comonomers AA and AEA, to introduce a charge in the matrix, and the 
characterisation of the nanogels obtained. The most important effect of 
introducing both AA and AEA into the polymerisation was the increased 
hydrophilicity of the nanogels, which increased their LCST. 
Section 7 described the importance of introducing a fluorescent tag and its 
effects on the nanogels obtained. Several unsuccessful attempts to introduce a 
fluorescent monomer were made, failing because of the insolubility of the 
nanogels. Subsequently, a naphthalimide derivative with interesting PET 
behaviour was successfully introduced, producing a thermoresponsive, 
fluorescent and water-soluble nanogel. On the other hand, the incorporation of 
the fluorescent tag in the polymer decreases the LCST of the nanogel. The 
fluorescence of the napthalamide tag and the nanogels with the tag was shown 
to be enhanced in acidic conditions. 
Section 8 described a novel approach to drug uploading namely, imprinting 
polymerisation. The fluorescent nanogels were synthesised in the presence of 
the drug (flufenamic acid). The addition of flufenamic acid to the nanogels 
showed that the drug enhanced the fluorescence of the tag (PET phenomena). 
The loading and the entrapment efficiency for the flufenamic acid were 
calculated by HPLC analysis of the samples. 
Finally, section 9 described the in vitro drug release profile of several 
formulations containing flufenamic acid. These demonstrated the different 
release behaviour of the nanogels at different temperatures. 
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The next chapter describes the in vivo testing of the nanogels described in this 
chapter. 
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3.1 Introduction 
This chapter contains the results and discussion of all the experiments carried 
out during this project related to the suitability of the materials described in 
Chapter II, for application as dermal drug delivery systems. The in vitro and 
ex vivo experiments described in this chapter can be divided into three main 
parts, each one related to an experimental test to determine the materials’ 
suitability for its final application. First, the nanogels were tested for skin 
irritation potential by the Zein protein test. This simple test allowed the 
characterisation of the materials, depending on how harsh they were deemed 
to be to skin. The second big section of experiments was carried out with cells. 
This section is divided in two parts: cell viability tests to evaluate the toxicity 
of nanogels in human keratinocytes, and cell internalisation experiments to 
study the ability of the cells to uptake nanogels. Finally, the last and most 
relevant section for this project is the skin penetration experiments, which 
were carried out using the materials developed in the chemistry laboratory and 
human excised skin. 
All the work described in this section (with the exception of the Zein protein 
test) was carried out in collaboration with Mr Ben Fell, PhD student in Prof D. 
Kelsell’s group in the Cutaneous Research Department of the Blizard Institute 
at Barts and the London School of Medicine and Dentistry at QMUL. Unless 
otherwise stated, all the experiments described in the thesis were carried out 
by the candidate herself, with the exception of the confocal imaging. 
3.2 Skin irritation with Zein protein solubilisation test 
3.2.1 The test 
The process of preparing formulations to be applied to human skin involves 
the use of surfactants as emulsifiers. However, surfactants are known to be a 
source of skin irritation. The skin irritation potential of a surfactant is believed 
to be the consequence of the surfactant binding onto, and then altering, the 
proteins present in the skin, especially the keratin in the corneocytes of the 
stratum corneum, causing skin irritation and other abnormal skin behaviour.1 
According to this hypothesis, surfactants that do not alter proteins are, 
therefore, expected not to irritate the skin.  
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The surfactant’s potential for altering a protein, e.g. one in the skin or the Zein 
protein, has been related to different manifestations of skin irritation in vivo, 
eg redness and inflammation of the skin (erythema) and changes in the skin 
barrier properties.2 On the basis of this relationship, in vitro skin irritation 
tests, such as the Zein protein solubility test, have been developed to measure 
the protein-alteration potential of a surfactant.3  
The Zein solubilisation test was introduced as an alternative to animal 
experimentation for personal care or pharmaceutical products. The protocol 
can be found online at the Database Service on Alternative Methods to Animal 
Experimentation and has been used since 1991 by the European Union 
Reference Laboratory and the European Centre for the Validation of 
Alternative Methods as a protocol for testing skin irritation and corrosion.4   
The Zein protein is found in corn and has a similar structure to keratin. Its 
solubility in water is very low due to its hydrophobic nature, but its solubility 
increases with the addition of a surfactant. The Zein is particularly rich in the 
following hydrophobic residues: leucine (20%), proline (10%) and alanine 
(10%), but deficient in basic and acidic amino acids. Glutamic acid accounts 
for 21–26%. Its isoelectric point is approximately 6.2.5 In this test, sodium 
dodecyl sulphate (SDS) (16), an anionic surfactant, is used as a control. SDS 
can partially solubilise the Zein protein and it is also known to cause skin 
irritation by removing skin oils, dissolving skin-lipids, disrupting the stratum 
corneum lipid bilayers and altering protein structures (denaturation). 
 
 
 
 
Ionic surfactants, such as SDS, are well known for their strong binding affinity 
for globular proteins. The solubilisation of the Zein occurs in two distinct 
stages. In the first stage, SDS is incorporated into the globular structure of the 
Zein protein, forming small hydrophobic domains. The electrically charged 
O
S
O
O O
Na
(16)
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head group of the ionic surfactant molecule binds with the oppositely-charged 
amino-acid group of the protein and the alkyl chains of the surfactant interact 
through hydrophobic bonding with the nonpolar regions present on the surface 
of the Zein protein. In the second stage, when the concentration of SDS is 
above 200mM, the protein unfolds.6 
The Zein solubilisation test assesses how surfactants interact with the protein 
by measuring their skin irritation potential compared to that of SDS. A 
surfactant is considered mild if the amount of solubilised protein compared to 
that of the SDS is around 40-50%. Values under 40% are considered safe. The 
concentration of solubilised Zein protein is measured by UV-Visible 
spectrophotometry at λ=265 nm, after centrifugation and filtration of a 
suspension of Zein with the surfactant that has been stirred for 48 hours in a 
sealed container. 
In this thesis project on transdermal drug delivery, the Zein protein test was 
therefore used to investigate the irritation potential of the fluorescent and non-
fluorescent NIPAM nanogels. 
 
3.2.2 Results for the Zein Protein testing with nanogels  
3.2.2.1 Testing non-fluorescent nanogels 
The nanogels were analysed, using the Zein Protein test, in the following 
order: i) those without any comonomer but with varying amounts of MBA 
cross-linker content (DF98-DF100); ii) AA negatively-charged nanogels, with 
different cross-linker content (DF172-DF174); and iii) positively-charged 
nanogels with AEA (DF186-DF188). The results of the relative irritation 
potential, with respect to SDS can be see on the following table. 
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Reaction 
Number 
Non-fluorescent nanogel 
composition 
Irritation relative to 
SDS 
DF98 20% MBA  8% 
DF99 10% MBA 7% 
DF100 5% MBA  8% 
DF172 20% MBA, 10%AA  5% 
DF173 10% MBA, 10%AA 5% 
DF174 5% MBA, 10%AA 3% 
DF186 20% MBA, 10%AEA 10% 
DF187 10% MBA, 10%AEA 11% 
DF188 5% MBA, 10%AEA 11% 
Table 3.1 – Results of Zein protein test on neutral, negatively and positively-charged 
nanogels formulations 
 
The results of the table above show that nanogels are relatively mild compared 
to SDS, as they dissolved a maximum of 11% of the amount of protein 
dissolved by SDS. These values are considerably lower than the 40-50% limit 
usually accepted as safe. Positively-charged nanogels have higher denaturation 
rates. This is probably linked to the fact that the isoelectric point of the Zein 
protein is under 7, meaning that more negatively-charged amino acids of the 
protein interact electrostatically with the positively-charged nanogel. 
Conversely, the Zein protein would be repelled by the negatively-charged 
nanogel, giving rise to the lowest irritation potential in the table. The degree of 
cross-linking in the samples seems to have had no effect on the relative 
irritation potential. This result is probably due to the fact that the difference in 
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hydrophobicity between nanogels with 5% - 20% of cross-linker is not 
significant enough to create variations between the samples.  
 
3.2.2.2 Testing fluorescent nanogels 
The second set of experiments was carried out on fluorescent nanogels with 
and without a comonomer (AA negatively-charged nanogels) with 5% of 
fluorescent monomer. 
 
Reaction 
Number 
Fluorescent nanogel composition 
(20%MBA) 
Irritation relative to 
SDS 
DF240 5% AA, 5% FM (negative) 15% 
DF241 5% FM (neutral) 12% 
Table 3.2 - Results of the Zein protein test on florescent negatively-charged and neutral 
nanogels formulations 
 
The results show a doubling of the irritation potential for these fluorescent 
nanogels, although the values are still far from the 40-50% limit accepted as 
safe. These nanogels DF240-DF241, are significantly more hydrophobic and 
interact better with the Zein protein, which is also hydrophobic. The 
fluorescent tag introduces a positive charge to the nanogels (as proved by the 
zeta potential readings presented in the previous chapter), favouring the 
interaction with the Zein protein, in a similar way to AEA. In this case, the 
interaction is stronger because there are two influencing factors: the charge of 
the nanogels and the hydrophobicity. 
3.2.2.3 Conclusions 
The results obtained show that both the fluorescent and non-fluorescent 
nanogels (described in Chapter II), are well below the value accepted as safe 
(40%). It can therefore be safely assumed that the skin irritation potential of 
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these materials is very low and that they can be used for applications in dermal 
drug delivery. 
3.3 Experiments with cells 
3.3.1 Overview 
The next step in the project was to test the particles obtained on skin cells for 
their suitability as skin applications. Human keratinocytes cell lines were 
selected to perform the experiments. Keratinocytes are epidermal cells found 
at the outer surface of the skin and constitute 90% of the cells found in the 
epidermis. Two types of experiments were carried out: (1) cell viability and 
(2) cell internalisation. The purpose of the first series of test was to assess the 
effect of the presence of nanogels in the cell media on the normal growth of 
the cells. The purpose of the second series was to evaluate the ability of the 
cells to internalise the nanoparticles. 
The selected cell line for both sets of experiments was K17 immortalised 
human keratinocytes, because it has been shown they have a relatively stable 
genome and maintain normal growth and differentiation characteristics in 
vitro. 
3.3.2 Cell viability experiments  
3.3.2.1 The test: cell viability with metabolic activity indicator 
After developing a library of materials, nanogel preparations with the most 
interesting features for the project were screened for their toxicity for 
keratinocyte cells.  
The cell viability assay selected was Alamar Blue, which detects metabolic 
activity as a viability indicator.7 Alamar Blue is a commercially available 
microplate assay that provides information on cell populations.  
This assay contains resazurin (17), a fluorometric growth indicator that is non-
fluorescent, cell permeable and non-toxic. When it enters viable cells, it is 
metabolised and reduced to resorufin (18), which is highly fluorescent 
(emission at 590nm).8 The amount of fluorescence produced is proportional to 
the number of living cells. By measuring the fluorescence emitted by the cells, 
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treated with nanogels, and comparing it to a control of non-treated cells, the 
cell viability percentage can be calculated. The tests show whether or not 
nanogels affect the normal growth and proliferation of the cells. 
 
 
Figure 3.1 – Microplate containing K17 cells with AlamarBlue after 4 hours incubation 
at 37°C: pink samples are viable cells where resazurin (indigo) has been metabolized 
into resorufin (pink), indigo samples are a negative control of nanogels without cells. 
 
Cultures of keratinocyte cells were therefore prepared with increasing 
concentrations of nanogels and incubated for 24 and 48 hours at 37°C with 
10% of CO2. Non-fluorescent and fluorescent nanogels were tested and the 
results presented in the sections below.  
3.3.2.2 Non-fluorescent nanogels 
The following sections describe the results obtained for cell viability using 
nanogels without the fluorescent tag. The cell toxicity was tested for nanogels 
made using EBA and MBA as a cross-linker, followed by the nanogels with a 
comonomer (AA and AEA) with different degrees of cross-linker (MBA). 
O
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3.3.2.2.1 EBA-based nanogels 
The first nanogels synthesised in this project were prepared using EBA as a 
cross-linker. The nanogels with the lowest degree of cross-linker were selected 
for testing in cells because of their lower LCST value, closer to skin 
temperature (as described in Section 2.5.1). The composition of the selected 
preparations is described in the table below. 
 NIPAM EBA 
DF74 80% 20% 
DF75 90% 10% 
DF76 95% 5% 
Table 3.3 – Composition EBA-based nanogels. 
 
In the early stages of this thesis, DF74 to DF76 were tested for their toxicity in 
keratinocytes K17 for 24 and 48hours at concentrations of 1, 5 and 10 mg/mL. 
The results are presented below.  
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Figure 3.2 – Cell viability results respect a control of untreated K17 cells for nanogels 
DF74, DF75 and DF76 incubated for 24 and 48 hours. Error bars represent standard 
deviation (n=3). 
 
In all cases, nanogels DF74-DF76 show an excellent cell viability (almost 
100% for all the samples and concentrations), demonstrating that these 
materials are non-toxic when incubated with the cells for 48h. The simple 
structure of the material, similar to that of a protein (with peptide bonds) and 
its high solubility in water make this material an excellent candidate as a drug 
delivery system.  
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3.3.2.2.2 MBA-based nanogels 
The next set of nanoparticles to be analysed for cell cytotoxicity in K17 were 
those prepared using MBA as a cross-linker. The composition can be found in 
the table below. 
 
 NIPAM MBA 
DF98 80% 20% 
DF99 90% 10% 
DF100 95% 5% 
Table 3.4 – Composition MBA-based nanogels. 
 
As with EBA, the results showed a low toxicity for the cells. Having observed 
the excellent performance of the EBA counterparts, these materials were 
tested directly for 48 hours. The results are presented in the graph below. 
 
 
Figure 3.3 - Cell viability results respect a control of untreated K17 cells for nanogels 
DF98, DF99 and DF100 incubated for 48hours. 
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The MBA nanogels show excellent cell viability. The statistical significance 
of changes in cell viability was calculated using a t-test (p<0.05) and showed 
that the results below 100% were not different from a control. These results 
are similar to those obtained for EBA. The key finding is that the 
concentration of nanogels used in these experiments is very high, up to 
10mg/ml and well above the values frequently reported in the literature. 
NIPAM microgels cross-linked with MBA have been reported by Mozumdar 
et al. to withstand concentrations up 0.2 mg/mL in HeLa cells and Nguyen et 
al. reported values of up to 1 mg/mL in fibroblast.9,10 
3.3.2.2.3 MBA-based, charged non-fluorescent nanogels 
As described in Chapter II, one of the main interests was to evaluate the effect 
of different surface charges on the skin permeability properties. This is why 
several nanogels were prepared with comonomers AEA and AA (introducing 
positive and negative charge, respectively) at different cross-linking 
concentrations. The composition of these materials is shown in the table 
below. 
 
 NIPAM MBA AA AEA Charge 
DF172 75% 20% 5% - 
Negative DF173 85% 10% 5% - 
DF174 90% 5% 5% - 
DF180 75% 20% - 5% 
Positive DF181 85% 10% - 5% 
DF182 90% 5% - 5% 
Table 3.5 – Negatively (AA) and positively (AEA) charged MBA-based NIPAM nanogels 
composition. 
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These six different preparations were tested in K17 keratinocyte cells for 48 
hours to assess their cytotoxicity. The results are presented in the following 
two graphs; the first one for DF172-DF174 (negatively-charged nanogels) and 
the second one for DF180-DF182 (positively-charged). 
 
 
 
Figure 3.4 - Cell viability results respect a control of untreated K17 cells for negatively-
charged nanogels D172, DF173 and DF174 incubated for 48hours. 
 
The incorporation of AA does not seem to affect the cell viability of the 
nanogels, except for high concentrations of nanogel DF172. Only the 
concentrations of 5 and 10 mg/mL for DF172 are statistically different from a 
control. For nanogels DF173 and DF174, although a decrease in cell viability 
can be observed for the highest concentrations, a test-t showed that the values 
are not significantly different from a control. Excluding the highest 
concentrations of the preparation DF172, the nanogels showed excellent cell 
viability, comparable to the non-charged nanogels. The viability rate was also 
higher than that previously reported in the literature for similar negatively-
charged nanogels, where up to 0.2 µg/mL was successfully tested.11,12 
The results of the cell viability test for positively-charged nanogels are shown 
in the graph below. 
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Figure 3.5 - Cell viability results respect a control of untreated K17 cells for positively-
charged nanogels D180, DF181 and DF182 incubated for 48hours. 
 
As can be seen above, the positively-charged nanogels DF181 and DF182 
showed increasing cell toxicity with decreasing MBA concentration and 
consequently a lower LCST. DF182 kills or prevents the normal growth of the 
cells present in the test. DF181 had a cell viability of around 70%. This can 
only be explained by a toxic effect of the nanogels.  
In these experiments, for the first time, the presence of aggregates (polymer 
thermoresponding) was observed under the microscope for samples DF181 
and DF182. The nanogels were forming spherical precipitates that were more 
abundant in wells containing higher concentrations of the nanogels. The lower 
the LCST of the nanogels, the higher was the quantity of aggregates in each 
well.  
3.3.2.3 Fluorescent charged and non-charged nanogels 
Having tested cell cytotoxicity for all the non-fluorescent nanogels the same 
test was performed with neutral, negative and positively-charged fluorescent 
nanoparticles. The samples tested are described in the table below. 
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 NIPAM MBA AA AEA FM 
DF202 (N) 75% 20% - - 5% 
DF203 (-) 70% 20% 5% - 5% 
DF204 (+) 70% 20% - 5% 5% 
Table 3.6 – Fluorescent neutral, negatively and positively-charged, MBA-based NIPAM 
nanogels composition. 
 
Having observed the toxic effect of the charged nanoparticles in the cell 
viability tests, this time the nanogels were incubated for 48hours in 
concentrations up to 1mg/mL. The results are presented in the graph below. 
 
 
Figure 3.6 - Cell viability results respect a control of untreated K17 cells for fluorescent 
nanogels D202, DF203 and DF204 incubated for 48hours. 
 
Neutral and negatively-charged nanoparticles showed excellent cell viability 
for all the concentrations tested. On the other hand, positively-charged 
nanogels (DF204) showed the cell viability significantly different from a 
control (t-test p<0.05). The nanogels DF204 and DF202 were both forming 
aggregates in media, easily identified because of the yellowish colour of the 
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polymer. Although these did not seem to be affecting cell viability for the 
neutral fluorescent nanogels (DF202), the toxicity of positively-charged 
fluorescent nanogels DF204, was evident. It is commonly reported in the 
literature that amine-containing polymers are related to cell toxicity, because 
they strongly interact with cellular membranes, destabilising them and causing 
cell death.13 
The above experiments led to the need for an in-depth study of the 
thermoresponsive behaviour of the nanogels within the cell media used to 
culture the keratinocytes.  
3.3.2.3.1 Thermoresponsive behaviour of fluorescent nanogels in water, 
Epilife cell media and PBS 
While performing the cell viability experiments it was evident that nanogels 
going through the phase transition were thermoresponding and therefore 
forming aggregates in the cell media (Figure 3.7). This was not necessarily 
linked to decreasing cell viability, because fluorescent neutral nanogels DF202 
also had aggregates but cell viability was excellent, however, with fluorescent 
positively-charged nanogels DF204 cells were not proliferating.  
If the aggregates were the cause of low cell viability, most probably, the 
nanogels were precipitating forming sedimentation at the bottom of the well 
thus preventing cell growth. It is essential for cell to be strongly attached to 
the bottom of the well. At this stage, the effect of temperature changes in the 
particles on cell viability was not clearly understood. 
 
Figure 3.7 – Light microscope picture of fluorescent aggregates formed in a sample of 
DF204 dissolved in EpiLife media, at the background K17 cells. (100X magnification) 
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A series of measurements were performed with samples DF202-203-204 
where the thermoresponse temperature was measured in water and the cell 
media (EpiLife) at different concentrations (1, 0.5, 0.25 and 0.1 mg/mL of 
polymer) to evaluate the difference between them. 
The transmittance experiments to determine the LCST of the polymers at 
different concentrations are shown below. LCSTW designates values recorded 
in water. 
 
 
 
Figure 3.8 – Top: Transmittance curves at different concentrations for DF202 in 
EpiLife. Bottom: Transmittance curves at different concentrations for DF202 in water at 
1mg/mLn , 0.5 mg/mLr , 0.25mg/mL , and 0.1 mg/mL¯ . 
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As for DF202, the LCST of the nanogels in the cell media decreased slightly 
by 1.5°C, from 35°C in water to 33°C in EpiLife at 1mg/mL. The 
transmittance curves as a function of temperature show similar patterns in 
EpiLife and water, the only difference lies in the fact that all transitions take 
place at lower temperatures when the nanogels are dissolved in the EpiLife 
media.  
 
 
 
 
Figure 3.9 - Top: Transmittance curves at different concentrations for DF203 in EpiLife. 
Bottom: Transmittance curves at different concentrations for DF203 in water at 
1mg/mLn , 0.5 mg/mLr , 0.25mg/mL , and 0.1 mg/mL¯ . 
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As with the fluorescent neutral nanogels, the LCST of the fluorescent 
negatively-charged nanogel DF203 (at 1 mg/mL) dropped from 42°C in water 
to 40°C in the cell media (EpiLife). 
 
 
 
Figure 3.10 - Top: Transmittance curves at different concentrations for DF204 in 
EpiLife. Bottom: Transmittance curves at different concentrations for DF204 in water at 
1mg/mLn , 0.5 mg/mLr , 0.25mg/mL , and 0.1 mg/mL¯ . 
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behaviour. First of all, the thermoresponsive behaviour in water of the 
nanogels was found to be smooth (no sudden change in transmittance) and 
occurring through a wide range of temperatures. On the other hand, in EpiLife, 
the thermoresponse was sharper. The second main difference was the LCST; 
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while the phase transition was at 34°C for a 1mg/mL solution of the nanogels 
in water, it dropped significantly (by 8°C) in EpiLife.   
This behaviour, has previously been reported in the literature by Mai-ngam et 
al., 14 where cationic copolymers of NIPAM-co-APMH N-(3-
aminopropyl)methacrylamide hydrochloride (APMH) were prepared and 
when their LCST was measured in water they showed no thermoresponse. 
This was attributed to the fact that in pure water, conformational transition of 
NIPAM in copolymers was disallowed by electrostatic repulsion among 
positively-charged amine groups along the chain. This resulted in copolymers 
that were soluble in the temperature range of 25–45°C. KCl salt was therefore, 
added to induce phase separation. 
 
LCST 1 mg/mL EpiLife Water 
DF202 (N) 33.5°C 35°C 
DF203 (-) 40°C 42°C 
DF204 (+) 27°C 35°C 
Table 3.7 – Summary table of LCST values in Epilife and water for a 1mg/mL solution 
of fluorescent nanogels DF202, DF203 and DF204. 
 
Samples DF202 (LCSTw 35°C) and DF204 (LCSTw 34°C) had aggregates. 
While for DF202 (N) there was almost no effect in the cell viability 
experiments, in the case of DF204(+) the drop in LCST in EpiLife cell media, 
seemed to be the cause of the low cell viability reported. 
It is evident from the data obtained so far, that the influence of EpiLife media 
in cell viability experiments is quite significant. There seems to be a very clear 
trend, as in all cases, the temperature at which the phase transition takes places 
in cell media decreases compared to that of water. Cell media is a complex 
mixture. EpiLife cell media contains amino acids, inorganic salts, vitamins 
and sugars amongst other essential components. According to the literature, 
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the effect of the LCST decreasing is due to the ionic strength of the cell media 
and its impact on the LCST of NIPAM.15  
To assess this hypothesis, LCST readings in saline phosphate buffer (PBS) 
solution were performed to understand the effect of ionic strength on the 
thermoresponsive properties of the nanogels. The buffered solution selected 
was PBS whose osmolarity and ion concentrations match those of the human 
body (NaCl 137 mM, KCl 2.7 mM, Na2HPO4 10mM and KHPO4 1.8mM). 
The results of the LCST measurements at 1mg/mL are presented in the graph 
below: 
 
Figure 3.11 – Transmittance of nanogels pDF202, DF203 and   DF204 at 1 mg/mL 
in PBS. 
 
LCST 1 mg/mL Water EpiLife PBS 
DF202 (N) 35°C 33.5°C 33°C 
DF203 (-) 42°C 40°C 40°C 
DF204 (+) 35°C 27°C 27°C 
Table 3.8 - LCST values comparison in PBS, EpiLife and water for a 1mg/mL solution of 
fluorescent nanogels DF202, DF203 and DF204. 
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The results obtained show a very good agreement for the LCST in EpiLife and 
PBS, only differing in 0.5°C for DF202 and being identical for DF203 and 
DF204, confirming the ionic strength as the cause for the LCST drop. 
Summarising, the LCST affects the outcome of the cell viability experiments. 
The experiments are carried out inside the incubator at 38°C and the nanogels 
that have a LCST at this temperature or lower, form large aggregates that 
affect the proliferation of the keratinocytes. This is accentuated in the case of 
the positively-charged nanogels (DF204) where the LCST decreases, 
dramatically affecting the cell viability results. 
 
3.3.2.4 Summary of the cell viability experiments 
Non-fluorescent NIPAM nanogels showed excellent cell viability, with 
keratinocytes being able to resist concentrations of up to 10 mg/mL for non 
fluorescent, MBA and EBA cross-linked nanogels without any comonomer. 
When AA an AEA were added, the cell viability decreased slightly for high 
concentrations of AA and suffered high toxicity in the case of AEA nanogels. 
Fluorescent nanogels showed lower cell viability, with cells only tolerating up 
to 1mg/mL except for the positively-charged nanogels where a definite toxic 
effect was observed. A study of the effect of the cell media (EpiLife) and PBS 
on the LCST proved that, while in general the LCST for neutral and 
negatively-charged nanogels dropped 1.5-2°C, the effect was much more 
accentuated in positively-charged nanogels, where the temperature dropped by 
8°C responding at room temperature. This is why the positively-charged 
nanogels were discarded as an optimal candidate for a drug delivery system. 
The experiments also concluded that the nanogels with an LCST in EpiLife 
significantly lower than 37°C (the incubators temperature), would form 
aggregates that would seriously affect cell proliferation. 
 
3.3.3 Cell internalisation  
The data on cell toxicity were of great importance. However the next essential 
step was a series of key experiments to evaluate whether the nanoparticles are 
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actually internalised within the cells and to evaluate the mechanisms by which 
it occurs, such as diffusion endocytosis or receptor-mediated.  
For the purpose of these experiments, an essential requirement was that the 
nanoparticles were fluorescently labelled, so that their position within the cells 
could be easily identified using the confocal microscope. 
The experiments were carried out at 35°C, as this is the temperature 
commonly accepted as the closest to human skin. The nanoparticles, at 
different concentrations (from 0.1 to 1mg/mL) were incubated for 24 and 48 
hours with the cells and were examined with confocal laser-scanning 
microscope. 
To help understand the location of the nanoparticles inside the cell an 
organelle-specific dye is usually used. In this research, two dyes were used. 
The first, DAPI (blue) was used to stain the cellular nuclei of the keratinocyte 
and the second, a fluorescent labelled-phalloidine, allowed the staining of the 
f-actin fibres of the cytoskeleton (red). DAPI (4',6-diamidino-2-phenylindole) 
is a fluorescent stain that binds strongly to adenine and thymine rich regions in 
DNA, therefore staining the nuclei of cells. As DAPI can pass through an 
intact cell membrane, it can be used to stain both live and fixed cells. When 
bound to double-stranded DNA, DAPI has an absorption maximum at a 
wavelength of 358 nm and its emission maximum is at 460 nm (blue). 
Therefore, for fluorescence microscopy DAPI is excited with ultraviolet light 
and is detected through a blue/cyan filter. 
 
 
Alexa Fluor 594 phalloidin is a f-actin probe conjugated to a red fluorescent 
dye. Phalloidin is a bicyclic peptide belonging to a family of toxins isolated 
N
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from the deadly Amanita Phalloides (mushroom) and is commonly used in 
imaging applications selectively to label f-actin. Fluorescently-labelled 
phalloidin binds to actin from different species including plants and animals. 
Actin is a globular multi-functional protein that forms microfilaments. It is 
found in essentially all eukaryotic cells. Actin is the monomeric subunit of two 
types of filaments in cells: microfilaments, one of the three major components 
of the cytoskeleton, and thin filaments, part of the contractile apparatus in 
muscle cells. It can be present as either a free monomer called G-actin 
(globular) or as part of a linear polymer microfilament called F-actin 
(filamentous), both of which are essential for cellular functions such as 
mobility and contraction of cells during cell division. 
The purpose of these experiments was to understand if the nanoparticles were 
entering the cells and if so, where, in the cell, they were accumulating. 
3.3.3.1 Fluorescent neutral and negatively-charged nanogels  
The materials used for the study of cell internalisation were nanogels DF240 
and DF241, which are equivalent formulations of DF202 and DF203. The 
composition and the LCST of these fluorescent neutral and negatively-charged 
nanogels are described in the table below. The nanogels have an emission 
maximum at 530nm in water (emission spectrum can be found in Section 
2.7.4.6), and display green fluorescence. 
 
 NIPAM MBA AA FM LCSTW LCSTEpiLife 
DF240 (-) 70% 20% 5% 5% 42°C 40°C 
DF241 (N) 75% 20% - 5% 35°C 33.5°C 
Table 3.9 – Composition and LCST in water and cell media EpiLife for a 1mg/mL 
solution for nanogels DF240 and DF241. 
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3.3.3.2 Cell viability and internalisation for fluorescent neutral and 
negatively-charged nanogels with nucleus staining at 24 and 48 
hours 
The green-fluorescent nanogels described in the Section 3.3.3.1 were cultured 
at 35°C with K17 kearynocytes for 24 and 48 hours, at concentrations of 0.1, 
0.3, 0.6 and 1 mg/mL. The cells were then fixed and treated with DAPI and 
visualised in the confocal microscope. They were also analysed for cell 
toxicity with Alamar Blue. The results are presented below. 
After 24 hours 
The fluorescent negatively-charged nanogels DF240 were internalised in the 
cells after 24 hours, as can be seen in the top left images (concentrations 1 and 
0.6 mg/mL). At lower concentrations it is difficult to observe any 
fluorescence. On the other hand, DF241 forms aggregates that can be seen 
floating in the cell media (LCSTEpiLife 33.5°C). The amount of aggregates 
decreases with the concentration. The cells present almost no fluorescence as a 
result of the big precipitates formed. 
DAPI, in blue, shows the location of the nucleus and the green light of the 
nanogels seems to be surrounding the cells nucleus. Therefore the nanogels 
are found in the cytoplasm of the cells. 
The nanogels could not be detected at the lowest concentrations. This it could 
be because the florescence was not intense enough. The option of adding more 
florescent tag to the nanogels was not possible due to the adverse effect on the 
LCST of the polymers, which would lead to more aggregates. The fact that the 
fluorescent tag is covalently linked to the nanogels is a confirmation that the 
nanoparticles have been internalised. 
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Figure 3.12 – Images of K17 cells incubated with DF240 and DF241 at different 
concentrations after 24h. (The bright field images are on the left of each pair of columns 
and the confocal images are on the right.) These images were obtained by Mr. Benjamin 
Fell. 
 
The viability for these cells, cultured at 35°C, present excellent results. The 
nanogels were not toxic for either of the nanogels (DF240 and DF241) when 
compared to a control of untreated cells. Despite the presence of aggregates, 
the cells were proliferating normally. 
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Figure 3.13 – Cell viability after 24h for DF240 and DF241 at 35°C 
 
After 48 hours 
The same cell internalisation experiments were carried out incubating the 
nanoparticles for 48 hours, doubling the exposure time. The negatively-
charged nanogels seem to be internalised at lower concentrations (0.3 to 
1mg/mL); the internalisation process was slow.  
The fluorescent neutral nanogels (DF241) showed less aggregates present in 
the cell media (after 48hours) and some nanogels started to be internalised 
inside the keratinocytes, which florescence at a concentration of 1 mg/mL. 
The results show that DF241 was internalised on the second day of incubation 
(being slower than the negatively-charged DF240). 
As described above, for the 24-hour experiment, the nanogels seem to be 
surrounding the nucleus (blue), and are therefore in the cytoplasm of the cells. 
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Figure 3.14 - Images of K17 cells incubated with DF240 and DF241 after 48h. (The 
bright field images are on the left of each pair of columns and the confocal images are on 
the right.) These images were obtained by Mr. Benjamin Fell. 
 
The cell viability after 48hours at 35°C showed that the negatively-charged 
nanogels, at concentrations of 0.6 and 1 mg/mL was low with respect to a 
control of untreated cells. This test was performed because in these series of 
tests the temperatures are 2°C lower than in the experiments performed in 
Section 3.3.2.3 - Figure 3.6 (at 37°C). 
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Figure 3.15 - Cell viability after 48h for DF240 and DF241 at 35°C 
 
The fact that previously absent cell cytotoxicity could be observed may be due 
to the fact that cells were incubated at 35°C. All the cells, control and treated, 
were proliferating less due to the lower incubation temperature and the Alamar 
Blue test had less intensity (with less cells metabolising the dye), leading to 
lower fluorescence readings. 
To confirm the cell localisation of the nanogels, a second staining agent was 
used that would allow to visualise the nanogels contained in the nucleus of the 
keratinocyte cells. 
3.3.3.3 Cell internalisation for fluorescent neutral and negatively-
charged nanogels with actin fibres staining after 48 hours 
The cells, incubated at 35°C for 48 hours with a 1 mg/mL concentration of 
fluorescent nanogels (DF240-DF241), were stained with a red fluorescently-
labelled phalloidin. This experiment aimed to confirm the localisation of the 
nanogels inside the cells. In this case the confocal microscope images are in 
the form of Z-stacks, which represent different sections on the Z-axis. These 
sections, form thin slices which enable inspection of the cell at different depth 
under the microscope. 
The pictures below show the Z-stacks for negatively charged and neutral 
fluorescent nanogels. The green can be observed, not only inside the cell in the 
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cytoplasm as confirmed previously by DAPI but also in the nucleus. The 
location of the nanogels in the nucleus (the non-red area in the middle of the 
actin fibres) is more intense in the case of the negatively-charged nanogels. 
This could explain why the cell viability was lower: the nanogels in the 
nucleus could be interacting with the nucleic acids and therefore affecting cell 
division. 
The last figure 3.18, shows a control of non-treated cells to visualise the 
staining of the cytoskeleton of the cells only. 
 
Figure 3.16 – Z-stacks for fluorescent negatively-charged nanogels incubated for 48h in 
a 1 mg/mL solution. These images were obtained by Mr. Benjamin Fell. 
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Figure 3.17 – Z-stacks for fluorescent neutral nanogels incubated for 48h in a 1 mg/mL 
solution. These images were obtained by Mr. Benjamin Fell. 
 
 
Figure 3.18 – Z-stacks for a control of untreated K17 cells (Alexa Fluor 954 Phalloidine 
staining visible). These images were obtained by Mr. Benjamin Fell. 
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3.3.4 Summary cell internalisation experiments 
It was demonstrated that the cells internalise the nanoparticles to different 
degrees, depending on the temperature at which they respond in the media. 
Negatively-charged fluorescent nanogels do not respond at the temperature at 
which the experiments are performed are internalised after 24 hours and they 
are further uptaken by the cells after 48 hours. In the other hand, neutral 
fluorescent nanogels respond at the temperature of the experiment and form 
aggregates. In this case, the nanogels are not visualised inside the cell until 
they have been incubated for 48 hours. In summary, cell internalisation was 
demonstrated for negatively-charged nanogels after 24 hours while neutral 
require 48hours. In both cases the nanogels can be found in both the 
cytoplasm and the nucleus of the cell. 
Cell viability at 35°C showed excellent results after 24 hours for both 
nanogels but some toxic effect was observed for negatively-charged nanogels 
after 48hours, shown to be related to higher amount of nanogels internalised. 
 
3.4 Skin Experiments 
3.4.1 Skin experiments overview 
The final goal of this project was the preparation of nanogels with 
characteristics that would allow their application as drug delivery vehicles 
targeting the skin. After developing a library of fully characterised nanogel 
preparations, two candidates, DF240(-) and DF241(N) were selected for 
testing the ability to permeate the skin. Given the nature of the experiments 
only fluorescently labelled nanoparticles could be used, so that their location 
in the skin could be monitored with the confocal microscope.  
This section will present the results of the work carried out in the laboratory of 
Professor Kelsell jointly by the candidate and Mr Benjamin fell. The candidate 
personally carried out all the experiments presented with the support of Mr 
Fell with the exception of the confocal images.  
The experiments were carried out using freshly excised human skin taken 
directly from the operating theatre. In most of the cases the skin came from 
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liposuctions and breast reductions where redundant skin had to be removed. 
The skin had to be used immediately so as not to lose its barrier function (i.e. 
within 2 hours). As it arrived in the laboratory, it was cleaned and cut into 
approximately 1x1cm squares, and the hypodermis removed. The skin was 
them placed on top of a grid and soaked in the cell media while the most 
external layers were exposed to air (as skin would be) and as shown in the 
picture below (Fig 3.19). 
 
Figure 3.19 – Excised skin samples lying on a grid soaked with cell media inside well 
plate. Left samples have ring prepared to contain nanogels sample for penetration 
studies. 
 
The skin penetration experiments were performed by placing a metallic ring 
on top of the skin, and filling it with a solution (reservoir) of nanogels. After 
24 hours the ring was removed. The skin was washed with PBS and snap 
frozen in liquid N2. Cryo-sections of 5-10 µm were then prepared, and the 
nucleus of the skin cells stained for observation under the confocal 
microscope. 
To test that the skin had not lost its functionality, i.e. the integrity of the 
stratum corneum, a control with Lucifer yellow was performed.16 Lucifer 
yellow 6-amino-2-(hydrazinecarbonyl)-1,3-dioxobenzo[de]isoquinoline-5,8-
disulfonate is a fluorescent dye used in cell biology.17  
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The key property of Lucifer yellow is that it can be visualized in both living 
and fixed cells using a fluorescence microscope. It is a water-soluble dye with 
excitation/emission peaks of 428/536 nm, which should not permeate the skin.  
 
Figure 3.20 – Lucifer yellow (light green) on the stratum corneum to confirm membrane 
functionality. In blue DAPI staining nucleus. Dark green skin autofloresence. This image 
was obtained by Mr. Benjamin Fell. 
 
The main problem in the skin experiments was the visualization of the skin in 
the confocal microscope, because skin has a high level of auto-florescence, 
which, protects cells from UV-light damage. The most commonly observed 
auto-fluorescent molecules are NADPH (emission 450nm) and flavins 
(emission 520-560). These are found inside the cells and in the extracellular 
matrix and can contribute to the level of fluorescence because of the intrinsic 
properties of collagen and elastin (emission 305-450nm).18,19 The most 
important molecule related to skin auto-florescence is melanin (emission 360-
560nm).20 
3.4.2 Penetration enhancers 
The skin is very effective as a selective penetration barrier. Cutaneous 
absorption involves the passage of a molecule from the skin surface into the 
stratum corneum, under the influence of a concentration gradient and its 
subsequent diffusion through the stratum corneum and underlying epidermis, 
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passage through the dermis, and into the blood stream. The skin behaves as a 
passive barrier to the penetrating molecule. The stratum corneum provides the 
greatest resistance to penetration, and it is the rate-limiting step in 
percutaneous absorption. To overcome this barrier effect, penetration 
enhancers are used. These substances facilitate the absorption of the penetrant 
through the skin by temporarily diminishing its impermeability. Ideally, these 
materials should be pharmacologically inert, nontoxic, non-irritating, non-
allergenic, compatible with the drug and excipients, inexpensive and have 
good solvent properties.21 The enhancer should not lead to the loss of body 
fluids, electrolytes and other endogenous materials; and skin should 
immediately regain its barrier properties on its removal. 
Penetration enhancers may act through one or more of the following 
mechanisms:22 
1. Disruption of the lipid structure of the stratum corneum 
2. Intercellular protein modification 
3. Partitioning promotion of the drug into the stratum corneum 
The key to altering the penetration of a polar drugs’ pathway is to cause 
protein conformational change or solvent swelling. The fatty acid enhancers 
increase the fluidity of the lipid protein portion of the stratum corneum. 
Enhancers can increase the drug diffusivity through skin proteins. The type of 
enhancer employed has a significant impact on the design and development of 
the product. 
Examples of commonly used chemical penetration enhancers include: 
sulfoxides (like DMSO), azone, pyyrrolidones, fatty acids, alcohol and 
polyols, essential oils, terpenes and terpenoids, oxazolidines, ureas and 
phospholipids.23 
 
3.4.2.1 Benzyl alcohol as penetration enhancer 
Alcohols are the most intensely investigated penetration enhancers and they 
are most commonly used in many transdermal formulations such as patches. 
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There are several mechanisms for the permeation-enhancing action of 
alcohols. As a solvent, ethanol is able to increase the solubility of the drug 
already in the formulation. Alcohols are able to extract lipids and proteins and 
thereby increase the porosity of the stratum corneum. Thus, the penetration of 
hydrophilic drug substances is facilitated.  
The penetration enhancement of lipophilic drugs by alcohols is due to the 
higher solubility of the drug substances in the lipophilic areas of the stratum 
corneum because of the presence of alcoholic enhancers. For water-soluble 
drugs a minimum amount of water is necessary to enable an optimal 
enhancement by alcohols. 
 
Benzyl alcohol (BA, 21) is a widely used preservative and fragrance additive 
in pharmaceutical and cosmetic systems. The incorporation of BA in topical 
formulations has been shown to increase drug retention and accumulation 
within the skin significantly. This is due to its ability to solvate hydrophobic 
compounds strongly, by forming micelles whilst maintaining contact with 
aqueous solutions because of its moderate hydrophilicity.24,25 BA is therefore 
ideal for penetration through the stratum corneum. BA does not bind to the 
dermis and the metabolic reactions within the epidermis help to clear it from 
skin and maintain sink conditions.26 
3.4.2.2 DMSO as a penetration enhancer 
Dimethyl sulfoxide is a molecule with a long history in pharmaceutics and is 
one of the most widely used penetration enhancers in topical pharmaceutical 
formulations. Dimethyl sulfoxide is a safe and effective mechanism for 
facilitating the transdermal delivery of both hydrophilic and lipophilic 
medications. 
Benzyl alcohol
OH
(21)
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Studies using Raman spectroscopy revealed that DMSO changes the stratum 
corneum keratin from alpha-helical to beta-sheet conformation at 
concentrations greater than 60% v/v, at which point, DMSO enhances the flux 
of the drugs, there was also evidence of its interaction with stratum corneum 
lipids.27 Dimethyl sulfoxide is an aprotic solvent, it increases drug-
partitioning, denatures proteins (changes the intercellular keratin 
conformation), and interacts with the intercellular lipid to distort their 
geometry.28  
A series of experiments were carried out using DF240 and DF241 in PBS, and 
in the presence of BA or DMSO dissolved in water, as penetration enhancers. 
The data and the results are reported in the following sections. 
3.4.3 Penetration without enhancer 
3.4.3.1 Nanogels in PBS 
Skin experiments were carried out for 24 hours with nanogels DF240 (-) and 
DF241 (N) dissolved in PBS (without enhancer). The skin was stained and 
visualised in the confocal microscope. The following pictures show, from left 
to right, a transversal section of skin where the blue filter is applied to show 
the nucleus of keratinocytes, in the middle the green filter is applied and the 
fluorescent nanogels can be seen mainly accumulating in the stratum corneum 
(that has corneocytes, which do not have a nucleus anymore) and finally the 
combined picture on the right. In this case the nanoparticles were almost 
concentrated in the stratum corneum. 
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Figure 3.21 – Confocal images for DF240(-) in PBS. Left blue DAPI, middle green 
nanogels and auto-fluorescence and right merged images. These images were obtained 
by Mr. Benjamin Fell. 
 
 
 
Figure 3.22 – Confocal images for DF241(N) in PBS. Left blue DAPI, middle green 
nanogels and auto-fluorescence and right merged images. These images were obtained 
by Mr. Benjamin Fell. 
 
3.4.4 Penetration with enhancers 
3.4.4.1 Nanogels with Benzyl Alcohol 
The same skin experiments were carried out by incubating the skin sample for 
24 hours with nanogels DF240 (-) and DF241 (N) dissolved in water and with 
a 2w/v% of benzyl alcohol as a chemical enhancer. 
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Figure 3.23 – Confocal images of D240(-) with 2% BA. Left blue DAPI, middle green 
nanogels and auto-fluorescence and right merged images. These images were obtained 
by Mr. Benjamin Fell. 
 
 
 
 
Figure 3.24 - Confocal images of D241(N) with 2% BA. Left blue DAPI, middle green 
nanogels and auto-fluorescence and right merged images. These images were obtained 
by Mr. Benjamin Fell. 
 
In this case, the nanogels behaved completely differently. While the 
negatively-charged particles seem to penetrate the neutral nanogels are now 
clearly moving away from the stratum corneum and penetrating into the viable 
epidermis (i.e. to the stained nucleus). 
3.4.4.2 Nanogels with DMSO 
The last skin experiments were carried out for 24 hours with nanogels DF240 
(-) and DF241 (N) dissolved in water and with a 2v/v% of DMSO as an 
enhancer. 
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Figure 3.25 - Confocal images of D240(-) with 2% DMSO. Left blue DAPI, middle green 
nanogels and auto-fluorescence and right merged images. These images were obtained 
by Mr. Benjamin Fell. 
 
 
 
Figure 3.26 - Confocal images of D241(N) with 2% DMSO. Left blue DAPI, middle 
green nanogels and auto-fluorescence and right merged images. These images were 
obtained by Mr. Benjamin Fell. 
 
 
In this case, both nanogels DF240(-) and DF241(N) seem to move away from 
the stratum corneum and penetrate the viable cell. The cell imaging allowed 
visual confirmation of the nanogels’ penetration abilities. The penetration 
needs to be quantified and the following section describes how this was 
carried out and the results of the quantification. 
3.4.5 Summary and quantification of the particles 
In order to quantify the amount of particles that had been able to penetrate the 
stratum corneum, the above set of images were treated electronically to obtain 
the ratio of nanoparticles found in the viable epidermis. 
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As an example, in the pictures below the area of interest was selected in the 
nucleated epidermis shown inside the yellow marking. The green signal was 
transformed into black pixels and the area that those occupy calculated. The 
total area contained within the yellow markings was calculated and by 
dividing the green area by the total area of the epidermis selected, the 
percentage of area occupied by the nanogels was obtained. The results are 
presented in the plot below (Figure 3.28). 
 
Figure 3.28 – Percentage of area occupied by negatively and positively-charged nanogels  
in the viable epidermis (DF240 and DF241 respectively). 
 
The negative control shows some signal under 0.5% due to the auto-
fluorescence of the skin. Fluorescent neutral nanoparticles DF241(N) are able 
to penetrate the viable epidermis without the help of any enhancer, while 
negatively-charged nanoparticles show almost no difference from the control. 
Nor do they show a change in penetration with addition of either enhancer: 
Negative 
Control Particles in PBS 
Particles with 
BA 
Particels with 
DMSO 
D240 0.43% 0.52% 6.57% 1.66% 
D241 0.43% 3.03% 2.67% 3.44% 
0.00% 
1.00% 
2.00% 
3.00% 
4.00% 
5.00% 
6.00% 
7.00% 
Figure 3.27 – Exemplification of the areas selected from the merged confocal image to 
calculate the area occupied by nanogels. These images were obtained by Mr. Benjamin 
Fell. 
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benzyl alcohol or DMSO.  On the other hand, while fluorescent negatively-
charged nanogels DF240(-) seem not to be able to diffuse through the skin by 
themselves they benefit greatly from the presence of DMSO and even more 
from benzyl alcohol. 
3.5 Chapter Summary 
The research presented and discussed in this chapter covers the in vitro and ex 
vivo testing of the most interesting nanogels described in Chapter II. 
In Section 3.2 the Zein protein solubility test was performed on a variety of 
nanogels and it was found that all the nanogels are, in general, quite mild and 
would not induce skin irritation.  
Section 3.3 covers all the experiments performed in K17 keratynocite cells. 
The results of the cytoxicity tests over 24 and 48 hours showed an excellent 
percentage of viable cells after 48h for non-fluorescent nanogels up to 
concentrations as high as 10 mg/mL. Introducing comonomers such as AA, 
AEA and fluorescent monomers decreased the viability to 1 mg/mL or lower.  
The cell viability experiments also showed that the cell media reduced the 
LCST.  
The experiments on the ability of the K17 cells to internalise nanoparticles 
showed that in all cases neutral and negatively-charged nanogels were 
internalised at skin temperature (35°C) after 48h and were located in the 
cytoplasm and the nucleus.  
Finally, Section 3.4 covers all the experiments performed with human excised 
skin. The experiments showed that the fluorescent neutral nanogels were able 
to diffuse through the stratum corneum and reach the viable epidermis without 
the help of any enhancer. However, fluorescent negatively-charged nanogels 
were unable to penetrate without the help of an enhancer, the most efficient 
being benzyl alcohol. 
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4.1 Conclusions on the synthesis of materials and characterisation 
Chapter II described the successful development of a methodology for the 
preparation of nanogels uploaded with drugs that can be released under 
controlled conditions as a function of temperature. 
By means of high dilution polymerisation, nanosized particles under 40nm 
have been successfully obtained in a reproducible and efficient manner. A 
detailed study of the polymerisation parameters allowed a fine-tuning of the 
polymerisation reagents to obtain nanoparticles with the desired 
physicochemical characteristics. Two crosslinkers (EBA and MBA) were used 
and their effect on the LCST evaluated. MBA was deemed the most 
satisfactory candidate, because it yields nanogels with a thermoresponse close 
to human body temperature. Through a careful selection of comonomers the 
neutral NIPAM nanogels were successfully modified into charged 
nanoparticles through the incorporation of AA and AEA. The most important 
effect of introducing both, AA and AEA into the polymerisation, was the 
increased hydrophilicity of the nanogels, which increased their LCST. 
The importance of an optimal fluorescent tag was put in evidence after several 
candidates were polymerised. The fluorescent unit, which enables in vitro 
tracking, was carefully assessed to minimise the impact on the nanoparticles’ 
properties. A water-soluble naphthalimide derivative was successfully 
polymerised, producing a thermoresponsive, fluorescent and water-soluble 
nanogel. On the other hand, the incorporation of the fluorescent tag in the 
polymer decreased the LCST of the nanogel. The amounts of incorporated 
fluorescent tag had to be maintained at a low level even though this could 
have compromised its visibility in the in vitro experiments. The fluorescence 
of the napthalamide tag and the nanogels with the tag was shown to be 
enhanced in acidic conditions and by flufenamic acid. Through this proven 
interaction, nanogels were them polymerised in the presence of the drug to 
obtain a molecularly imprinted drug delivery system. The loading and the 
entrapment efficiency for the flufenamic acid through this method were highly 
satisfactory. 
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Finally, the analysis of the in vitro drug release profile of several formulations 
containing flufenamic acid demonstrated the different release behaviour of the 
nanogels at temperatures above and below the LCST. 
4.2 Future work 
Chapter II focused on the synthesis and characterisation of nanogels for drug 
delivery systems to the skin. There are several areas of interest for future 
work. 
The first issue is the possibility of performing the high dilution radical 
polymerisation in water. The utilisation of water would be regarded as a more 
ecological option; it is also significantly cheaper than using DMSO. During 
this research project, a few studies were carried out using water. All the 
reactants described in this research are soluble in water in the working 
concentrations required (CM around 1%, NIPAM, MBA, EBA, AA, AEA and 
FM), with the exception of AIBN. AIBN was replaced by amonium persulfate 
(APS) (NH4)2S2O8 which is also a radical initiator that decomposes at 70°C 
and is water-soluble. Although more environmentally friendly, this 
polymerisation procedure would not allow the uploading of hydrophobic (non 
water-soluble) drugs by imprinting polymerisation. A few attempts were made 
to carry out the nanogel synthesis in water but without successful 
polymerisation. The polymerisation at CM 1% was cloudy after 1h, 
demonstrating that the polymers had formed and macrogelation was taking 
place. To obtain smaller particles, the CM was reduced to 0.1%, as was the 
APS concentration (which had usually been 1% of the double bond in the 
polymerisation mixture). The polymerisations still gave rise to macrogels. Due 
to time constrains no further work was carried out, but it would be interesting 
to continue this line of research by further reducing the CM and the 
concentration of initiator, in order to see if it is possible to obtain nanogels in 
water by high dilution radical polymerisation. 
The second major area of future interest is the technique used to determine the 
LCST of the materials synthesised in this research project: turbidimetric 
analysis. DSC is a powerful technique for studying a thermodynamic process 
like the phase transition. DSC instrumentation requires a very powerful sensor 
to measure the LCST. The energies involved are very small and not all the 
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instruments are set up to measure them. The samples to be measured are 
prepared in a liquid, which is unusual for this instrument because it usually 
measures solid samples. This requires the reference cell of the instrument to be 
changed, and adjustment to the scanning rate and the use of a different 
crucible. At the beginning of this project, some DSC measurements of the 
nanogels’ LCST were carried out successfully for linear NIPAM, MBA and 
EBA based nanogels with a low degree of cross-linking. As the amount of 
NIPAM decreased in the sample it was difficult to detect the phase transition. 
The same problem arose from the addition of comonomers to the 
polymerisation. From the experiments performed during this project, it was 
concluded that, unless the phase transition takes place in a fast (sharp) manner, 
so that the energy release (ΔH) is high, it could not be detected. In the event of 
having access to a suitably powerful instrument, it would be interesting to use 
DSC to study the temperatures and energy involved in the phase transition. 
This would make it possible to compare the ability of different nanogels to 
respond to temperature and to have a better understanding of the 
thermodynamic characteristics of the phase transition phenomena. 
The third area of interest concerns the preparation of fluorescent nanogels, as 
there were some initial difficulties during this project. It would be interesting 
to design a new fluorophore, with a smaller molecule and, ideally, with higher 
quantum yields which would have a minimum impact on the materials’ 
properties. 
Furthermore it would be interesting to study the uploading approach with 
hydrophilic water soluble drugs such as lidocaine hydrochloride, a well know 
skin anaesthetic. This would allow further exploration of the scope for using 
of these stimuli-responsive drug delivery sytems. The nanogels with 
comonomers (AA and AEA) would be excellent candidates to be conjugated 
with drugs of the opposite charge. For example AA-based nanogels would be 
conjugated with basic drugs, while AEA-based nanogels could be conjugated 
with acid drugs, like FA. 
4.3 Conclusion on the biological experiments 
The research presented and discussed in Chapter III covered the in vitro and ex 
vivo testing of the most interesting nanogels described in Chapter II. 
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After applying the Zein protein test to a variety of nanogels, it was found that 
nanogels are, in general, quite mild and would not induce skin irritation. The 
values found for the fluorescent nanogels were generally twice those found 
with the non-fluorescent, although this was still below the level normally 
considered to be mild irritants.  
The toxicity of the nanogels was tested with Alamar Blue to determine the cell 
viability of keratinocytes incubated for 24 and 48 hours with the nanogels. The 
results show an excellent percentage of viable cells after 48h for non-
fluorescent nanogels with concentrations of up to 10 mg/mL. Introducing 
comonomers like AEA and fluorescent monomers decreased the viability to 
1mg/mL or lower. The experiments on cell viability elucidated the influence 
of the cell media on the LCST. A study of the LCST in EpiLife established the 
drop in temperature to be around 1.5-2°C in fluorescent, neutral and 
negatively charged nanogels. The decrease in the LCST for fluorescent, 
positively charged nanogels was around 8°C, bringing the response 
temperature too close to room temperature for this nanogels to be suitable for 
the final application. The drop in the LCST was shown to be caused by the 
ionic strength of the cell media. 
The fluorescent, neutral and negatively-charged nanogels were used to study 
the ability of keratinocyte cells to internalise them at skin temperature (35°C). 
The former ones were internalised after 48 hours and caused aggregates; the 
latter were internalised after 24 hours. In both cases the nanogels were 
localised in the cytoplasm and nucleus. 
Finally, the experiments with human excised skin showed that the fluorescent, 
neutral nanogels were able to diffuse through the stratum corneum and reach 
the viable epidermis without the help of any enhancer. Furthermore, the 
presence of benzyl alcohol or DMSO did not improve the penetration of the 
nanogels. In the other hand, fluorescent negatively-charged nanogels were 
unable to penetrate the skin without the help of an enhancer, the most efficient 
being benzyl alcohol. 
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4.4 Future work 
Chapter III focused on testing the nanogels in biological systems as drug 
delivery vehicles. There are several areas for possible future work. 
The first area of study would be the viability of keratinocyte cells treated with 
the drug FA in its free form, compared to cells treated with FA-loaded 
nanogels, containing the equivalent amount of the drug. This study would 
show the potential of the drug delivery system for sustaining the drug release 
and delivering it inside the cell. In addition, if the nanogels are able to release 
the drug more slowly, the LD50 should be higher than for the free drug alone, 
making it safer to use. (LD50 is a measure of a drug’s lethal dose and it refers 
to the concentration of drug required to kill half the cells after an specified test 
duration.) 
The efficacy of non-steroidal, anti-inflammatory drugs (NSAIDs) such as FA 
is considered to be a result of their inhibitory effect on cyclooxygenase (COX) 
activity. As COX is the rate-limiting enzyme in prostaglandin biosynthesis, it 
can be inferred that the beneficial effect of NSAIDs may be achieved through 
the inhibition of prostaglandin biosynthesis. To assess the efficacy of the 
loaded nanogels, compared to the free drug, cells should be incubated with FA 
and FA-containing nanogels, in order to check the protein expression after the 
exposition time. If the nanogels uploaded with FA performed better at 
inhibiting the effect of COX, it would show a successful internalisation of the 
drug in to the skin cells. 
The cell viability experiments, measured the percentage of cells that were 
alive after incubation with nanogels but did not give any information about the 
type of cell death when the nanoparticles were cytotoxic. A flow cytometer 
could give information on the type of cellular death: apoptosis (programed cell 
death, a regulated process, during an cells’ lifecycle) or necrosis (non-
physiological process that occurs as a result of external factors such as trauma 
or infection). Such a study would be a logical continuation of the work on the 
viability of the keratinocyte cells 
The second area of interest is how long it takes to be able to detect the 
nanogels in the cells. The cell uptake experiments on keratinocyte cells were 
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carried out at the same time interval as the cell viability experiments, 24 and 
48 hours. It would be of interest to perform more experiments at more time 
points, specifically to assess how long it takes to be able to detect the nanogels 
in the cells. For this experiment high concentrations of fluorescent polymer 
should be used, probably at 1mg/ml or higher. It would be interesting to see if 
the nanogels are located in specific organelles during the early part of the 
experiment.  
Linked to these experiments, it would also be interesting to study the cell-
uptake pathways, which are either by passive diffusion, endocytosis, 
phagocytosis, etc. Organelle location gives clues to the type of uptake 
pathway; for example, early location of the nanogels in the lysosomes 
indicates endocytosis. 
The third issue is the easy availability of fresh human skin from the operating 
theatre. It would be an appropriate additional protocol to screen potential 
formulations with a Franz Cell, using porcine skin from the abattoir or 
synthetic skin. This would allow a first pre-selection of candidates for later 
testing in human skin.  
Fourthly, because of the reduced amount of skin available for experiments, 
some were never performed. It would therefore be of interest to perform 
sensitivity studies of nanogel penetration, using skins from different genders, 
ages, races and parts of the body. 
Finally, if more human excised skin were to be available, penetration 
experiments with FA-containing nanogels could be performed, to assess the 
ability of this carrier to deliver the drug. After the penetration experiments, the 
skin should be washed, ground and extracted with chloroform (CHCl3), in 
order to remove the drug and quantify how much of it had been able to 
penetrate the cells. 
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5.1 Materials 
5.1.1 Chemicals and materials for the polymerisation and purification of 
nanogels and the synthesis of the comonomers and the fluorescent 
tag 
N-isopropylacrylamide (98%), N,N′-ethylenebisacrylamide (EBA, 99%), N,N′- 
methylenbis acrylamide (MBA, 99%) acrylic acid (AA, 99%, 200 ppm MEHQ 
as inhibitor), triethylamine (TEA, 99%), 1,2-diaminoehtane (99.5%) were 
purchased from Sigma-Aldrich (Gillingham, Dorset, UK) and used as 
received.  
Hydrochloric Acid (37%) and 2,2’-azobisisobutyronitrile (AIBN, 98%) were 
purchased from Across (Loughborough, Leicestershire, UK) and the latter, 
recrystallized from ethanol before use. N-tert-butoxycarbonyl-1,2-
diaminoethane (98%), flufenamic acid (FA, 99%),  4-bromo-1,8-naphtalic 
anhydride  and  acryloyl chloride (95%) were purchased from Fluka 
(Gillingham, Dorset, UK). Methanol (HPLC grade, 99.99%), water (HPLC 
grade, 99.99%), Methanol (99%) tetrahydrofuran (THF, 99%), 
methoxyethanol (97%), dioxane (98%) and anhydrous dichloromethane 
(DCM, 99%) were purchased from Fisher Scientific (Loughborough, 
Leicestershire, UK).  
McIlvaine universal buffers were prepared mixing Citric Acid (99%) and 
Na2HPO4 (98%), both from Fisher Scientific UK (Loughborough, 
Leicestershire, UK). 
For the nanogels purification, dialysis membranes of 22.0 mm diameter and a 
molecular weight cut-off of 3500 Daltons, were purchased from Medicell 
International Ltd. Dialysis devices Float-A-Lyzer 5 mL, MWCO 3.5 kDa were 
bought from VWR (Lutterworth, Leicestershire, UK) for the drug release 
experiments. 
5.1.2 Chemicals and materials for Zein Protein Testing 
Sodium dodecyl sulphate (SDS, 98%) was purchased from Across 
(Loughborough, Leicestershire, UK) and the Zein Protein was purchased from 
Fisher Scientific UK (Loughborough, Leicestershire, UK). 
5.1.3 Chemicals and materials for biological experiments 
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The K17 cells were generated in-house using healthy primary keratinocytes 
and immortalising them via a HPV16 E6/7 gene.1 The following materials 
were purchased from Invitrogen (Life Technologies, Paisley, UK): cell media 
EpiLife for cell growth and for skin DMEM, which were supplemented with 
10% of fetal bovine serum, penicillin at 100 U/mL and streptomycin at 100 
mg/ml. Alamar Blue, DAPI, Alexa Fluor 594 phalloidin and Lucifer Yellow 
CH, Potassium Salt were purchased also from Invitrogen. PBS (10× 
concentrate, suitable for cell culture), paraformaldehyde for cell fixing and the 
penetration enhancers DMSO (99.9%, for molecular biology) and Benzyl 
alcohol (99.8%) were purchased from Sigma Aldrich (Gillingham, Dorset, 
UK).  
5.2 Instruments 
5.2.1 NMR Spectroscopy 
Proton (1H NMR) and Carbon (13C NMR) were recorded at 400 MHz on a 
Brucker Avance III 400 spectrometer. The chemical shifts (δ) were given in 
parts per million (ppm) and the coupling constants (J) were given in Hertz 
(Hz). The proton spectra were reported in δ/ppm as follows: the number of 
protons, the multiplicity, the coupling constant J/Hz and the assignment. The 
1H-NMR peak multiplicity was reported as follows: s(singlet), d(doublet), 
t(triplet), q(quartet), m(multiplet), br(broad). All the deuterated solvents for 
NMR analysis were purchased from Cambridge Isotope Laboratories. Inc. 
5.2.2 UV-Vis Spectroscopy 
Samples were analysed using a Varian Cary 300 BIO UV-Vis 
spectrophotometer, equipped with an internal thermostat. The calibration of 
the temperature of the instrument was performed using a RS51 Digital 
Thermometer (Model 206-3722). 
5.2.3 Freeze-dryer 
Nanogel samples were recovered after purification in water using a Labcoco 
Freezone 6 Litre Benchtop Freeze Dry System. 
5.2.4 Dynamic Light Scattering 
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The DLS measurements were performed in the department of materials and 
engineering in Queen Mary University of London, with a Malvern Zetasizer 
Nano ZS.  
5.2.5 TEM 
Images of the nanogel particles stained with OsO4 were obtained using a 
JEOL 1200EX (120kV), with a beam at 90° and with a 300mesh copper grid, 
coated with a thin carbon layer. The experiments were performed at the 
NanoVision Centre of the School of Materials and Engineering at Queen Mary 
University of London. 
5.2.6 Fluorometer 
The fluorescent properties of the fluorescent tag and the new nanogels were 
investigated using a Horiba, FluoroMax-3 spectrofluorometer. 
5.2.7 Microscope 
Confocal microscope analysis of the nanogels in skin and cells was carried out 
using a Zeiss 510 Confocal Microscope.  
5.2.8 HPLC 
The exact amount of drug in the nanogels was evaluated using a HPLC system 
(Agilent 1200 Infinity Series), equipped with a Hichrom 5 C18 250 x 4.6mm 
column and a multichannel UV-Vis spectrophotometer; using a 20:80 
water/methanol solution as the mobile phase, at a flow rate of 1.2 mL/min, 
injecting 10µL of sample and reading at 300nm. 
5.2.9 Plate reader 
A Thermo Scientific Varioskan Flash Multimode Reader was used to read the 
fluorescence of cell media after cell viability reagent was added. 
5.2.10 IR 
FTIR - Perkin Elmer Spectrum 65 
 
5.3 Methods  
5.3.1 Synthesis of the comonomers 
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5.3.1.1 N-(2-Aminoethyl)acrylamide hydrochloride synthesis (AEA) (6) 
 
 
A solution of acryloyl chloride (16) (0.6 mL, 7.4 mmol) in anhydrous CH2Cl2 
(5 mL), was added in a series of drops, over a period of 30min, to a solution of 
1,2-diaminoethane (17) (0.5 mL, 7.4 mmol) in CH2Cl2 (45 mL) at -40°C. 
After stirring at ambient temperature for 24 h, the mixture was filtered and the 
solid precipitate washed with CH2Cl2 (6x100 mL). The product was obtained 
as a white powder in a 68% yield.  Spectroscopic analysis was in agreement 
with literature data.2 
1H NMR (400 MHz, D20): δ 6.19 (dd, J=12.16 Hz, 1H), 6.12 (dd, J=17.12 Hz, 
1H), 5.69 (dd, J=9.32 Hz, 1H), 3.48 (t, J=5.76 Hz, 2H), 3.09 (t, J=5.76 Hz, 
2H). 
13C NMR (400 MHz, D20): δ 169, 131, 127, 41, 37. 
IR: nmax / cm-1: 3600–2400 (br) 
m.p. 77-79°C 
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5.3.1.2 Synthesis of N-(2-(6-(4-methylpiperazin-1-yl)-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl-ethyl)acrylamide (9) 
 
Synthetic pathway for the synthesis of N-(2-(6-(4-methylpiperazin-1-yl)-1,3-
dioxo-1H-benzo[de]isoquinolin-2(3H)-yl-ethyl)acrylamide (9) 
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5.3.1.2.1 Synthesis of Tert-butyl-2-(6-bromo-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)ethylcarbamate (12) 
 
 
6,49 g (40.5 mmol) of N-tert-butyloxycarbonyl-1,2-diaminoethane (11) were 
added to a suspension of 4-bromo-1,8-naphtalic anhydride (10) (7.5 g, 27.1 
mmol) in 350 mL of 1,4-dioxane. The suspension was heated at 105°C 
overnight to give a dark red solution. The end of the reaction was monitored 
by TLC (30% of ethyl acetate in hexane). After cooling down at room 
temperature, the addition of 500 mL of brine to the reaction solution led to the 
formation of a yellow precipitate, which was filtered off and dried under 
vacuum. The product was a pure yellow solid obtained in a quantitative yield.  
1H NMR (400 MHz, CDCl3): δ 8.63 (d, 1H), 8.53 (d, 1H), 8.35 (d, 1H), 8.01 
(d, 1H), 7.69 (t, J=7.9 Hz, 1H), 4.96 (br, 1H), 4.34 (m, 2H), 3.53 (m, 2H), 1.27 
(s, 9H).  
13C NMR (400 MHz, CDCl3): δ 164.06, 164.04, 156.2, 133.48, 132.32, 
131.49, 131.22, 130.7, 130.5, 129.16, 128.20, 123.04, 122.17, 79.29, 40.17, 
39.64, 28.34. 
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5.3.1.2.2 Synthesis of Tert-butyl-2-(6-(4-methylpiperazin-1-yl)-1,3-dioxo-
1H-benzo[de]isoquinolin-2(3H)yl)ethylcarbamate (14)  
 
 
2.52 g of (12) (6 mmol) were dissolved in 25 mL of methoxyethanol at 105°C. 
3.0 mL (30 mmol) of 1-methylpiperazine (13) were added and the solution 
was stirred overnight. The end of the reaction was monitored by TLC (50% of 
ethyl acetate in hexane). After cooling at room temperature, 300 mL of brine 
were added to the solution to precipitate the compound as a brown-orange 
solid. The precipitate, which was filtered off and dried under vacuum 
compound, was obtained as a yellow solid with a 80.2% yield.  
1H NMR (400 MHz, CDCl3): δ 8.55 (d, 1H), 8.48 (d, 1H), 8.37 (d, 1H), 7.66 
(t, J=7.8 Hz, 1H), 7.19 (d, 1H), 5.05 (br, 1H), 4.33 (m, 2H), 3.5 (m, 2H), 3.29 
(m, 4H), 2.74 (m, 4H), 2,43 (s, 3H), 1,27 (s, 9H).  
13C NMR (400 MHz, CDCl3): δ 164.92, 164.44, 156.18, 132.89, 131.32, 
131.39, 130.51, 130.09, 126.23, 125.72, 123.17, 116.58, 115.08, 79.11, 55.25, 
53.06, 46.22, 40.05, 39.73, 28.38. 
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5.3.1.2.3 Synthesis of 2-(2-aminoethyl)-6-(4-methylpiperazin-1-yl)-1H-
benzo[de]isoquinoline-1,3(2H)-dione hydrochloride (15)  
 
 
1.32 g (4.00 mmol) of (14) were added to 15 mL of a 4M solution of HCl in 
tetrahydrofurane and were stirred for 2 h at room temperature. The reaction 
was monitored by thin-layer chromatography (20% methanol in 
dichloromethane) and, after the complete consumption of the starting material, 
the reaction was diluted with 300 mL of THF and kept at 0°C for 1 hr. After 
filtration and drying, 0.66 g of a pure yellow solid were obtained with a 50.4% 
yield.  
1H NMR (400 MHz, DMSO-d6): δ 11.70 (br, 1H), 8.51 (app d, 2H), 8.44 (d, 
1H), 8.06 (br, 3H), 7.87 (t, J=7.9 Hz, 1H), 7.46 (d, 1H), 4.33 (m, 2H), 3.7-3.4 
(m, 8H), 3.11 (m, 2H), 2.87 (d, 3H). 
13C NMR (400 MHz, CD3OD): δ 166.74, 166.21, 156.7, 134.13, 132.81, 
132.21, 130.93, 127.58, 127.21, 123.52, 117.60, 116.93, 55.13, 52.00, 44.72, 
39.83, 38.91 
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5.3.1.2.4 Synthesis of N-(2-(6-(4-methylpiperazin-1-yl)-1,3-dioxo-1H-
benzo[de]isoquinolin-2(3H)-yl)ethyl)acrylamide (9)  
 
 
0.84 g (2.0 mmol) of (15) were dissolved at room temperature in 100 mL of 
dry dichloromethane, in the presence of 4 equivalents of triethylamine. 180 µL 
(2.2 mmol) of acryloyl chloride (16) were added to the solution, in a series of 
drops, over 10 minutes and the reaction was monitored by TLC (0.5% of 
Methanol in dichloromethane). After 4 h the solvent was removed under 
vacuum and the raw product was purified by flash chromatography with the 
same eluent as for the TLC. 0.42 g (1.2 mmol) of a pure yellow solid were 
obtained with a 87.1% yield. Spectroscopic data was in agreement with 
literature.3 
1H NMR (400 MHz, CDCl3): δ 8.58 (dd, 1H), 8.52 (d, 1H), 8.42 (dd, 1H), 
7.69 (app.t, J=7.5Hz, 1H), 7.22 (d, 1H), 6.50 (br, 1H), 6.17 (dd, J=17.1Hz, 
J=1.5Hz, 1H), 6.06 (dd, J=17.1Hz, J=10.1Hz, 1H), 5.55 (dd, J=10.1 Hz, J=1.5 
Hz, 1H), 4.44 (m, 2H), 3.73 (m, 2H), 3.33 (m, 4H), 2.76 (m, 4H), 2.45 (s, 3H).  
13C NMR (400 MHz, CDCl3): δ 166.74, 165.34, 164.93, 156.55, 133.16, 
131.61, 131.29, 130.89, 130.19, 126.31, 125.88, 125.80, 123.02, 116.28, 
115.17, 55.27, 53.14, 46.25, 40.29, 39.31.  
IR: nmax / cm-1: 3277, 2924, 2849, 2793, 1692, 1646, 1591, 1287, 1234. 
m.p. 126-129°C 
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5.3.2 General procedure for nanogel polymerisation 
5.3.2.1 Synthesis of the nanogels 
Polymers were prepared using the standard protocol for high dilution radical 
polymerisation. The monomer concentration, CM, was varied at 1%, 2%, 3% 
and 5% (in weight). The concentration of monomer is expressed by the 
following formula, !!% = !!!!!!!!"#$%&"'  ×!""	
where m is mass and n the total number of monomers, comonomers and cross-
linker. The numerator contains the mass of all the components of the 
polymerisation, except the initiator and the solvent. The denominator contains 
the mass of all the solution (this includes all the components of the reaction). 
The cross-linker content was varied, depending on the experiment, from 5 to 
70% (in mol). The amount of comonomer used (eg AA, AEA or fluorescent 
monomer), also given in % mol, was deducted from the total by reducing the 
amount of NIPAM added. For example, a preparation of 5% AA, 5% FM, and 
20% MBA was created by calculating 100%-5%-5%-20% = 70% NIPAM.  
The quantity of AIBN initiator used was 1%, 2% or 3% of the moles of total 
double bonds, depending on the preparation. The total number of double 
bonds can be calculated by adding the moles of monomers, comonomers and 2 
times the amount of moles of cross-linkers (because they have two double 
bonds) as described in the equation below: 
 !"#$% !" !"#$%& !"#$% = [!"#$% !" !"#"!$% +!"#$% !" !"#"$"#%&' + (!"#$% !" !"#$$%&'()")×2]  
	
therefore the moles of initiator used can be calculated as follows: 
		
!"#$% !" !"!#!$#!" = !"#$% !" !"#$%& !"#$× !100 
 
A typical polymerisation using NIPAM (20.00 mg, 1.767 10-4 mol, 70 eq.), 
MBA (7.790 mg, 5.050 10-4 mol, 20 eq.), AA (0.9 µl, 1.262 10-5 mol, 5 eq), 
FM (4.950 mg, 1.262 10-5mol, 5 eq), and AIBN (0.500 mg, 3.030 10-6) would 
be dissolved in DMSO (3.032 ml) in a 50 ml Wheaton glass bottle. The 
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solutions would be flushed with nitrogen, bubbled through the solution for a 
few minutes, and then heated at 70°C for 6 h, 1 day or 4 days. 
For preparations containing Flufenamic Acid, the previous protocol was 
followed and an equivalent amount of moles of FM was added (3.549 mg, 
1.262 10-5 mol, 5eq). The polymerisation followed the same reaction 
conditions. 
5.3.2.2 Purification of the nanogel 
After polymerization, the resulting solution was left to reach room temperature 
and dialyzed against 5L of distilled water for 2 days, the water being changed 
at least 2 times a day, using a dialysis membrane with a pore size of 3,500 Da.  
After 2 days of dialysis, the dialyzed solutions were frozen with liquid 
nitrogen and then freeze-dried. Fluffy solids were recovered. 
For preparations containing Flufenamic Acid, the protocol followed was the 
same. The only difference was that, at the beginning, the nanogels with the 
drug remained soluble in the DMSO solution. As soon as the DMSO content 
decreased, the polymers became insoluble. When the free, un-reacted drug 
was released, the dialysis bag recovered the initial, transparent appearance, 
indicating that the nanogels with the drug were soluble again. All the solutions 
were prepared at the same concentration. The amount of water used to recover 
the polymer on the walls of the Wheaton bottle, was the equivalent of 50% of 
the water in the dialysis tube. As this procedure was used in every case, the 
rate of dilution for each sample was exactly the same. 
5.3.3 Polymer characterisation 
5.3.3.1 General procedure for size characterisation using the Zetasizer 
The nanogels were dissolved in MilliQ water, at a concentration of 0.1 mg/ml. 
The samples were analysed after filtration, using an Acrodisc 13 GHP with a 
pore size of 0.45 micrometre, in order to eliminate any dust or aggregates that 
might disturb the measurements and induce an error. (The error would be 
large, given the relative size of the particles and the nanogel.) Size distribution 
in intensity, volume and number were obtained by adding the refractive index 
of polymethacrylate. 
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5.3.3.2 General procedure for the Transmission Electron Microscopy 
(TEM)  
One millilitre of nanogel solution of 1 mg/ml was prepared and 250 µl of 4% 
wt OsO4 solution was added. The mixture was stirred for 30 minutes and then 
dialyzed overnight, to remove any excess oxidant that could interfere with 
particle detection by TEM. The solution was deposited onto a 300 mesh 
copper grid coated with carbon and allowed to dry for 10 min. 
5.3.3.3 General procedure for LCST determination by turbidimetric 
analysis 
One millilitre of nanogel solution was prepared at 1 mg/ml (except for 
experiments that were concentration dependant) and the sample was stabilized 
for 5 min at the initial temperature; this being 25°C for most of the samples. A 
temperature programme was then set up to run from 25°C to 65°C, at a rate of 
1°C/min. 
Measurements were taken every minute at a wavelength of 550 nm. 
5.3.3.4 General procedure for the drug release experiments 
10 mL of a 1mg/mL water solution of the nanogels containing flufenamic acid 
were prepared and a small aliquot (t = 0) was kept. The remaining solution 
was divided into two identical aliquots. The aliquots were placed in a special 
dialysis device (Float-A-Lyzer 5 mL, MWCO 3.5 kDa), floating in a 3L water 
container (sink conditions), at controlled temperatures of 37°C and 25°C 
respectively, and stirred constantly. Over 6 hours, samples of 0.5 mL were 
taken from the dialysis bags at 30min and then 1-hour intervals. The samples 
were freeze-dried and reconstituted in the same volume with MeOH/H20 
80:20 and analysed by HPLC. 
5.3.4 Biological experiments 
5.3.4.1 General procedure for the Zein Protein skin irritation testing 
Nanogel solutions and a control solution of Sodium dodecyl sulphate (SDS), 
at 1 mg/mL with Zein Protein (10mg/mL), were prepared in sealed vials and 
stirred for 48 hours at 25°C. To compare the relative amounts of the Zein 
Protein dissolved in the different solutions, its concentration was measured by 
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UV-Visible spectophotometry, at λ=265nm, and the readings compared, to 
calculate the relative percentage of dissolved protein. 
5.3.4.2 General procedure for measuring cell toxicity 
A line of immortalised human keratinocyte cells K17 was used for the testing, 
as they have been shown to have a relatively stable genome and to maintain 
normal growth and differentiation characteristics in vitro. K17 keratinocytes 
were cultured at 37°C (35°C on the modified experiments at skin 
temperature), humidified in a 10% CO2 incubator in EpiLife, modified and 
supplemented with 10% fetal bovine serum, penicillin at 100 U/mL and 
streptomycin at 100 mg/ml. 2x105 cells/well were plated into a 24-well plate 
containing 0.5 mL of EpiLife. After 24 h, when the cells were 60-70% 
confluent, the nanogels at different concentrations (3 replicates per level) were 
added to the media and incubated for 24 and 48 h at 37°C (35°C on the 
modified experiments) to test their cytotoxicity. The cells were washed once 
with phosphate buffered saline, before a fresh amount of the medium and a 50 
µL Alamar Blue stock solution (5mg/mL in EpiLife) were added to each well. 
After a further 3 h incubation, the absorbance at λ = 585 nm was analysed in a 
plate reader. The results were reported as the percentages of viable cells with 
respect to the negative control of untreated cells (100%). 
5.3.4.3 General procedure for measuring cellular uptake 
To evaluate cellular uptake, cells were seeded onto 12 well plates for confocal 
imaging. When the cells were 60-70% confluent, fluorescent nanogels were 
added to the media and incubated for 24 and 48 hours. The cells were then 
washed with PBS and fixed with 4% paraformaldehyde, and stained with 
DAPI or Alexa Fluor 594 phalloidin (following the indications of the 
manufacturer) so that the confocal microscopy imaging analysis could be 
performed. 
5.3.4.4 Ex-vivo experiments  
Redundant, full thickness, human skin was obtained from caucasian female 
patients after breast reduction surgery and was used as soon as received 
(within several hours of surgery). Fresh skin was washed in a buffer and 
excessive fat and connective tissue was removed using a scalpel. The skin was 
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then cut into pieces of approximately 1.5 cm2 and placed on a grid at the 
interface between DMEM media, with supplements, and the air. A small metal 
ring, circumscribing an area of 1cm2, was pressed onto each skin sample, with 
a moderate pressure, in order to create a reservoir. Each ring chamber was 
filled with 0.5mL of 1 mg/mL solution of nanogels in PBS or water and 2% 
w/v of penetration enhancer (BA or DMSO) and incubated at 35°C for 24 
hours. After the incubation, the skin was washed, fixed and stained with DAPI 
(following the indications of the manufacturer) and frozen for cryo-section 
and confocal analysis. 
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